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Our limited understanding of the molecular mechanisms driving the onset of normal 
human parturition makes it difficult to identify ‘what goes wrong’ in conditions such as 
preterm labour (PTL), preterm prelabour rupture of membranes (PPROM) and 
postpartum haemorrhage (PPH). This incomplete understanding seriously hampers the 
development of effective ways to predict, prevent and treat parturition complications, 
which are a cause of significant neonatal and maternal morbidity. Two principal barriers 
to improving our understanding are 1) the great complexity of both the molecular 
interactions initiating parturition and the aetiology of parturition complications, and 2) 
the difficulty in generating relevant high quality molecular and epidemiological data. To 
help make sense of this complexity, data should be analysed comprehensively to maximise 
the amount of useful information gleaned from it. 
This thesis aimed to explore the use of specialist methods to analyse novel and previously 
published data to study the molecular mechanisms initiating human parturition and the 
epidemiology of parturition complications.  
The molecular mechanisms initiating parturition were explored through a gene expression 
microarray of labouring and non-labouring myometrial tissue. This is the largest 
microarray of its kind to date. Functional analysis and a network graph approach were 
used to reveal genes and molecular pathways associated with labour. The first ever meta-
analysis of similar myometrial microarray datasets was also conducted to assess the 
reliability and generalisability of the results. This work supported the hypothesis that 
labour is associated with inflammatory events in the myometrium. A computer model of 
an inflammatory signalling pathway associated with infection-induced PTL was then built 
to provide proof of concept that such models can be used to study parturition. The model 
was based on published data and described lipopolysaccharide-induced activation of the 
transcription factor Nuclear Factor kappa B (NF-κB). This is the first attempt to generate a 
dynamic kinetic model that has relevance to the molecular mechanisms of PTL, and the 





The epidemiology of complications at parturition was explored using three methods. 
Firstly, a novel approach was developed to use network graphs to visualise and analyse a 
dataset of nearly 50,000 birth records. The approach provided a quick and effective way to 
preliminarily explore relationships between exposures and pregnancy outcomes in an 
unbiased data-driven manner. Secondly, a record-linkage study of two datasets of birth 
records was conducted to determine risk factors for PPH, including intergenerational 
transmission of risk. This confirmed several known risk factors of PPH and showed that 
women whose mothers or grandmothers had PPH do not appear to be at increased risk 
themselves. Finally, a systematic review and meta-analysis of three randomised controlled 
trials investigated the effectiveness of fetal assessment methods in improving maternal 
and neonatal outcomes following PPROM. The review concluded that there is currently 
insufficient evidence on the benefits and harms of any method of fetal assessment, and 
further randomised controlled trials are required. jjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj                    
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1 LITERATURE REVIEW:  EFFECTIVE DATA ANALYSIS TO STUDY 
PARTURITION 
1.1 INTRODUCTION  
Our limited understanding of the molecular mechanisms driving the onset of normal 
human parturition makes it difficult to identify ‘what goes wrong’ in conditions such as 
preterm labour, preterm prelabour rupture of membranes and postpartum haemorrhage. 
This incomplete understanding also seriously hampers the development of effective ways 
to predict, prevent and treat parturition complications, which are a cause of significant 
neonatal and maternal morbidity. Two principal barriers to improving our understanding 
are 1) the great complexity of both the molecular interactions initiating parturition and 
the aetiology of parturition complications, and 2) the difficulty in generating relevant high 
quality molecular and epidemiological data. To help make sense of this complexity, data 
should be analysed comprehensively to maximise the amount of useful information 
gleaned from it (Figure 1.1).   
This review explores barriers to data acquisition and analysis in parturition research and 
outlines some of the methods that can be used to ensure generated data is analysed 
appropriately. 




Figure 1.1.  An overview of the argument for comprehensive data analysis  in helping to 
overcome barriers to parturit ion research.  
1.2 THE MOLECULAR MECHANISMS DRIVING THE INITIATION OF 
PARTURITION ARE COMPLEX 
At the molecular level, parturition research aims to identify genes, proteins and molecular 
pathways that play a role in initiating and regulating parturition. Through this work, many 
inflammatory and endocrine factors from the mother, fetus and placenta have been shown 
to play a role in human parturition (Figure 1.2).  




1.2.1  INFLAMMATORY EVENTS A SSOCIATED WITH PARTURITION  
Increasingly, evidence suggests that the initiation of parturition is associated with an 
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activation status of populations of immune cells. For example, studies conducted more 
than 10 years ago revealed that leukocytes (mostly neutrophils, macrophages and T cells) 
are attracted by increased tissue expression of chemokines and cell adhesion molecules 
(1,2) to invade the cervix, myometrium, and fetal membranes at parturition (3,4). This, in 
part (5), leads to increased cytokine expression in the myometrium and cervix (3). These 
cytokines attract yet more leukocytes (6), but also have a pronounced effect on the 
reproductive tissues, including remodelling of the cervix (7) and stimulating myometrial 
contraction through prostaglandin synthesis (8–13). Prostaglandins mediate 
inflammation, and prostaglandin production is increased in the fetal membranes and 
myometrium at labour. Chorionic prostaglandin dehydrogenase (PGDH) activity decreases 
in late pregnancy, which exposes the decidua and myometrium to pro-inflammatory 
prostaglandin F2 alpha (PGF2α) (14). PGF2α and prostaglandin E2 have a direct 
contractile effect; they bind to their receptors on myometrial myocytes to activate a 
signalling pathway, resulting in the activation of myosin light chain kinase and the release 
of intracellular calcium (15–17). Prostaglandins also mediate the release of 
metalloproteases, which weaken the placental membranes and facilitate membrane 
rupture and cervical ripening (18,19). 
1.2.2  ENDOCRINE EVENTS ASSOCIATED WITH PARTURIT ION  
Endocrine-dependent events associated with parturition include functional progesterone 
withdrawal, functional estrogen activation, myometrial stimulation by corticotrophin-
releasing hormone, and regulation by oxytocin.  
1.2.2.1   FUNCTIONAL PROGESTERO NE WITHDRAWAL  
Progesterone plays a critical role in maintaining myometrial relaxation throughout much 
of pregnancy (20). In many mammals, circulating progesterone levels fall prior to labour, 
and this is thought to promote increased myometrial contractility.  However, it has been 
recognised for over three decades that in women, circulating progesterone levels remain 
constant in the late third trimester of pregnancy and at parturition (21–25). It has 
therefore been proposed that the onset of human parturition is associated with a 
‘functional progesterone withdrawal’, whereby circulating concentrations of progesterone 
are maintained but they have a diminished effect on the uterus. Mechanisms proposed for 
this include changes in the ratios of the progesterone receptor isoforms (specifically, an 
increase in progesterone receptor A (PR-A) relative to B (PR-B)) (26), local metabolism of 
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progesterone (27), and changes in levels of cofactors affecting progesterone receptor 
function (28). Interestingly, prostaglandin PGF2α is able to stimulate preferential 
expression of progesterone receptor A (PR-A) in myometrial cells (29), which provides a 
potential link between inflammation, prostaglandins, progesterone and the onset of labour 
(30). 
1.2.2.2  FUNCTIONAL ESTROGEN A CTIVATION  
Estrogen stimulates uterine contractions by increasing the expression of contraction-
associated protein genes such as connexin-43, the oxytocin receptor, PTGS2 
(prostaglandin endoperoxide synthase 2) and the PGF2α receptor (26,31–35). This has 
recently been shown to be mediated by extranuclear signalling through estrogen receptor 
alpha (ERα) via activation of the ERK mitogen-activated kinase (MAPK) pathway (36). In 
women, there is a gradual increase in circulating estrogens throughout pregnancy (37), 
and this is accelerated in the final few weeks, but estrogen levels during parturition are 
not significantly different to those just before it (21,38). In a study conducted on a small 
number of myometrial samples from labouring and non-labouring women, Mesiano et 
al.(26) reported that both the PR-A/PR-B mRNA ratio, and ERα mRNA were significantly 
increased in labouring myometrium. They also showed that the expression of ERα mRNA 
was positively correlated with expression of COX2 and oxytocin receptor mRNAs in non-
labouring myometrium and suggested the coordination of progesterone withdrawal and 
estrogen activation may be required for parturition. 
1.2.2.3   CORTICOTROPIN -RELEASING HORMONE  
Corticotropin-releasing hormone (CRH) is released from the placenta in human pregnancy 
(39), and this is associated with an increase in maternal plasma CRH levels that peaks at 
delivery (40,41). The bioavailability of CRH is limited by a binding protein (CRH-BP), but 
levels of CRH-BP decline in the last six weeks of pregnancy further increasing the 
circulating concentrations of unbound “active” CRH (42). Mclean et al. found associations 
between faster rises in CRH levels and preterm birth, and between slower rises and post-
term birth (43). Subsequently, they put forward the ‘placental clock hypothesis’ – that CRH 
controls the timing of parturition. It is unclear exactly how CRH might exert this effect, 
however CRH can stimulate the activity of the COX2 that synthesizes PGF2α (44), which 
provides a potential link between placental production of CRH, prostaglandins and 
functional progesterone withdrawal. 
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1.2.2.4   OXYTOCIN AND ITS  RECE PTOR  
Although not fully understood, oxytocin is known to play an important role in human 
parturition. Synthetic oxytocin is used to augment labour in a clinical setting (45), and 
oxytocin receptor antagonists show some success in treating preterm labour and are 
licenced for this purpose in the UK (46). Oxytocin concentrations in the maternal plasma 
(47) and gestational tissues (48) increase with labour, which causes prostaglandin 
formation in the chorion, decidua and amnion (49–52). Oxytocin receptor expression also 
increases in term myometrial tissue (33,53) and this leads to direct contractile effects 
(53). 
1.2.3  THE RELATIVE IMPORTAN CE OF THESE  MECHANISMS IS  UNCLEAR  
Despite decades of work elucidating several molecular mechanisms associated with the 
onset of human parturition, the relative importance of each of these factors or their 
interactions is still unclear.  Crucially, this knowledge has also not led to a substantial 
improvement in the ability to predict, prevent or treat parturition complications and 
improve clinical outcomes. Clearly there are still large gaps in our knowledge, particularly 
regarding the potential complex interactions that may exist between the molecular 
pathways identified thus far.  
1.3 THE MOLECULAR BIOLOGY OF PARTURITION IS DIFFICULT TO 
STUDY 
One of the main reasons we have a limited understanding of the molecular mechanisms 
initiating parturition is that it is a difficult system to study in humans. Attempts to improve 
our understanding are often restricted by the relative inaccessibility of human gestational 
tissues to study during pregnancy, and by the lack of fully informative animal models. 
1.3.1  EXPERIMENTS USING HUM ANS  
Ideally, the most effective experiments to study human parturition would use human 
participants. However, there are obvious ethical, clinical and economic considerations that 
make this impossible (54). Most human gestational tissues are inaccessible during 
pregnancy without causing harm.  Some tissues such as the umbilical cord, amnion, 
chorion and placenta are relatively easy to collect post-partum. However collection of 
maternal tissues is more difficult. At Caesarean section, decidua and myometrium can be 
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extracted opportunistically, but ethical regulations regarding informed consent are 
necessarily stringent. Myometrial tissue is usually collected from the lower segment of the 
uterus as this offers least procedural complication whilst yielding useful amounts of 
starting material for a variety of experimental purposes.  One has to be aware nonetheless 
that molecular pathways active in this region of the tissue may differ from those in other 
areas such as the fundus (54–56). Therefore the lower segment may not be an appropriate 
model of the whole uterus. Tissue from labouring women is particularly difficult to obtain 
because in these cases, the Caesarean section is performed as an emergency. Additionally, 
results from any investigations using these tissues may be affected by the clinical 
indications for Caesarean delivery (54). 
1.3.2  ANIMAL MODELS  
The use of animal models can overcome some of the problems inherent in human studies. 
Tissue can be collected at precise time-points throughout gestation and parturition, and 
the importance of certain molecular mechanisms can be investigated using genetic 
manipulation. Many of the molecular mechanisms that play a role in initiating parturition 
are likely to be common to humans and animal models. However, there are no fully 
informative animal models of parturition. In most mammals, such as the sheep, rat and 
mouse, a fall in maternal circulating progesterone appears to be the initiating mechanism 
(54,57,58). This differs from humans where, as discussed above, progesterone levels 
remain stable at the end of pregnancy and during parturition (21,22). In fact, in one 
comparison of genome-wide gene expression detected by microarray, surprisingly few 
genes that changed significantly throughout pregnancy were the same in the mouse and 
human (59). Nonhuman primates also show no maternal serum progesterone withdrawal 
and have a uterine anatomy closer to that of humans (54), there are stringent ethical 
regulations surrounding the use of nonhuman primates, and the studies are often 
financially and logistically impractical.  
The molecular mechanism of parturition in these animal models appears to be far simpler 
than the mechanisms initiating and regulating human parturition. Human parturition does 
not appear to be associated with a single ‘trigger’, but rather a more gradual culmination 
of several different pathways (54). In other mammals, spontaneous preterm labour is rare 
but can be reliably induced pharmacologically, suggesting that the mechanisms initiating 
animal parturition are also more efficient than in the human (58).  The limitations of 
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taking the human-only approach to parturition research (outlined in Section 1.3.1) 
highlight the need to also access information from appropriate non-primate animal 
models. Mitchell and Taggart argue that the guinea pig is a more relevant model for 
several reasons such as the absence of systemic progesterone withdrawal and the natural 
occurrence of spontaneous preterm labour in this species. However, further 
characterisation of the model is necessary (54).  
1.4 THE AETIOLOGY OF PARTURITION COMPLICATIONS IS COMPLEX 
Largely due to the complexity of human parturition and the difficulties inherent in its 
study, the causes of complications related to parturition are often unclear. This limits the 
development of effective strategies to predict, prevent and treat such complications. 
However, it is important that we improve our understanding, because parturition 
complications are a cause of significant neonatal and maternal morbidity and mortality.  
Epidemiological research aims to elucidate aetiology by identifying causative risk factors 
that may lead to the development of effective management strategies. A better 
understanding of the risk factors associated with parturition complications will help 1) 
identify at-risk patient and develop risk-specific treatments, 2) define a subset of women 
in which to study specific interventions, and 3) provide important insights into the 
mechanisms behind the complication. Table 1.1 outlines what is known about the 
epidemiology of some of the major parturition complications. Risk factors and current 
management strategies are discussed below. 
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Table 1.1.  The epidemiology of some of the major complications associated with 
parturit ion. 




 Spontaneous labour 
(regular uterine 
contractions associated 
with cervical ripening) 
occurring before 37 
weeks’ gestation. 






 Preterm birth, which is the 
leading cause of neonatal 
morbidity and mortality and 
often associated with long-term 
morbidity such as 






 Rupture of the fetal 
membranes more than 
one hour before the 
onset of labour, and 
before 37 weeks’ 
gestation. 
 1-2% of all 
deliveries 
(61).  
 30-40% of PPROM cases are 
related to preterm birth. 
 Morbidity including cord 
prolapse placental abruption. 
 Increased susceptibility to 
intrauterine infection. 
Dystocia 
 Abnormal or difficult 
parturition.  
 3-8% of all 
deliveries(62). 
 Assisted delivery (forceps, 
ventouse or Caesarean section). 





 ≥500ml blood loss from 
the genital tract in the 
first 24 hours after 
childbirth. 
 3-26% of all 
deliveries 
(63,64). 
 Leading cause of maternal death 
worldwide. 
 Sixth highest direct cause of 
maternal death in the UK (65). 
 Maternal morbidity including 
coagulopathy, respiratory 
failure, renal failure, sepsis and 
hysterectomy. 
1.4.1  SPONTANEOUS PRETERM L ABOUR  
Spontaneous preterm labour (regular contractions associated with cervical ripening, 
occurring before 37 weeks’ gestation) is the cause of 40-45% of preterm births. The 
aetiology is unclear, and it is now considered to be a syndrome composed of multiple 
mechanisms (66). It may represent an early idiopathic activation of the normal 
mechanisms that initiate labour, or be associated with different mechanisms related to 
pathological insults. It is associated with many risk factors including intrauterine infection, 
previous preterm birth, black race, low socioeconomic status, low and high maternal age, 
short inter-pregnancy interval, low BMI, sociological and psychological stress and smoking 
during pregnancy (66–68). These risk factors are of only some use in predicting preterm 
labour (69). Similarly, biomarkers such as cervical length and cervicovaginal 
measurements of fetal fibronectin show a disappointing ability to predict preterm labour, 
especially in asymptomatic women (70). Current strategies to treat preterm labour once it 
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has begun involve tocolytic drugs to suppress uterine contractions. Such tocolytics include 
beta-agonists, calcium ion channel blockers, prostaglandin synthetase, nitric oxide donors 
and oxytocin antagonists (71). However, systematic reviews of randomised controlled 
trials (RCTs) have shown that there is no clear evidence tocolysis improves neonatal or 
maternal outcomes (72,73), but it may be useful if the small increased time to delivery 
allows  in utero transfer to a hospital with specialist facilities, or completion of a course of 
corticosteroids to improve fetal lung function (71). 
1.4.2  PRETERM PRELABOUR RUPTURE OF MEMBRANES  
Twenty-five to 35% of preterm births are associated with preterm prelabour rupture of 
membranes (PPROM), which can precede preterm labour or indicated preterm delivery. 
Risk factors associated with PPROM are similar to those associated with preterm labour, 
including smoking, previous preterm delivery or PPROM, uterine overdistension, black 
race, and low socioeconomic status (74–77). The pathophysiology of PPROM is largely 
unknown, but excessive stretching of the membranes, decreased collagen content, 
placental abruption, and programmed amniotic cell death have all been proposed as 
mechanisms (78). However, 25 to 50% of cases are associated with intrauterine infection 
and inflammation (79). Methods to predict PPROM are also similar to those used to 
predict preterm labour, with short cervical length and PPROM in a previous pregnancy 
being the most effective predictors (80,81). Strategies to manage pregnancies with PPROM 
include tocolysis, antibiotics to treat intrauterine infection, and amnioinfusion to restore 
amniotic fluid volume. Although these interventions can increase time to delivery, there is 
limited evidence that they significantly reduce neonatal death and morbidity (82–84). 
1.4.3  DYSTOCIA  
Dystocia is the result of weak or uncoordinated uterine contractility. It is one of the most 
common causes of prolonged labour and occurs most frequently in nulliparous 
pregnancies (85). The pathophysiological mechanisms behind dystocia are not fully 
understood, but could be myogenic, neurogenic, hormonal, or (most likely) multifactorial 
(86,87).  There is some evidence of a genetic component to dystocia (62), with dystocia  
being more prevalent among women whose mothers had dystocic labours than among 
those whose mothers had normally progressing labours (88). Previous dystocia also 
appears to increase the risk of dystocia in a subsequent delivery (89). Other risk factors 
include a large interpregnancy interval, older maternal age, high maternal BMI, short 
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maternal stature, high caffeine intake, gestational diabetes, hypertension and hydramnios 
(90–95). Vaginal examination during labour can provide information on cervical dilatation 
and fetal head-to-cervix contact that could be useful in predicting dystocia in labouring 
women (96). Interventions to augment labour, such as amniotomy and oxytocin, are used 
to treat dystocia. These show some success in reducing the length of labour and the need 
for operative delivery (45,97,98), however dystocia is a large contributor to the rate of 
assisted delivery by forceps/ventouse or Caesarean section (99).  
1.4.4  POSTPARTUM HAEMORRHAGE  
The annual incidence of  postpartum haemorrhage (PPH) appears to be rising steadily, 
even in high resource countries (100). PPH can be associated with a failure of the uterus to 
contract adequately after birth (atonic PPH; 90% of cases), trauma to the genital tract 
(traumatic PPH; 7% of cases), or bleeding due to retention of placental tissue or failure in 
the coagulation system (3% of cases) (101). Known risk factors include young or old 
maternal age, Caesarean delivery, hypertension, polyhydramnios, intrauterine infection, 
multiple gestation and antepartum haemorrhage (64), however the aetiology is often 
unclear and PPH may occur in women with no identifiable risk factors. Few studies have 
investigated the power of these risk factors to predict PPH, but those that have found low 
predictive values (102,103). Treatments include drugs (such as oxytocin and 
prostaglandins) to increase uterine contractions, blocking the uterine artery, haemostatic 
drugs to stop the bleeding and active management of the third stage of labour. In severe 
cases, hysterectomy may be necessary. Few trials have assessed the efficacy of these 
interventions in improving outcomes (104–106), but two trials comparing misoprostol 
(synthetic prostaglandin E1) with placebo showed that treatment with misoprostol was 
not associated with any significant reduction in maternal mortality, hysterectomy, blood 
transfusion or rates of manual removal of retained placenta (107,108). 
1.5 EPIDEMIOLOGICAL STUDIES ARE DIFFICULT TO CONDUCT 
A better understanding of the aetiology of parturition complications should lead to better 
prediction and treatment strategies, which will hopefully result in a reduction in incidence 
and improved neonatal and maternal outcomes. Population-level epidemiological studies 
are necessary to explore risk factors and the efficacy interventions for parturition 
complications. However, large clinical study designs (including epidemiological studies 
such as longitudinal cohort studies, case-control studies) require appropriate validated 
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datasets and randomised controlled trials are time-consuming, logistically difficult and 
expensive. 
Although all are significant clinical problems, the complications discussed above occur in a 
relatively small percentage of pregnancies. This means large numbers of pregnant women 
need to be recruited to ensure the sample contains a sufficient number of cases for 
adequate power. Furthermore, to identify lifestyle risk factors for complications, it may be 
necessary to follow women for years prior to their pregnancy. Again, this means very large 
numbers of women need to be recruited. Women may be less likely to take part in an 
intervention trial during pregnancy, especially if they are asymptomatic or at low risk, so 
recruitment may be difficult. The drop-out rate may be high if pregnant women, who often 
have other commitments, are expected to attend a clinic or research centre to receive an 
intervention or provide data. 
1.6 ATTEMPTING TO OVERCOME THESE BARRIERS TO PARTURITION 
RESEARCH 
The complexity of normal and complicated parturition and the difficulties inherent in its 
study mean that relevant, high quality molecular and epidemiological data is precious. In 
order to maximise the amount of useful information gleaned, existing available data 
should be analysed comprehensively, using the most up to date analytical techniques.  
Table 1.2 outlines some useful strategies to conduct comprehensive analysis of existing 
data. 
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Table 1.2.  An overview of some useful strategies in conducting comprehensive analysis  of 
existing molecular and epidemiological data.  
 
1.6.1  MAKING EFFICIENT USE OF EXISTING DATA  
Molecular and epidemiological data can be made available to researchers in a variety of 
ways. Published papers are the most abundant source, although these generally provide 
the least amount of detail. Data is often presented in the form of a summary table or graph, 
so its interpretation may be limited by the chosen method of analysis and aims of the 
original work. Data in published papers is also open to reporting bias, whereby ‘positive’, 
confirmatory findings are more likely to be reported than important but negative findings 
that might refute current ideas (109). Increasingly however, raw data from published 
studies is being made available to download from online repositories as well as in the form 
of supplementary files linked to their publications. In ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/), the database of gene expression microarray data, 
there are currently 11 datasets relevant to human parturition. The raw data files are freely 
available to download for further analysis. Considering microarray experiments are 
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expensive to conduct and human gestational tissue is difficult to collect, online 
repositories such as ArrayExpress are extremely valuable resources. Other online 
repositories combine data from published studies to create useful, searchable catalogues 
of specific information. Examples include: 
 KEGG Pathway (Kyoto Encyclopaedia of Genes and Genomes; 
http://www.genome.jp/kegg/pathway.html) – a collection of manually-drawn 
pathway maps representing knowledge of molecular interaction and reaction 
networks. 
 BioModels (http://www.ebi.ac.uk/biomodels-main/) – a repository of 
computational models of biological processes, collected from the scientific 
literature and curated and cross-referenced to external data resources. The 
original model files are available for download. 
 Uniprot (http://www.uniprot.org/) – a comprehensive, high-quality resource of 
protein sequence and functional information. 
Alternatively, authors may be willing to provide raw data on request, or it may be made 
available for a fee through research institutions or other organisations. For example, the 
Health Informatics Centre (HIC) at the University of Dundee makes Scottish patient health 
records from the Information Services Division (part of NHS Scotland), and data from 
cohort studies available to researchers from other institutions. They maintain several 
databases that could be used to study the epidemiology of parturition complications in 
Scotland, including SMR02 (Scottish Morbidity Records 02), which contains detailed 
information on hospital maternity admissions in collected from January 1975 to present.  
Improving access to quality data is critical to facilitating research, and could lead to 
advances in our understanding of normal and complicated parturition (110). 
1.6.2  USING SPECIAL ANALYTI CAL METHODS  
Good access to high quality data is only beneficial if it is analysed appropriately and 
comprehensively. Special analytical methods should be employed to analyse data in the 
most efficient, useful way. These methods include, 1) using a data-driven ‘systems’ 
approach to generate as well as test hypotheses, and 2) combining data from different 
sources to provide extra information, increase the power and generalisability of results, 
and to compare and contrast different studies. 
1 - Literature review 
 
15 
1.6.2.1  SYSTEMS BIOLOGY APPRO ACHES  
Much of the research conducted in the field of obstetrics to date has applied the traditional 
‘reductionist’ approach, with an emphasis on single cells or tissues focussing on the 
functions of certain molecules or key pathways, or the prevalence of certain risk factors. 
Although this approach has undoubtedly advanced our knowledge of the molecular and 
epidemiological mechanisms of parturition, it has not led to a significant improvement in 
neonatal or maternal outcomes. The novel paradigm of ‘systems biology’ provides a way to 
consolidate and extend current knowledge to characterise complex processes through 
describing the components of a system and their interactions at a global level. It considers 
the molecular biology and epidemiology of parturition from a holistic perspective and 
attempts to identify emergent properties. 
1.6.2.1.1 SYS T EMS  BIO LO GY IN  MO LEC ULAR RES EA RC H  
Research that uses a systems approach to study the molecular mechanisms initiating and 
regulating parturition is increasingly appearing in the literature thanks to recent advances 
in techniques that allow whole systems and emergent properties to be studied (55,110–
128). These techniques fall broadly into two main categories: 1) methods to analyse high-
throughput data, and 2) computational modelling. Both techniques involve large amounts 
of molecular data and existing knowledge of molecular pathways.  
1.6.2.1.1.1 H IGH -THRO UGH PUT D ATA -  TRANS CRIPTO MI CS  
High-throughput data can be generated to study biological systems at a global level. This 
means that rather than choosing certain genes/proteins/etc. to study in isolation, 
elements of all these entities in a biological system can be studied simultaneously. 
Examples of high-throughput techniques include: 
 Transcriptomics – to study global gene expression through quantification of mRNA 
transcripts using microarray technology. 
 Genomics – to study DNA variants between individuals using high throughput 
genome-wide sequencing. 
 Proteomics – to study global protein expression using mass spectrometry and 
protein microarray technology. 
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 Metabolomics – to study metabolites (the products of cellular metabolism) at a 
global level using mass spectrometry. 
 Epigenomics – to study epigenetic modifications to the genome such as DNA 
methylation using global methylation arrays. 
Of these techniques, microarray experiments to study the transcriptome have been most 
commonly applied in parturition research. 
Microarrays allow the expression of tens of thousands of genes to be monitored 
simultaneously in cells or tissues in a wide range of physiological or pathophysiological 
situations. They generate vast quantities of data that are analysed comprehensively using 
statistical and bioinformatics techniques to suggest biological processes and pathways 
associated with changes in gene expression (129). Microarray analysis of pregnant non-
labouring and labouring gestational tissues aims to identify genes and pathways 
associated with the onset and regulation of labour. This will improve our understanding of 
the mechanisms initiating parturition, and expression of these genes may act as useful 
biomarkers to predict preterm labour (113). Several microarray experiments conducted in 
the last 10 years have reported labour-associated changes in gene expression in the cervix, 
myometrium and the placenta in both humans (55,59,112,114,115,119,120,130–143) and 
rodents (59,144–147). These have offered support for the observation that parturition is 
an inflammatory event associated with an upregulation of several inflammatory cytokines 
in the gestational tissues. One study also suggests there is a different gene expression 
signature associated with preterm compared to term labour in humans (115). Two 
microarray studies have compared gene expression in normal term labouring 
myometrium with labouring myometrium from women with dystocia. These have also 
identified genes that are differentially expressed in myometrium from complicated 
compared to normal parturition (148,149). 
Thorough, appropriate analysis of microarray data is crucial. The mathematical method 
used to normalise expression values to allow direct comparison between samples can 
have a substantial effect on downstream analysis. Box-plot and principal component 
analysis of raw and normalised gene expression values can be useful in identifying 
biological samples that vary significantly from other samples and might be best excluded. 
Gene expression fold changes give a reasonable measure of effect size, but should be 
combined with a statistical method to define the level of ‘confidence’. Similarly, the 
1 - Literature review 
 
17 
threshold beyond which fold changes are considered biologically interesting requires 
some consideration. Certain genes (for example a transcription factor) that might show a 
small change in expression may be overlooked, but even a small change in their expression 
could have a large downstream effect. Therefore, lists of up- and down-regulated genes 
can be informative, but are sometimes of limited value. Bioinformatics techniques can 
provide more interesting insights into the data by identifying clusters of genes with 
similar expression patterns over all samples, or mining gene lists for enrichment of genes 
involved in certain biological processes or KEGG protein pathways. Recently developed 
network graph approaches (in which proteins/genes are represented as nodes connected 
by edges representing interaction relationships or the degree of similarity in expression) 
are also a valuable tool in microarray analysis (150). These have identified patterns in 
gene expression data in other biological systems (151–154), but have been used relatively 
infrequently to investigate human parturition. However, since 2010 several investigators 
have applied this approach to microarray data and shown that the majority of the genes 
differentially expressed in labouring compared to non-labouring tissue are downstream 
targets of the transcription factor nuclear factor-kappaB (NF-κB) and pattern recognition 
receptors such as toll-like receptors (TLRs)(130,133,155). This supports the hypothesis 
that labour is associated with an inflammatory event.  
1.6.2.1.1.2 CO MPUTATIO NAL  MO D ELL I NG  
Computer models assemble complex experimentally-derived data into concise 
mathematical representations of biological systems that reveal more about their operation 
and structure than wordy descriptions and/or diagrams ever could. They can consolidate 
the current state of knowledge of a system, test that it is correct, highlight gaps in our 
understanding and can inform design of biological experiments to bridge those gaps. 
Furthermore, a well-validated model that describes the system accurately can be used to 
predict how the system will react to different stimuli in ‘virtual’ experiments that might be 
time consuming and expensive in the lab (156). Such models are particularly useful if they 
can reproduce or predict behaviours beyond those they were initially designed to 
describe. They can then be used to generate and test hypotheses about how the biological 
system might be organised and regulated. These hypotheses can be tested using wet lab 
experiments, and models can be updated with new data and used to generate further 
hypotheses.  
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It is important to note that the reliability of a model hinges on the availability and quality 
of the data obtained through such experiments. Models are also heavily dependent on 
decisions made regarding model design and which data to include or exclude. Wet lab 
validation helps to reduce this risk of bias, as does the availability of high quality 
published desciptions of the structure and dynamical behaviour of the system (157). 
Therefore, it is crucial that researchers have access to high quality data through online 
repositories. Model files should also be made available to the research community to allow 
testing by other groups and inform the design of further models (158). Online repositories 
of published models such as BioModels (159), and standardised file formats such as SBML 
(Systems Biology Markup Language) (160) facilitate this. 
Computer modelling of the events involved in initiating parturition should help identify 
key pathways or mechanisms that might be altered in pathologies such as preterm labour 
or dystocia. Such models have several potential applications. For example, they could be 
used to test, in silico, hypotheses about drugs to treat or prevent such complications. 
Models could also help identify a sub-group of women who are likely to respond best to 
certain treatments. In this way, they could provide a useful tool to help design expensive 
time-consuming clinical trials more efficiently. With further development, an effective in 
silico model could be used by health care practitioners to develop personalised medicine 
for patients on a pregnancy-by-pregnancy basis.  
Despite the explosion in the use of bioinformatics in the past decade, computer models 
have been used relatively infrequently to study pregnancy (110). Table 1.3 outlines the 
models that have been developed to date to describe uterine electrophysiology and 
propagation and the molecular mechanisms that initiate parturition (these are reviewed in 
more detail in Sharp et al.(161), which was written during the course of this PhD). Far 
more models focus on uterine electrophysiology than molecular pathways to uterine 
activation, but models of molecular mechanisms will be useful in identifying the key 
pathways and predicting the effects of drugs to alter such pathways. Computer models 
that integrate models of electrophysiological and molecular mechanisms will be 
particularly useful. 
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Table 1.3.  Computer models developed to describe uterine electrophysiology and 
propagation and the molecular mechanisms that init iate partur ition. 






A statistical model of uterine wall 
thickness, volume and tension 
throughout gestation. 
Published intrauterine 
pressure catheter data and 
ultrasound measurements of 
the shape of the uterus in 






A model of uterine smooth muscle 
cell excitation with three elements: 
1) intracellular calcium 
concentrations, 2) myosin light 
chain phosphorylation and 3) stress 
produced by the cell in response to 
depolarisation of the cell 
membrane. 
Published results of voltage-
clamp experiments using 
pregnant rat uterine smooth 
muscle cells, and data on 
myosin light chain 
phosphorylation and force 
production in non-pregnant 







A detailed model involving all the 
main ionic mechanisms controlling 
uterine smooth muscle cell 
contraction. 
Published data from voltage-
clamp experiments, 
predominantly on rat uterine 






A comprehensive model of uterine 
smooth muscle cell contraction, 
incorporating 13 types of ionic 
current and cell size. The model 
included a reconstruction of 
cellular changes in response to 
estradiol. 
Published and unpublished 
data from voltage-clamp 
experiments on pregnant rat 
uterine smooth muscle cells 
in the presence and absence 
of estradiol, and 
experimental recordings of 
spontaneous action potential, 
calcium ion and phasic force 









A model to explain how 
contractions spread throughout 
the uterus, in which the uterus was 
represented as a hollow ovoid 
shape composed of discrete 
contracting cells that send 
electrical impulses to their 
neighbours, generate tension, and 
have defined periods of 
contraction and refraction 
No experimental validation, 
but it was able to reproduce 
complex contraction patterns 
similar to published reports 







A tissue propagation model in 
which intercellular communication 
occurs via action potential and 
calcium wave propagation.  
One in vivo recording of 








A model that uses physiologically 
significant parameters to simulate 
the changes in intrauterine 
pressure associated with a 
contraction during labour. The 
model takes into account the 
In vivo recordings of 
intrauterine pressure during 
human labour. 
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number of cells in each of three 
states (contracting, refractory and 
resting), the excitability of the cells 
in the resting state, the lifetime of 
the contraction state, and the 






A preliminary multiscale model 
that combines a simplification of 
Rihana’s cell excitation model with 
a model of electrical conductance 
from the myometrium to the skin. 
It aimed to describe the pattern of 
uterine electrical activity from its 
onset at the cell level, to its 
propagation throughout the 
myometrium, to its conduction to 
the abdominal surface. 
Electrohystograms 





A multiscale model that combined 
a simplification of uterine anatomy 
with a cell excitation model and a 
tissue propagation model to 
simulate uterine electrical activity 









A current multi group effort to 
build a comprehensive multiscale 
model of the human uterus while 
pregnant. The model combines a 
model of the three-dimensional 
geometry of the uterus during 
pregnancy with cell excitation and 
tissue propagation models. 
In vivo MRI and ex vivo 
DTMRI to reconstruct 






An early model that described an 
increase in uterine tension in 
response to an oxytocin stimulus, 
mediated by intracellular calcium 
concentration. 







Directed acyclic graph (DAG) 
approach to model the alternative 
hypotheses of pathways to the 
initiation of labour: functional 
progesterone withdrawal, 
inflammatory stimulation, and 
oxytocin receptor activation. 
Information from the 
literature about different 
hypotheses, plus published 
qRT-PCR data of transcripts of 







An intracellular model of the 
immune-endocrine interactions 
associated with the initiation of 
labour. They also looked at the 
behaviour of the model in response 
to progesterone and COX2-
inhibitor treatment. 
Existing knowledge about 
immune-endocrine 
interactions in the 
myometrium, but no 
experimental validation. 
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1.6.2.1.2 CO MPUTATIO NAL  EPID E MI O LO GY  
Computational techniques such as those discussed above have been increasingly applied 
to molecular research over the past decade. However, most epidemiological studies still 
use traditional statistical approaches, and ‘computational epidemiology’ is in its infancy 
(170,171). Traditional approaches rely on researchers generating hypotheses about the 
epidemiology of a disease, and then applying statistical techniques to test these 
hypotheses. In contrast, computational epidemiology looks for patterns in unstructured 
sources of data and serves as a useful means of generating hypotheses (171,172). 
Computational epidemiology applies computational concepts to provide tools that aid in 
the prediction and analysis of disease manifestation and spread. Accordingly, much of the 
work that has been conducted in this field to date focusses on modelling the 
spatiotemporal spread of infectious disease throughout populations (171,173). A generic 
formal disease model (DisMod) has been developed that is applicable to a wide range of 
non-communicable diseases. DisMod is based on a set of differential equations that 
describe age-specific incidence, remission, case fatality and ‘all other causes’ mortality. 
The model returns predicted prevalence and case-specific mortality as outputs, and allows 
the impact of different scenarios to be assessed. It is particularly useful for analysing 
epidemiologic data that are incomplete (174). There are undoubtedly more ways in which 
computational methods may be useful for analysing epidemiological data.  
There are no reports of computational epidemiology being applied to pregnancy research, 
although it could be a useful, novel approach that may help generate interesting 
hypotheses about the epidemiology of parturition complications. 
1.6.2.2  COMBINING DATA FROM DIFFERENT SOURCES  
Data from different sources can be combined to aid analysis. Linking data on the same 
subjects from different studies can provide additional information that allows the scope of 
the analysis to be extended.  Additionally, combining and meta-analysing data from 
separate studies that use similar methods can increase the power of analyses and the 
generalisability of results. 
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1.6.2.2.1 RECO RD -L INKAGE  
Records from clinical databases or epidemiological studies can often be linked to other 
datasets to increase the breadth of data available for each patient. If the datasets were 
collected at different times, this allows later life health outcomes to be compared to earlier 
exposures without using an expensive and difficult to conduct longitudinal cohort design. 
For example, in Scotland each patient is assigned a unique identifier called a Community 
Health Identifier (CHI number) at birth or when they register with a general practitioner, 
which allows record-linkage between different databases of health records. Databases of 
birth records, such as Scottish Morbidity maternity admissions (SMR02) and the Walker 
database of 48000 births in Dundee between 1952 and 1966, can be record-linked via the 
CHI number to databases of other health information such as the Tayside prescriptions 
database.  
To date, only two record-linkage studies have been conducted using the Walker database 
to investigate the impact of parturition complications on later life health outcomes. 
Murphy et al. (175) investigated the relationship between forceps delivery and epilepsy in 
adulthood by linking 21,441 Walker births to the Tayside prescriptions database and 
Scottish Morbidity records hospital admissions database (SMR01). The authors found that 
delivery by forceps was not associated with epilepsy compared with all other deliveries 
(adjusted odds ratio = 1.0, 95% confidence interval = 0.6-1.8), but preterm birth was 
associated with an increased risk of epilepsy (adjusted odds ratio = 2.0, 95% confidence 
interval = 1.2-3.2). Uma et al. (176) conducted a study to determine the influence of 
intrapartum care during a first delivery on the risk of pelvic floor surgery in later life. 
Primiparous women from the Walker cohort were linked to surgical data in SMR02. The 
authors found that delivery by Caesarean section was associated with a reduced risk of 
pelvic floor surgery in later life compared with spontaneous vaginal delivery (odds ratio = 
0.16, 95% confidence interval = 0.05-0.55).  
The benefits of carrying out record-linkage studies are clear, and there is scope to 
investigate the epidemiology of other parturition complications using this approach. 
1.6.2.2.2 META-ANALYS IS  
The statistical power and generalisability of results can be improved by combining data 
from different studies for meta-analysis. This technique is most commonly applied in 
1 - Literature review 
 
23 
systematic reviews of RCTs, but it can also be useful in analysing molecular data, such as 
those produced by microarray experiments. 
RCTs are useful for evaluating the efficacy of health interventions. Subjects are randomly 
allocated to receive one intervention or another/no interventions. Care is taken to reduce 
bias in the study design to increase the likelihood that any difference in outcome between 
the different treatment arms is due to the treatments being compared. However, RCTs are 
very time-consuming, expensive and difficult to conduct. Consequently, they are often 
performed using a small number of patients, and RCTs of the same interventions may 
disagree on their efficacy in different populations. Systematic reviews that attempt to 
identify and appraise RCTs are helpful in drawing a consensus on the efficacy of 
interventions. Most systematic reviews combine results from the RCTs under review and 
use statistical techniques to perform a meta-analysis which gives an idea of the overall 
effect size (for example, odds ratio or mean difference) of the intervention on specific 
outcomes, and also assesses heterogeneity. In evidence-based medicine, systematic review 
and meta-analysis of RCTs is considered the highest level of evidence used to inform 
clinical decision making. Systematic reviews help to highlight and reduce the impact of 
selective reporting of results from RCTs (reporting bias). A recent large systematic review 
of RCTs for women with breast cancer found that 33% of the 164 included trials 
selectively reported the primary endpoint and 67% selectively reported toxicity (177). 
Positive effects of the intervention were more likely to be reported than negative effects.  
In order to reduce bias and maintain standards in systematic reviewing, precise guidelines 
on how to conduct systematic reviews are produced by the Cochrane Group, which is a 
group of health-care specialists that also publishes in their own journal, the Cochrane 
Library.  The Cochrane Pregnancy and Childbirth Group, a subdivision of the Cochrane 
Group, focuses on systematic reviews of interventions involving the mother or baby 
during and after pregnancy and childbirth. To date, they have published over 480 reviews.  
Less often, similar techniques are applied to meta-analyse molecular data. Individual 
microarray studies sometimes report findings that are not reproducible or robust to 
different forms of data analysis. It is often difficult to make direct comparisons between 
results obtained in different laboratories using different platforms and different methods 
of analysis. Additionally, small sample sizes in individual studies can lead to less robust 
results that are difficult to generalise. This problem is magnified when using human tissue 
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samples, which are highly susceptible to inter-patient variation (178). Meta-analysis of 
microarray data increases the statistical power to detect differentially expressed genes 
and allows the variation across studies (herterogeneity) to be assessed. This can result in 
more accurate, reproducible, and robust predictions (179–182). 
There is one published meta-analysis of microarray data to study parturition (113). This 
study, which was published in 2007 combined lists of genes reported to be differentially 
expressed in five human studies of myometrial gene expression in pregnancy, term and 
preterm labour. The authors found that the remodelling and maturation processes 
associated with pregnancy last the full course of gestation, but genetic regulation of the 
onset of parturition was less well characterised. However, this study’s use of published 
gene lists rather than raw microarray data ignores information on genes showing lower 
levels of differential expression, and does not account for the different methods used to 
generate and analyse the data. Similar meta-analyses using raw data and analytical 
techniques allowing the studies to be more directly comparable are needed. Initiatives 
such as MIAME (Minimum Information About a Microarray Experiment), which provide 
guidelines for the standard reporting of microarray experiments, specify that the raw data 
must be made available to the research community to allow different groups to analyse 
the data themselves, potentially using different techniques (183). Insistence on authors 
complying with such guidelines has greatly facilitated meta-analysis of existing data, and 
the validation of new analytical methods.  
1.7 CONCLUSION  
A limited understanding of the molecular mechanisms initiating human parturition stems 
from the great complexity of the system, and difficulties in studying it. This seriously 
hampers attempts to predict, prevent and treat parturition complications. Similarly, these 
complications are often idiopathic or have an unknown aetiology, and epidemiological 
studies to study aetiology are expensive and/or time-consuming. These barriers to 
parturition research can be partly overcome by making efficient use of existing data and 
by using special analytical methods to maximise the amount of useful information gleaned 
from it. Such methods include use of data-driven systems approaches, computational 
modelling, record-linkage and meta-analysis. 
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1.8 AIMS AND HYPOTHESES  
This work aims to explore the use of special methods in analysing novel and previously 
published data to study the molecular mechanisms initiating human parturition and the 
epidemiology of parturition complications. Specifically, the hypotheses are: 
 Exploring myometrial microarray data using functional analysis and a network 
graph approach will reveal genes and molecular pathways associated with labour 
and other patient characteristics. 
 The reliability and generalisability of these findings will be increased through 
meta-analysis with other, similar myometrial microarray datasets. 
 Published knowledge of a signalling pathway relevant to preterm labour can be 
integrated to build a computational model that successfully simulates in vitro 
behaviour. 
 A network graph approach can be used to visualise and explore epidemiological 
data relating to birth outcomes. 
 Data from two birth cohorts can be record-linked to assess if the risk of PPH is 
higher in women whose mothers had PPH in their pregnancies.  
 Systematic review and meta-analysis of RCTs can be useful in assessing the 
efficacy of fetal assessment following PPROM in improving neonatal and maternal 
outcomes. 




This chapter describes and provides a rationale for the techniques used to generate and 
analyse data throughout this PhD. A table of all computer applications and online tools 
used is provided in Appendix 1. 
2.1 MICROARRAY ANALYSIS  
The results of these analyses are discussed in Chapter 3. 
Microarrays were first designed to improve our understanding of gene functions and 
molecular mechanisms (184–186). They are most commonly used to analyse expression of 
multiple genes simultaneously. Microarrays are particularly useful for comparing gene 
expression in different biological situations. For this PhD, a microarray experiment was 
conducted to investigate gene expression in labouring and non-labouring human 
myometrial tissue. Modern microarray techniques involve tens of thousands of ‘probes’ 
(short sections of genes) attached to microscopic beads or a ‘chip’ made of a solid surface, 
such as glass. Each probe is complementary to a cDNA or cRNA target transcript. Usually, 
the target is labelled with a fluorescent dye and then hybridised to the chip. The 
fluorescence intensities of each spot give a relative measure of transcript expression 
levels. 
There are several microarray platforms available, and the choice of platform can have a 
large impact on analysis. Affymetrix and Illumina are the most common commercial 
microarray platforms and each version has a highly standardised protocol that facilitates 
inter-experiment comparisons. Here, the Illumina HT-12 v4.0 Expression BeadChip 
platform (Illumina, San Diego, CA, USA) was chosen because it offers the highest 
multiplexing capabilities for whole genome gene expression, is highly accurate and 
relatively inexpensive. 
2.1.1  MYOMETRIAL TISSUE SAM PLES  
Biopsy samples of full thickness lower segment specimens of human myometrium were 
selected from the Edinburgh Reproductive Tissue Biobank (ERTBB, 
http://www.crh.ed.ac.uk/biobank/), which is managed by staff within the MRC Centre for 
Reproductive Health. For each patient, samples are split and processed in two ways – wax 
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embedded for immunohistochemistry and frozen (with or without RNAlater®) for RNA 
and protein extraction. Forty-eight ERTBB frozen myometrium samples were selected for 
RNA extraction. Forty-five of the samples selected had been transferred into RNAlater® 
(Life Technologies, Invitrogen, Carlsbad, CA, USA) immediately after collection and then 
frozen at -80°C. Three labouring samples had not been transferred to RNAlater® before 
freezing. The latter were included in the array analysis in order to maximise the number of 
labouring samples, and because a previous microarray experiment has shown that fresh or 
frozen myometrial tissue shows no systematic shift in quantitative RNA expression 
compared to myometrial tissue stored in RNAlater® (187). To minimise any effect of this 
difference in storage, all three frozen samples were washed briefly in RNAlater® before 
RNA extraction. 
Labouring myometrium is usually collected during emergency Caesarean section. Such 
women are more difficult to recruit because of the unpredictable nature of the procedure. 
Therefore, the ERTBB contains fewer labouring myometrial samples compared to non-
labouring samples. In order to maximise biological replicates on the array, all 22 labouring 
samples in the ERTBB as of August 2012 were selected. Non-labouring samples were then 
selected by loosely matching to labouring samples on certain patient characteristics. An 
effort was made to ensure mean values for key demographics (maternal BMI, gestational 
age, parity and maternal age) were similar between labouring and non-labouring groups. 
2.1.2  RNA  PREPARATION  
Total RNA was isolated using TRI Reagent® and the Qiagen RNeasy Lipid Tissue kit 
protocol (Qiagen, Valencia, CA, USA). This method exploits the ability of nucleic acids to pH 
hybridise onto silica within an RNeasy column (Qiagen) when tissue is homogenized in a 
high pH buffer. Briefly, tissue was homogenised in a solution of RNeasy lysis buffer. 
Chloroform was added and tubes were vigorously shaken before centrifuging for 15 
minutes at 12000g and 4°C. The homogenate separates into three phases – the upper 
aqueous (RNA) phase, a white inter-phase and a lower organic phase. The aqueous phase 
was transferred to a new tube and ethanol was added. Samples were centrifuged for 15 
seconds at 8000g at room temperature on RNeasy mini spin columns. The flow through 
was discarded and centrifugation was repeated. RW1 buffer was added to the spin 
columns and then centrifuged for 15 seconds at 78000g at room temperature. The flow 
through was discarded and the RNA was resuspended in 50μl RNase free water. 
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The quantity and quality of RNA was assessed using a NanoDrop 1000 (Thermo Scientific, 
Wilmington, DE, USA). This exposes the sample to ultraviolet light at 260nm and a photo-
detector measures the light that passes through. The more light that is absorbed, the 
higher the concentration of RNA. The ratio of light absorbance at 260nm and 280nm is 
used to assess the purity of the RNA. A ratio of around 2.0 is considered “pure”, but 
substantially lower readings may indicate contamination.  
RNA quality was further assessed in the biotin-labelled samples by the Wellcome Trust 
Clinical Research Facility using  the Bioanalyzer 2100 (Agilent Technologies, Wilmington, 
DE, USA). The Bioanalyzer reads a gel chip containing up to 12 RNA samples in micro-
channels. Nucleic acid fragments within the samples are driven through the gel 
electrophoretically and this separates the fragments according to their size. The fragments 
are then detected by laser-induced fluorescence detection. This generates an 
electropherogram showing the concentration and ribosomal ratio.   
To prepare samples for the microarray experiment, 450ng total RNA was amplified and 
biotin-labelled using the Illumina® TotalPrepTM RNA Amplification Kit (Ambion, Austin, 
TX, USA). This produces hundreds to thousands of biotinylated antisense RNA copies. 
Biotin is a small water-soluble B vitamin that is useful for labelling and isolating proteins 
for biochemical assays. The procedure consists of reverse transcription with a reverse 
transcriptase enzyme called ArrayScript. This enzyme catalyses the synthesis of virtually 
full-length cDNA, thus ensuring maximum production of reproducible microarray samples. 
After undergoing second strand synthesis and cleanup, the cDNA becomes a template for 
in vitro transcription with T7 RNA Polymerase. Ambion® MEGAscript in vitro 
transcription (IVT) technology and biotin-UTP is used to generate multiple biotinylated 
antisense RNA copies of each mRNA in a sample. Antisense RNA is referred to as cRNA 
(and sometimes aRNA in the literature). This kit was developed to produce labelled cRNA 
for hybridisation with Illumina arrays. The protocol is summarised in Figure 2.1. 




Figure 2.1.  A summary of the I llumina® TotalPrepTM  RNA Amplification Kit  protocol.  
Figure taken from the I llumina® TotalPrepTM  RNA Amplification Kit handbook (Ambion).  
RNA extraction and labelling was carried out by myself under the guidance and training of 
Dr Lawrence Hutchinson. 
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2.1.3  ILLUMINA HT-12  V4.0  BEADCHIP EXPRESSION MICROARRAY  
PLATFORM  
The Illumina HT-12 v4 Expression BeadChip is a direct hybridisation whole-genome 
expression assay used to analyse intact complementary strand RNA samples. The set-up is 
slightly different to that of an Affymetrix microarray. Oligonucleotide probes are 
immobilized to beads held in microwells on the surface of an array substrate (Figure 2.2). 
The beads are randomly distributed across the surface of the substrate. Each bead 
contains a 29 nucleotides long (29-mer) address sequence, used to identify the location of 
the bead and validate its hybridisation. Biotin-labelled sample cRNA is hybridised to 50-
mer probes on the BeadChip, and after washing and staining with a fluorescent protein 
that binds to biotin the BeadChips are scanned. There are 47231 probes in total, with 
28,688 of those coding a transcript with well-established annotation. Probes were 
designed by Illumina using the HumanRef-8 beadchip, with additional probe designs 
based on UniGene release 188. There are 12 microwells on each chip (Figure 2.2), which 
allows up to 12 samples to be processed on the same chip. Not only does this multi-sample 
format increase throughput, but it also reduces sample-sample variability. 
 
Figure 2.2.  I llumina ht-12 v4.0 beadchip expression array technology. A) the chip 
contains 12 microwells  that are each loaded with a s ingle sample.  Each microwell 
contains oligonucleotides immobilized to beads. B) each bead is  attached to a 29 -mer 
address  sequence and a 50-mer probe. Biotin-labelled cRNA is  hybridised to the probe 
(redrawn from the I llumina literature).  
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The Wellcome Trust Clinical Research Facility (WTCRF) at the Western General Hospital in 
Edinburgh conducted the microarray experiment and scanned the chips. Samples were 
split randomly over the four chips to minimise any effect of inter-chip variability 
interfering with differential expression between labouring and non-labouring groups.  The 
chips were imaged using a BeadArray Reader and raw data was obtained with Illumina 
BeadStudio software. The raw gene expression data was returned as tab delimited files. 
2.1.4   DATA PREPROCESSING  
Raw data was preprocessed by the Cardiovascular Sciences (CVS) Bioinformatics team 
using the Lumi package (188–191) in R. They subjected the data to Robust Multichip 
Average (RMA) background correction before quantile normalisation to remove non-
biological systematic variation. Background correction removes signal caused by 
nonspecific binding of the fluorescent protein. Quantile normalisation is used to remove 
any ‘batch effect’ due to sample-sample and chip-chip variation (192). Quantile 
normalisation is a widely used standard method, based on the assumption that the 
distributions of expression values are similar in every sample. For each sample, the probes 
are arranged in ascending order of expression value. These arranged values are then 
averaged over all the samples. The original expression values for the features for each 
sample are then replaced by their mean over all samples. This brings expression values 
into the same register so that meaningful comparisons can be made. CVS Bioinformatics 
provided box plots and intensity plots to visualise the distribution of expression values 
across all probes and all samples before and after normalisation. Large variations may 
indicate poor quality RNA. 
2.1.5   ANNOTATION  
Also using the Lumi package, CVS Bioinformatics annotated the data according to the 
Illumina probe ID. They incorporated information on the gene name, official gene symbol, 
Unigene ID, Entrez gene ID, and Gene Ontology (GO) terms. 
CVS Bioinformatics returned the normalised data as comma delimited files in which each 
row represents a probe with its ID in the first column and annotation information in 
subsequent columns followed by expression values for each sample.  
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2.1.6   BACKGROUND CUT-OFF DETERMINATION  
Most of the probes in an array are not expressed in most experiments but have low 
‘background’ level expression values. Removing these probes is important because they 
may mask any true changes in gene expression between groups (for example, it is not 
uncommon for an unexpressed gene to appear to be differentially expressed between 
groups because its low expression value varies slightly but the fold-change appears 
significant).  
The median expression value over all probes and all samples can be taken as the cut-off 
value used to define background expression. Another method to define this cut-off is to 
take the mean expression value of negative control probes included on the array. These 
negative control probes contain sequences not expected to hybridise to most genomes, so 
they provide a measure of non-specific hybridisation, non-specific dye signal and scanner 
background.  
Here, the mean expression value over all probes was 168.78 (median=64.05) and the 
mean expression value of negative control probes was 81.4. The final background cut-off 
value was rounded up to 100, as advised by the CVS Bioinformatics team. Probes for which 
the labouring and non-labouring group mean expression values were both below 
background (≤100) were removed. All further analysis was performed using this 
background-removed data. 
2.1.7  DETERMINING SAMPLE RELATIONS  
To assess the similarity of expression values between samples and sample groups 
(labouring/non-labouring), a correlation matrix was created using the cor() function in R 
(see Appendix 3). The correlation values in the matrix are computed using the Pearson’s 
method and describe the between sample expression value similarity on a scale of 0-1 
(0=perfectly uncorrelated, 1=perfectly correlated). The minimum and mean correlation 
values between all samples, and between labouring and non-labouring sample groups 
were observed to assess whether or not there are differences between sample groups.  
To help with the interpretation of this correlation matrix, the data were also visualised 
using two methods. Firstly, the matrix was used to draw a heatmap using the heatmap.2() 
function in the gplots R package (193) (see Appendix 3). The heatmap represents the 
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strength of each correlation value using colours on a scale. Secondly, the matrix was 
loaded into BioLayout Express3D as a .matrix file to create a network graph where each 
sample is represented as a node (sphere) connected to others by ‘edges’ weighted 
according to the strength of the correlation. All correlation values above 0.95 were used to 
draw the graph. As a rule of thumb, a correlation of at least 0.95 is usually expected from 
samples that are biological replicates. Markov Chain clustering (MCL) was performed to 
assess how the samples cluster into groups (inflation value=7). Biolayout Express3D and 
MCL clustering are discussed in more detail below in section 2.1.10. 
Additionally, the nodes were coloured by key patient characteristics (labouring/non-
labouring, BMI group, preterm/term, maternal age category and para=0/para≥1) to 
visualise the effect of these characteristics on between-sample correlation. The association 
between cluster membership and membership to these patient characteristic groups was 
assessed using Fisher’s exact or χ2 tests. Another network graph was built in the same way 
but using only labouring samples. MCL clustering was performed in the same way and 
nodes were coloured according to whether or not the patient was administered 
syntocinon/prostaglandins and the rough stage of labour (assessed as ‘early’ if cervical 
dilation was ≤3cm, and ‘late’ if cervical dilation was ≥6cm). Again, the association between 
MCL cluster and these categories was assessed using Fisher’s exact or χ2 tests. 
2.1.8  ASSESSING DIFFERENTIA L EXPRESSION BETWEEN  GROUPS  
CVS Bioinformatics used R package Limma (194) (part of Bioconductor) to provide a 
means through which I could assess differential expression between groups. I requested 
that two comparisons could be made: labouring versus non-labouring samples (in line 
with the aims of the experiment), and para=0 versus para≥1 samples (chosen after further 
analysis of results). Limma calculates the fold-change in mean expression between groups 
for each probe. It is reported as a ratio where a value of 1 indicates no change, 2 indicates 
a doubling in expression and -2 indicates a halving in expression. Fold change values are in 
relation to the base level group (non-labouring or para=0). Confidence intervals for the 
fold changes were calculated using Fieller’s theorem (195) via an R function (see Appendix 
3). Limma was also used to perform statistical testing between the groups. The method 
relies on linear modelling and empirical Bayesian methods to give modified t-test p-values 
for group comparisons for each probe. Because of the large number of t-tests being 
performed, there is a high risk of false-positive significant values. Therefore, an adjusted 
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P-value is calculated that corrects for the false discovery rate. Smallest p-values (most 
significant) are associated with probes that have similar expression values within a group, 
but a clear difference between groups. Absolute P-values should be interpreted cautiously 
because they describe not only the biological significance, but also the sum of the 
biological effects and other sources of variability or noise in the data. Therefore, CVS 
Bioinformatics also reported the significance of differential expression using a non-
parametric statistical method called Rank Product (196). This method is based on the 
ranks of fold-changes rather than individual values, which reduces the chance of false 
negative results. This is particularly useful in noisy data. It is corrected for multiple testing 
using the percentage of false positives (PFP) and reported as an RP-PFP value. This value 
is roughly equivalent to a P-value, so values ≤0.05 can be considered statistically 
significant. 
CVS Bioinformatics built data into a filterable database that could be used to filter 
differentially expressed genes by specifying fold-change and adjusted-P-value/RP-PFP 
criteria. In general, I used fold-changes >1.2 or <-1.2 and RP-PFP ≤0.05 to define 
differential expression. There is no ‘correct’ way to select a fold-change/significance level 
cut-off, so these liberal values were chosen in an attempt to maximise true positive 
findings. 
Differentially expressed genes were also visualised using a heatmap. The heatmap 
represents expression values as colours on a colour scale. Columns represent samples and 
rows represent differentially expressed genes. To make the list small enough to enable 
clear visualisation, a fold change cut-off of >2 or <-2 and an RP-PFP cut-off of ≤0.0001 
were used. A hierarchical clustering algorithm is used to sort samples according to the 
similarity of their expression values for all the genes included in the map. The heatmap 
shows 1) which genes are up/down regulated in which samples, and 2) how samples 
cluster. 
2.1.9  RESOLUTION OF THE MAN Y-TO-MANY ISSUE BETWEEN PROBES AND 
GENES 
Where multiple probes exist for the same gene, searches were carried out over all probes. 
To investigate single genes in more detail, the gene was ‘summarised’ by selecting the 
probe with the smallest adjusted P-value for its fold change, because it is the least likely to 
occur by chance. This summary method was assumed to be more accurate than simply 
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taking an average of the probe expression values (which would be inaccurate because 
different probe sequences have different binding affinities and therefore different 
measurement scales) or selecting a probe at random (which would lose information and 
risk under/overestimating the degree of differential expression).  
2.1.10  NETWORK GRAPH ANALYSI S  
Further analysis and visualisation of the data was conducted using a network graph 
approach. Biolayout Express3D was used to draw a weighted, non-directed graph in which 
probes are represented as ‘nodes’ (spheres) connected by ‘edges’ (lines) weighted 
according to similarity in expression value. Representing data visually in this way makes it 
easier for humans to infer relationships and identify structural features such as clusters, it 
also allows interactive analysis of the data. The approach uses no prior assumptions about 
the likely structure within the data or the questions to be addressed. 
Biolayout Express3D uses the Pearson correlation coefficient as a measure of similarity 
between expression profiles. An expression profile is the expression of each probe over 
the range of samples analysed. Pairwise pearson correlation coefficients are calculated for 
every probe on an array and correlations beyond a threshold are used to draw edges 
between nodes (probes). It is necessary to impose a correlation threshold to avoid 
generating an overly large graph dominated by uninformative edges. 
Probes with similar expression profiles appear closer to each other in the graph, creating 
clusters of probes. These clusters are expected to be biologically significant, containing 
genes with similar biological functions or involved in similar mechanisms. Biolayout 
Express3D uses the Markov cluster algorithm (MCL) to define clusters within the graph. 
The MCL algorithm is appropriate because it avoids incorrectly defining clusters in data 
that contains a lot of spurious (false positive) correlations. MCL clustering is partly 
dependent on the “inflation value” used to run the algorithm. Lower inflation values result 
in fewer, larger, noisier clusters and higher inflation values result in many, smaller, 
cleaner clusters. 
Data was loaded to Biolayout Express 3D as a tab delimited .expression file. A range of 
Pearson correlation coefficient thresholds and MCL inflation values were explored. A 
correlation cut off of 0.8 and an MCL inflation value of 2.2 were determined empirically to 
be optimal to fragment the data into meaningful clusters.  
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2.1.11  FUNCTIONAL ANALYSIS  
Functional analysis aims to infer biological meaning from expression data. DAVID (The 
Database for Annotation, Visualization and Integrated Discovery) (197,198) is a popular 
web-based tool used to analyse gene lists according to different functional categories and 
pathways. The Functional Classification Tool within DAVID assesses whether certain 
functional categories appear more frequently in the gene list than over the rest of the 
genome. It uses over 75000 terms from 14 functional annotation sources to generate 
generates a gene-to-gene similarity matrix. The clustering algorithm classifies highly 
related genes into functionally related groups and assigns each group an ‘enrichment 
score’ to gauge how important the group is in the overall list. 
DAVID offers a large choice of functional annotation categories. A widely used category is 
Gene Ontology (GO) (199). One of the aims of the GO project is to develop and maintain 
standardised annotations for genes and gene products. The GO terms cover three 
domains: 1) cellular component, 2) molecular function, and 3) biological process. DAVID’s 
Functional Annotation Clustering tool groups similar annotations together to make the 
biology clearer and reduce the redundancy of multiple similar annotations. 
KEGG (Kyoto Encyclopedia of Genes and Genomes) Pathways (200,201) is also useful for 
annotating gene lists in DAVID. KEGG Pathways is a database of canonical molecular 
pathways. Gene lists can be tested for enrichment to certain KEGG pathways. 
In this analysis, lists of official gene symbols representing 1) down-regulated genes (fold 
change <-1.2 and RP-PFP ≤0.05), 2) up-regulated genes (fold change >1.2 and RP-PFP 
≤0.05), and 3) MCL cluster specific genes were uploaded to DAVID. The lists were assessed 
for biological process GO term enrichment and KEGG pathway enrichment. DAVID 
integrates with KEGG to help visualise gene expression data by mapping it onto KEGG 
pathway diagrams. 
2.1.12  IMMUNOHISTOCHEMISTRY  
Immunohistochemistry refers to the process of localising antigens in a tissue section 
through binding to a specific primary antibody. This technique was performed to detect 
the leukocyte marker CD45 in labouring and non-labouring myometrial tissue samples. 
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The same technique was also applied to a human tonsil sample, acting as a positive control 
known to contain an abundance of leukocytes. 
2.1.12.1  SAMPLES  
Of the patients used in this microarray experiment, five labouring and five non-labouring 
tissue samples were chosen at random (patients were first allocated and then sorted by a 
random number, the top five patients in each category were chosen). The non-labouring 
samples were NL3095, NL2275, NL2158, NL2410 and NL3114. The labouring samples 
were L3189, L0190, L3132, L3197 and L3226. 
2.1.12.2  EMBEDDING AND SLIDE C UTTING  
At the time of collection, myometrial tissue samples from the ERTBB were fixed 
immediately in 4% NBF for 24 hours and transferred to 70% ethanol. Tissue was 
subsequently wax embedded using standard protocols. 
Tissue sections were cut at 5µM sections and adhered to glass slides by flotation in warm 
water. Slides were then incubated at 37°C for at least 24 hours to ensure complete 
adherence to the slide. This work was performed by the SuRF@QMRI Histology 
department. 
2.1.12.3  STAINING FOR CD45 
The CD45 antibody was supplied by Dako (CD45, Leucocyte common antibody Clone 
2B11+PD7/26; Santa Clara, CA, USA) and was used at a dilution of 1:1000. Slides were 
dewaxed in xylene for 5 minutes, rehydrated in ethanol (absolute, 90%, 80% and then 
70%), and washed in water.  Antigen retrieval was performed using Novocastra pH6 
retrieval buffer (Leica microsystems, Wetzlar, Germany). Staining was carried out using 
the Bond-max automated immunostaining machine (Leica microsystems, Wetzlar, 
Germany), via a service supplied by the SuRF@QMRI Histology department. 
Slides were washed five times in Bond Wash Solution for a total of 15 minutes. Following 
this, endogenous peroxidase activity was blocked by incubating the slides for 10 minutes 
in 3% hydrogen peroxide in PBS. Slides were washed in Bond Wash Solution for two 
minutes prior to incubating the sections for 2 hours at room temperature in primary 
antibody diluted in 1 part normal goat serum to 4 parts bond wash buffer. Slides were 
2 – Methodology 
 
38 
then washed in Bond Wash buffer for 10 minutes before incubation with the pre-polymer 
for 15 minutes at room temperature. Following further washes slides were incubated with 
an HRP polymer. Binding of the antibody was visualised by incubating in 
3,3’diaminobenzidine (DAB) substrate for peroxidase for a maximum of 5 minutes, 
resulting in positive brown staining. Slides were then counterstained in haematoxylin, 
dehydrated in increasing concentrations of ethanol, incubated in xylene for 5 minutes and 
coverslips were mounted using pertex mounting medium. 
A negative control, where the primary antibody was replaced with normal goat 
serum/Bond wash buffer, was included in each run. 
Images of stained sections were obtained using the Olympus PROVIS microscope 
(Shinjuku, Tokyo, Japan) and AxioVision Rel 4.8 software (Carl Zeiss microscopy, 
Oberkochen, Germany). 
Figure 2.3 shows positive staining for CD45 in the positive control (human tonsil) tissue 
and no staining for CD45 in myometrial tissue incubated without the antibody. 
 
Figure 2.3.  Immunohistochemistry controls.  A.  Positive control, human tonsil stained for 
CD45. B.  Negative control, human myometrial t issue incubated without  the antibody. 
2.1.13  VALIDATION WITH TAQMAN REAL-TIME PCR 
Microarrays are an excellent tool for initial target discovery, but the relatively limited 
dynamic range of fluorescent microarrays limits the sensitivity and specificity of the 
technology. It is therefore essential to validate differential expression of some genes using 
an alternative method.  
2 – Methodology 
 
39 
TaqMan Gene Expression Assays were chosen to validate this microarray because they 
have a high specificity, sensitivity and large dynamic range. A TaqMan probe is labelled 
with a fluorescent reporter dye at the 5’ end and a second ‘quencher’ dye at the 3’ end, 
which quenches light emitted from the reporter dye. The probe hybridises to the target 
DNA sequence between specific forward and reverse primers. During the amplification 
phase of PCR, the Taq polymerase enzyme moves from the 5’ to 3’ end, thereby cleaving 
the probe and releasing the reporter dye from the proximity of the quencher. The reporter 
dye emits light when excited by a laser, and the amount of fluorescence is measured as 
directly proportional to the amount of target present in the PCR. 
2.1.13.1  SAMPLES  
qRT-PCR was performed using the original RNA samples used in the microarray 
experiment. Generally, more reliable validation is achieved using samples from different 
patients, however, this was impossible because such samples were unavailable. The large 
number of samples (48) used in this experiment means that this is less of a limitation than 
it would be for smaller experiments. 
2.1.13.2  THE RELATIVE QUANTIFICAT ION STANDARD CURVE METHOD  
Relative gene expressions were determined using the standard curve method. Relative 
quantification is based on the expression levels of a target gene versus a reference gene 
and is considered appropriate in this scenario. The standard curve uses multiple serial 
dilutions of sample to plot a curve from which relative concentrations can be read. The 
advantage of this method over other relative quantitative RT-PCR methods is that it 
requires no assumptions about amplification efficiency. Expression values of target genes 
from the standard curve are then normalised against those from a reference gene. 
Here, the standard curve method was used to evaluate the relative expression of levels of 
target genes between labouring (test) samples and non-labouring (calibrator) samples.  
2.1.13.3  CDNA  SYNTHESIS  
cDNA synthesis was performed by Nanette Hibbert. 
1μg of total RNA of each sample was reverse transcribed to cDNA using a cDNA synthesis 
kit (4368813-Applied Biosystems, Carlsbad, US). A “mastermix” was prepared according 
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to Table 2.1. For each sample, 1μg (10μl) of total RNA was added to 10μl of mastermix. A 
negative control containing 4.2μl RNase free water instead of the reverse transcriptase 
was included to measure residual genomic DNA, and another negative control containing 
13.2μl of RNase free water instead of the total RNA was included to assess contamination. 
Transcription was performed using a G-Storm GS1 thermal cycler (G-Storm, Somerton, 
Somerset, UK) with a cycle of 25˚C for 10 minutes, 37˚c for 120 minutes and 85˚C for 5 
minutes. Samples were stored at -20˚C until needed. 
Table 2.1 cDNA synthesis mastermix.  
cDNA synthesis mastermix component Volume/sample (μl) 
10x Reverse transcriptase buffer 2 
25x dNTPs 0.8 
10x random primers 2 
Reverse transcriptase 1 
RNase inhibitors (1unit/μl) 1 
RNase free water 3.2 
Total 10 
2.1.13.4  HOUSEKEEPING AND TARG ET GENES  
Expression of the target genes was normalised to the amount of the housekeeping gene, 
18s ribosomal RNA. 18s expression was found to be consistent between labouring and 
non-labouring myometrial samples, and its use as a housekeeping gene in these tissues is 
well described in the literature. 
Pre-designed, inventoried TaqMan gene expression assays (Applied Biosystems, Foster 
City, CA, USA) were used to measure the expression of ten genes.  These assays are 
optimised for use in quantitative real time polymerase chain reaction (qRT-PCR). The gene 
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Table 2.2.  Information about the gene assays used to validate the microarray.  
Gene ID Gene name TaqMan assay ID Reason gene chosen for validation 
RBM42 
RNA binding motif 
protein 42 
Hs00225667_m1 
Not differentially expressed according 





Not differentially expressed according 
to the array. 
FABP4 
Fatty acid binding 
protein 4 
Hs01086177_m1 







Downregulated in labour according to 
the array. 
MYH11 
Myosin heavy chain 
11 
Hs00224610_m1 
Downregulated in labour according to 
the literature. Smooth muscle marker. 
TPM1 Tropomyosin 1 Hs00165966_m1 
Downregulated in labour according to 
the literature. Smooth muscle marker. 
IL6 Interleukin 6 Hs00985639_m1 
Upregulated in labour according to the 
array and the literature. 
IL8 Interleukin 8 Hs00174103_m1 
Upregulated in labour according to the 
array and the literature. 
MT1E Metallothionein 1E Hs01938284_g1 
Upregulated in labour according to the 
array and the literature. 
OXTR Oxytocin receptor Hs00168573_m1 




18S ribosomal RNA 
1 
Hs03928985_g1 
Housekeeping gene classically used in 
previous studies comparing labouring 
vs. non-labouring human myometrium. 
2.1.13.5  QRT-PCR 
qRT-PCR was conducted by Nanette Hibbert and myself (under Nanette’s guidance).  
qRT-PCR was performed using an ABI 7900HT (Applied Biosystems, Carlsbad, US), on a 
384 well plate with inventoried gene-specific Taqman assays (Table 2.2). The reaction mix 
is shown in Table 2.3.  
Table 2.3.  qRT-PCR mastermix. 
qRT-PCR mastermix component Volume/reaction (μl) 
TaqMan mastermix 5 
Primers and probes 0.5 
RNase-free water 2.5 
Total 8 
The standard curve was obtained by diluting a pool of equal volumes of all labouring and 
non-labouring samples (dilutions: neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256). All 
samples and RT negative controls were diluted 1:10 using RNase-free water. This ensures 
that the expression values correspond with the linear part of the standard curve, which 
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allows relative values to be compared more accurately. For each sample/point of the 
standard curve, 8μl of mastermix was added to 2μl (diluted) cDNA. All standard curve 
points, RT negative and water controls were assayed in technical triplicate for each 
gene.All non-labouring and labouring samples were assayed in technical duplicate. All 
targets and controls were run in separate wells. The reaction involved three stages, the 
third of which was repeated 40 times: 1) incubation at 50˚C for 2 minutes, 2) incubation at 
95 ˚C for 15 seconds, and 3) incubation at 95 ˚C for 15 seconds, then at 60˚C for 1 minute. 
Where the mean cycle threshold (CT) values of technical duplicates had a standard 
deviation over 0.2, the reaction was repeated. If this did not resolve the difference, the 
results were included in further analysis but the implications of this were noted in the 
discussion of the results. 
2.1.13.6  DATA ANALYSIS  
All data analysis was carried out by myself. 
For each target gene and 18s, a nine-point standard curve was plotted of the log total 
cDNA (ng) against the raw CT (cycle threshold) value. For each dilution, there were three 
technical replicates. Figure 2.4 shows an example of a standard curve used in this study. 
The slope of the standard curve is used to estimate PCR amplification efficiency. A slope of 
-3.32 indicates a reaction with 100% efficiency. Slopes more negative than -3.32 are less 
than 100% efficient and slopes more positive than -3.32 may indicate problems with 
pipetting or sample quality. Slopes should be between -3.3 and -3.6 (90-100% efficient). 
Regression analysis was used to draw a regression line for the data and to calculate its 
slope and Y intercept. These values were used to determine the quantity of cDNA 
generated for each sample by the PCR reaction. For each target gene and 18s, the log total 
cDNA (ng) was interpolated by dividing the sample’s CT value minus the intercept, divided 
by the slope.  




Figure 2.4.  An example of a standard curve used to interpolate cDNA concentrations from 
CT values. 
The cDNA quantity mean and standard deviation of the technical duplicates was 
calculated, followed by the cDNA quantity mean and standard deviation of the biological 
replicates (i.e. all labouring samples and all non-labouring samples). The mean values for 
target genes were divided by  the mean values for 18s to give normalised cDNA quantities 
of target genes. The standard deviations of these normalised values were calculated using 
the coefficients of variation. The fold change in normalised target gene cDNA quantity 
from non-labouring to labouring samples was calculated by dividing the normalised target 
gene cDNA quantity for labouring samples by the normalised target gene cDNA quantity 
for non-labouring samples. The standard deviation of this fold change was calculated using 
the coefficient of variation for labouring samples.  
2.1.14  M ICROARRAY META-ANALYSIS 
In addition to the wet-lab validation of this microarray, a meta-analysis was also 
conducted to assess how the results compare to the published results of similar 
microarrays. Ramasamy et al. (178) provided useful guidelines for the conduct of this 
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meta-analysis. The chosen meta-analysis technique was similar to that used by Hu et 
al.(182). The microarray experiment described in this thesis is referred to as “Sharp 2013” 
for the purposes of the meta-analysis. 
2.1.14.1  SEARCH STRATEGY  
A systematic approach was used to search the literature to identify all eligible studies and 
minimise the effect of bias that would arise from selectively choosing which studies to 
include. The online repositories of abstracts PubMed (http://www.pubmed.gov/), Google 
Scholar (http://scholar.google.com/),  Web of Science (http://wos.mimas.ac.uk) and 
SCOPUS (http://www.scopus.com), and the microarray data repositories Array Express 
(http://www.ebi.ac.uk/arrayexpress/) and Gene Expression Omnibus 
(GEO)(http://www.ncbi.nlm.nih.gov/geo)  were searched using the following search 
terms: “myometrium” and “microarray”, “uterine smooth muscle” and “microarray”, 
“myometrium”, “myometrial”, “uterine smooth muscle”. 
2.1.14.2  INCLUSION -EXCLUSION CRITERIA  
Any human studies investigating myometrial gene expression in labouring or non-
labouring pregnant women were included in the meta-analysis. Criteria for excluding 
studies were as follows: 
 No human samples. 
 No myometrium samples. 
 Myometrium collected from a location other than the lower uterine segment. 
 No pregnant samples. 
 No opportunity to compare labouring to non-labouring myometrial samples. 
 Study does not report the results of a microarray experiment, or is a review. 
 Samples were prepared from cells in culture rather than tissue.  
 Tissue samples were cultured and/or treated before RNA extraction. 
2.1.14.3  DATA IDENTIFICATION AND A CQUISIT ION  
Where the raw data had not been made available via an online repository, authors were 
contacted.  Despite this effort, the data for only three studies (Bukowski 2006 (55), 
O’Brien 2008 (119), Weiner 2010 (115)) could be included in the meta-analysis, along 
with Sharp 2013.  O’Brien provided normalised data on request via email. The Bukowski 
(accession number E-MEXP-106) and Weiner (accession number GSE9159) raw data were 
downloaded from ArrayExpress. 
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2.1.14.4  PREPROCESSING  
Where possible, arrays were preprocessed consistently to remove any systematic 
differences. The CVS Bioinformatics team subjected the Sharp 2013, Weiner 2010 and 
Bukowski 2006 arrays individually to RMA background correction before quantile 
normalisation to remove non-biological variation. Due to the small sample size, the 
O’Brien 2008 array did not undergo consistent preprocessing. Instead, the preprocessed 
data (method not reported) supplied by the authors was analysed. 
2.1.14.5  ANNOTATION MATCHING  
The CVS Bioinformatics team used the annotation packages in BioConductor to map probe 
IDs to Entrez Gene IDs, Ensemble IDs, UniGene IDs, UniProt IDs, Gene symbols, gene 
descriptions and GO Terms, as described for Sharp 2013 above. 
2.1.14.6  DETERMINING BACKGROUN D CUT-OFF FOR EACH STUDY  
The background expression level for each study was determined by comparing the study-
specific expression of certain genes to their expression in Sharp 2013, which acted as a 
reference. The background level in Sharp 2013 was set at 100 (explained above), so all 
genes with a mean expression (over all samples) of between 99.9 and 100.1 in Sharp 2013 
were selected as “at background level”. Official Gene IDs of these genes were used to 
search datasets from the other studies. Six of these genes appeared on all four arrays. The 
mean expression values of these genes were roughly rounded to give the background level 
for each array. Figure 2.5 shows a plot of the expression values of each of these genes for 
each study and indicates that there is not much variation between the “at background” 
genes. The graph includes two genes expected to have low expression (DCX, double cortin, 
which is known to be expressed exclusively in brain tissue, and LIPC, hepatic lipase, which 
is known to be expressed in the liver and adrenals), and two genes expected to have high 
expression (TAGLN, transgelin, which is expressed in fibroblasts and smooth muscle, and 
HBB, beta globin, which is a constituent of the most common form of haemoglobin in adult 
humans). These genes show the range of expression values exhibited in each array, and 
fall the expected side of the background cut-off. For each array, the background cut-off 
levels were set at: 
 Bukowski 2006 = 5 
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 O’Brien 2008 = 10,000 
 Weiner 2010 = 150  
 (Sharp=100). 
 
Figure 2.5.  Determining the background expression cut -off for each study. A plot of each 
study’s expression values for two genes not expected to be expressed (DCX, LIPC), s ix 
genes expected to be expressed at around background level (GTF3C2, MALMLD1, SLC1A3, 
TACC2, TYMS, WNK1) and two genes expected to show high expression (HBB, TAGLN), 
compared to their expression in Sharp 2013. 
2.1.14.7  ASSESSING DIFFERENTIA L EXPRESSION BETW EEN  GROUPS FOR 
INDIVIDUAL AND COMBINATIONS OF STUDIES  
For each study individually, CVS Bioinformatics used R package Limma to assess 
differential expression between groups, as described above for Sharp 2013. CVS 
Bioinformatics built this data into a filterable database that could be used to filter 
differentially expressed genes by specifying fold-change and adjusted-P-value/RP-PFP 
criteria for each study individually. Searches can be combined to give lists of genes for 
which criteria is true across studies, for example, a search could identify all genes 
upregulated > 1.2 with a P-value of <0.05 in Sharp 2013 and Weiner 2010. 
2 – Methodology 
 
47 
I identified differentially expressed genes by filtering out genes below study-specific 
background cut-offs in both labouring and non-labouring samples, and using an arbitrary 
but liberal fold-change cut-off of >+/<- 1.2  and a rp-pfp value <0.05.  
Lists of differentially expressed genes were produced for each study individually and for 
agreed genes in each combination of studies (i.e. Sharp 2013 and Weiner 2010, Sharp 
2013 and Bukowski 2006, Weiner 2010 and Bukowski 2006, and Sharp 2013, Weiner 
2010 and Bukowski 2006). O’Brien 2008 could not be included in these searches because 
no RP-PFP value could be calculated for this study, and all adjusted P-values were non-
significant (>0.05). 
To visualise the number of differentially expressed genes in each study and how well 
studies agree, a proportional Venn diagram was created using an online tool at 
http://apps.bioinforx.com/bxaf6/tools/app_venndiagram.php. This is described as a valid 
technique in Ramasamy et al.(178). 
2.1.14.8  FUNCTIONAL ANALYSIS  
Functional analysis was performed on lists of official gene symbols representing 1) down-
regulated genes (fold change <-1.2 and RP-PFP ≤0.05) and 2) up-regulated genes (fold 
change >1.2 and RP-PFP ≤0.05) for each study individually. The same technique was also 
applied to lists of genes each combination of studies agreed to be differentially expressed. 
Again, these analyses could not be conducted using the O’Brien data. Gene lists were 
uploaded to DAVID and assessed for biological process GO term enrichment and KEGG 
pathway enrichment. 
Lists of GO terms found to be associated with labour by each study were also compared 
using a proportional Venn diagram, as described above. 
2.1.14.9  RESOLUTION OF THE MAN Y-TO-MANY ISSUE BETW EEN P ROBES AND 
GENES  
Where multiple probes exist for the same gene, searches were carried out over all probes. 
To investigate single genes in more detail, genes were ‘summarised’ as described above for 
Sharp 2013. 
 
2 – Methodology 
 
48 
2.1.14.10  META-ANALYSIS  TECHNIQUE  
In order to understand whether or not individual studies agreed on the direction (up 
regulated or down regulated) of the difference in expression between labouring and non-
labouring samples, and to give an idea of heterogeneity between studies, Forrest plots of 
the effect sizes were created. Forrest plots list the names of the studies on the left-hand 
side and plot the measure of the effect (for example, a fold-change) as a square with 
confidence intervals on the right. The area of each square is proportional to the weight of 
the study in the meta-analysis. The overall ‘summary’ meta-analysed measure of effect is 
also plotted, often plotted as a diamond with the lateral point indicating the confidence 
intervals. A vertical line is plotted to represent the point of no effect. Forrest plots were 
drawn for each gene that was agreed to be significantly differentially expressed in Sharp 
2013, Weiner 2010 and Bukowski 2006. The O’Brien 2008 results were also included on 
the Forrest plots. Forrest plots were also drawn for genes that have previously been 
associated with labour, and genes used to validate Sharp 2013 by q-PCR. 
Two approaches to create the forrest plots were tried. Firstly, GraphPad Prism was used to 
plot the study-specific effect sizes as the log2 ratio of the mean expression values for 
labouring and non-labouring samples. Confidence intervals for the ratios were conducted 
using Fieller’s theorem (195) and by writing an R function to do the calculation (see 
Appendix 3). The overall ‘summary’ effect size was calculated as the mean of the other 
study-specific effect sizes, and the confidence intervals for these were calculated as the 
95% confidence intervals of that mean. This approach provided easy to interpret plots, but 
there was no way to change the size of the square to indicate the weight of the study, and 
the summary effect size was not adjusted for the weight of the studies. Additionally, when 
the confidence interval of the denominator (non-labouring) mean includes zero, the 
confidence interval of the mean ratio could not be calculated. 
Instead, a more robust approach was taken utilising Review Manager, which was 
developed specifically for performing Cochrane systematic reviews and meta-analyses. 
Study-specific effect sizes were plotted as the standardised mean difference between 
labouring and non-labouring samples. The standardised mean difference was used 
because all the studies assess the same outcome (differential expression) but assess it in a 
variety of ways (using different platforms, leading to different expression value scales). 
The results of each study must be standardised to a uniform scale before they can be 
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combined. A random effect model was then used to integrate the study-specific effect sizes 
and give an overall summary measure of effect that takes into the weight of the study into 
account. A random effects model was used rather than a fixed effects model to allow for 
both within-experiment sampling error (variance) and between-studies variation to be 
included in the calculation of the confidence interval. To assess heterogeneity, Review 
Manager also reports the results of a Chi2 test (to test whether the observed differences 
are compatible with chance alone) along with the Tau2 statistic (an estimate of the 
between-study variance in the random-effects meta-analysis). If the Chi2 statistic is 
significant at P<0.1 then there is likely to be substantial heterogeneity. Similarly if Tau2 is 
more than 1 there is likely to be substantial statistical heterogeneity. 
2.2 IN SILICO MODEL  
The results of these analyses are discussed in Chapter 4. 
In silico models translate biological systems into mathematical representations that can be 
used to simulate the behaviour of that system. Models can be built at several levels using 
various approaches. For this PhD, an in silico model of a key signalling pathway in preterm 
birth (lipopolysaccharide (LPS)-induced activation of Nuclear Factor kappa B (NF-κB)) 
was built using published data and an ordinary differential equation (ODE) approach.  
2.2.1  CHOICE OF MODELLING T ARGET 
When modelling a system as complex as human parturition, it is especially important to 
clearly define, and limit, the scope for the model. So rather than attempt to model all the 
elements of a system concurrently, it is more sensible to focus on a single aspect, such as a 
functionally relevant intracellular signalling pathway, and model that accurately before 
building in more elements (202). Intracellular signalling pathways allow cells to respond 
to extracellular stimuli in order to perform their functions and survive. They are 
particularly appropriate targets for computational models, because they are relatively 
simple (in comparison to systems at the tissue or organ level for example) and they can be 
observed and manipulated in vitro. Models of such pathways are increasingly appearing in 
the literature thanks to recent advances in the quality, quantity and availability of 
modelling software and experimentally-derived parameter data (202). 
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Here, to maximise the likelihood that sufficient published data would be available, a well 
characterised pathway was chosen to model: lipopolysaccharide (LPS)-induced 
translocation of nuclear factor kappa B (NF-κB) p65-p50 heterodimer to the nucleus. The 
reasons for choosing this pathway are discussed in more detail in Chapter 4. 
2.2.2  CHOICE OF MODELLING APPROACH  
Dynamic models that describe the behaviour of the system over time are most useful for 
studying signalling pathways (202), and the most well-established way to do this is using 
deterministic models based on ordinary differential equations (ODEs) (203). ODEs have a 
well-established biophysical basis and straightforward molecular interpretation. ODE 
models are very comprehensive because they include all the known molecular entities in a 
system and quantitatively describe the kinetics of each physical interaction between them. 
This increases the likelihood that the model will allow us to fully understand and 
manipulate the complex behaviour of the system (203). 
Furthermore, ODE models are highly detailed and require specific information about 
initial concentrations of reactants and rates of reactions (kinetic parameters). Therefore 
attempting to build a kinetic ODE model using solely published data is a challenge and a 
good test of the current level of knowledge and data accessibility. 
An approach using partial differential equations (PDEs) was also considered, because this 
approach often allows more in-depth kinetic analysis. However, the PDE approach 
requires even more specific data (for example, on spatial distribution of molecules within 
cells). Therefore, due to limited data availability, we favoured an ODE approach.  
2.2.3  L ITERATURE SEARCH  
Comprehensive searches of the current literature are necessary to provide specific 
information on the structure of the pathway, its expected behaviour and reaction kinetic 
parameters such as initial concentrations of reactants and reaction rates. Searching 
databases of abstract repositories can be frustrating because papers often depict 
signalling pathways using simplified diagrams, with little information about the specific 
interactions between the components of the pathway. Curated pathway databases are 
more useful for gathering specific information, particularly annotated databases that link 
to the primary literature.  
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For this PhD, searches were conducted of the abstract repository PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) and the curated pathway databases KEGG 
(http://www.genome.jp/kegg/), Nature Pathway Interaction Database 
(http://pid.nci.nih.gov/) and Reactome (http://www.reactome.org/). Previously 
described computational models of NF-κB activation in scenarios outwith pregnancy(204–
206) were also useful for finding reaction kinetics and were accessed via Biomodels 
(http://www.ebi.ac.uk/biomodels-main/), the online database of peer-reviewed 
published models. Figure 2.6 shows terms that were used to conduct these searches. 
 
Figure 2.6.  Search terms can be broadly grouped into three categories: 1) parturit ion-
related terms, 2) pathway  components and related terms , and 3) computational biology 
terms. Searches were carried out with in dividual search terms and various combinations.  
2.2.4  GRAPHICAL REPRESENTAT ION  
Graphical representations of all the reactions in a model are useful when building or 
interpreting the model. They depict every entity (for example a protein or a complex), the 
reactions they are involved in, and in what way they react (binding, phosphorylation, etc.). 
The graphical depiction acts as a blueprint to the static structure of the model. 
It is helpful to use a standard graphical notation that can be interpreted precisely and 
unambiguously by scientists from different disciplines. Examples include Systems Biology 
Graphical Notation (SBGN)(207) and modified Edinburgh Pathway Notation (mEPN) 
(208), which have both been developed over several years by biochemists, modellers and 
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computer scientists. These notations use a set of symbols to represent the different 
components, reactions, relationships and cellular compartments in the pathway. A range 
of tools exists to build and edit topological maps of pathways. SBGN maps can be built 
using dedicated pathway editing tools such as CellDesigner (209) and mEPN maps can be 
loaded using general network and visualisation software such as yED (210). Both 
approaches were used in this PhD. Reference keys for SBGN (process description) and 
mEPN are shown in Appendix 4. 
2.2.5  MODEL DEVELOPMENT  
A graphical representation is useful for visualising a pathway, but to turn it into a 
quantitative computational model differential equations must be generated to describe 
each reaction. There are many tools designed to help researchers create, simulate and 
analyse computational models. Copasi (211) is a particularly intuitive, purpose-built tool 
that is freely available for academic use. It can import and export models in systems 
biology mark-up language (SBML), which is particularly beneficial because SBML is a 
universal programming language that is software-independent. SBML models built in 
Copasi are compatible with different programs and can be made available to other 
researchers via online repositories (160). 
Reaction equations are generated to describe each reaction in the topological map. These 
follow a simple format where a binding reaction could be represented by: 
“SUBSTRATE A” + “SUBSTRATE B” = “PRODUCT C” 
 Where “SUBSTRATE A” binds to “SUBSTRATE B” to produce a complex called 
“PRODUCT C”. The reaction is reversible, as indicated by the equals sign. 
An enzymatic reaction could be represented by: 
“SUBSTRATE A” -> “PRODUCT C” ; “ENZYME D” 
 Where “PRODUCT C” is converted from “SUBSTRATE A” via a reaction 
catalysed by “ENZYME D”. Reaction modifiers are separated from the main 
reaction by a semi-colon. The reaction is irreversible, as indicated by the 
unidirectional arrow, “->”. 
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Entering these reaction equations into Copasi generates a list of all the necessary ‘species’ 
(components of the pathway). Each reaction is automatically assigned an ordinary 
differential equation to describe its rate. As a default this is generated according to mass-
action kinetics, but this can be changed to one of the default rate equations in Copasi (such 
as Michaelis-Menten, which is more commonly used to describe enzymatic reactions) or a 
custom, user-defined rate equation. 
Copasi was used to develop the LPS–NF-κB pathway model described in this PhD. The 
structure of the IκB-NF-κB signalling portion of the model is largely based on a high 
quality model developed by Hoffmann et al. (204).  All other portions of the model were 
based on information derived from the literature. The final model was developed through 
successive rounds of model building and simulation within Copasi. Model development 
was performed by myself, with guidance from Dr Hongwu Ma. 
Throughout the modelling process, model refinements were made to ensure the model is 
accurate but simple: 
 Initially the formation of the receptor complexes was modelled using separate 
reactions. For example: 
o LPS + LBP = LPS:LBP 
o LPS:LBP + CD14 = LPS:LBP:CD14 
o LPS:LBP:CD14 + TLR4 = LPS:LBP:CD14:TLR4 
o LPS:LBP:CD14:TLR4 + TIRAP = LPS:LBP:CD14:TLR4:TIRAP 
o LPS:LBP:CD14:TLR4:TIRAP + Myd88 = 
LPS:LBP:CD14:TLR4:TIRAP:MyD88 
o LPS:LBP:CD14:TLR4:TIRAP:MyD88 +  IRAK4 = 
LPS:LBP:CD14:TLR4:TIRAP:MyD88:IRAK4 
o LPS:LBP:CD14:TLR4:TIRAP:MyD88:IRAK4 + TRAF6 = 
LPS:LBP:CD14:TLR4:TIRAP:MyD88:IRAK4:TRAF6 
This represents the order of pathway events described in the literature. However, 
these are a linear series of mass-action reactions, which are now modelled more 
appropriately as a single mass action reaction: 
o LPS + LBP + CD14 + TLR4 + TIRAP + MyD88 + IRAK4 + TRAF6 
= LPS:LBP:CD14:TLR4:TIRAP:MyD88:IRAK4:TRAF6 
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 All the enzymatic phosphorylation reactions are reversible, meaning that the 
dephosphorylation step is incorporated in the Michaelis-Menten ODE. The reference 
to the phosphatase is omitted because its total concentration can be considered 
constant and, unlike the kinase, it does not need to be activated by the pathway. 
Furthermore, less is known about phosphatase concentrations, specificities and 
kinetic parameters than is known about the kinase enzymes, so incorporating more 
detailed information about the dephosphorylation step would be difficult. 
 Iterative rounds of model development and simulation (described below) were 
completed until the model was able to recapitulate the timecourse of active NF-κB 
reported in the literature (205). For example, early versions of the model showed the 
TRIF-dependent pathway was having more of an effect on IKK phosphorylation and 
downstream NF-κB activation than the MyD88-dependent pathway. This is the 
opposite of what is reported in the literature. The problem was traced to the TRIF-
dependent pathway producing very high levels of TNFα, which meant none of the 
reactions downstream of TNFα were rate-limited. Therefore, we altered the values of 
parameters involved in the production of TNFα. 
2.2.6  MODEL SIMULATION  
When all the reactions have been added, the model’s behaviour can be analysed. The 
stability of the model can be ascertained by its ability to reach a steady-state (at which 
components are no longer changing over time). The behaviour of the components of the 
model over time can be analysed by calculating a time course. Plots of the time course 
trajectory are useful for analysing model behaviour. If the model is not behaving as 
expected it may be necessary to deconstruct the model to find which parameters to 
amend. 
The final model was produced after successive rounds of simulation and model parameter 
adjustments to fit published data.  To run the final model, initial concentrations are first 
updated to reflect the steady-state concentrations with LPS = 0 µmol/ml. This represents 
the initial steady-state of the cell before treatment. LPS treatment is then simulated by 
running a time course simulation with LPS arbitrarily set at 1 µmol/ml. The model was 
run for 250 minutes (model time). This produces graphs showing the concentration of 
each non-fixed model species over time. 
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The behaviour of the model was compared to published behaviour of the system in vitro. 
An attempt was made to test the ability of the in silico model to recapitulate the in vitro 
behaviour of the system when either of two proteins (Myeloid Differentiation Primary 
Response Gene 88 (MyD88) and Tir-Domain-Containing Adapter-Inducing Interferon-β 
(TRIF)) in the pathway are knocked out.  The in vitro behaviour is published in Covert et 
al. (205) ‘Knock-out’ models were created by fixing the concentration of either of the 
proteins to 0 (thus removing their contribution) and running simulations as described for 
the full model. The model was developed under “wild-type” conditions , and tested under 
“wild-type”, MyD88- and TRIF- “knock-out” conditions. Several “tests” and subsequent 
changes to the wild-type model were made during model development. 
2.3 A  NETWORK GRAPH OF EPIDEMIOLOGICAL DATA 
The results of these analyses are discussed in Chapter 5. 
As mentioned above, representing large datasets visually as network graphs makes it 
easier for humans to infer relationships and identify structural patterns. Network graphs 
also allow interactive analysis of the data and provide an unbiased insight into how data 
points cluster. The network graph tool Biolayout Express3D was first developed to visualise 
and analyse gene expression data; its use for this purpose is described above. In theory 
however, the tool can be used with any large datasets to explore complex systems of 
interaction. These include patient health record databases to explore interactions between 
different health characteristics and disease outcomes.   
For this PhD, a network graph approach to study epidemiological data was conducted for 
the first time. Using birth data collected for the Walker cohort, several options for using 
this approach were explored. 
2.3.1   THE WALKER COHORT  
The Walker cohort (212) is a dataset of 48985 birth records that contains meticulously 
recorded details of pregnancy, labour and care before discharge for births in hospital in 
Dundee between 1952 and 1966. These babies accounted for 75% of all births in Dundee 
at this time (212). 
Data was collected by Professor James Walker and his senior obstetric colleagues on 
purpose-written record cards according to a predefined dataset. Three types of card were 
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used (Card 0 for 1952-58, Card 1 for 1959-63, and Card 2 for 1964-66), with an increasing 
number of details being recorded on each.  
The written data from the cards were computerised between 2000 and 2001. The date of 
birth and sex of each baby was used to identify the Community Health Number (CHI 
number), which is a unique personal identifier assigned to all people registered with a 
general practitioner in Scotland. These CHI numbers allow linkage of Walker data to 
demographic data such as postcode, Scottish Index of Multiple Deprivation score, and date 
of death. 
2.3.2  DATA PREPARATION  
2.3.2.1  RAW DATA PREPARATION  
The Health Informatics Centre (HIC) at the University of Dundee stores and maintains the 
Walker data. They provided access to the data via a secure online environment. The data 
was provided as a separate comma delimited file for each Walker card, in which each row 
represented a delivery, usually identified by the CHI number of the baby. Card 0 contained 
20683 deliveries, Card 1 contained 15132 deliveries and Card 2 contained 13170 
deliveries. All delivery records were unique (i.e. there were no erroneous duplicates). CHI 
numbers were used to record link to demographic and additional birth information 
provided in separate comma delimited files. Records were linked using the =lookup() 
function in Microsoft Excel. 
All three cards with additional variables obtained through linkage were merged to create 
one spreadsheet containing all 49585 deliveries. The variables present in this file are 
listed in Appendix 5. 
2.3.2.2  DATA CLEANING  
Large datasets often contain a proportion of inaccurate datapoints, introduced through 
human error either at data collection or computerisation. Most of the Walker data is 
binary (1=characteristic is present, 0=characteristic is absent), so inaccurate data is 
difficult to identify if it is simply recorded as the opposite value.  
Some of the binary variables listed in Appendix 5 were derived from continuous variables 
(see below) that first had to be ‘cleaned’ to identify and remove inaccurate data. If not 
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removed, this data will introduce bias and distort the results of analyses. A useful, 
objective way to identify these data points is to use a statistical method to detect ‘outliers’ 
– measurements that significantly deviate from what one would expect based on the rest 
of the data.  
Here, outliers were usually defined as any value falling outside of a certain percentage of 
the data. This was considered to be a more accurate method than using the standard 
deviation or variance to define outliers, because these statistics are calculated using the 
entire data set and are therefore “dirtied” to some degree by the outliers themselves, 
whereas the median and percentiles are more robust to errors in the data (213). 
Before defining outliers, all 0 values were deleted. Table 2.4 lists the method of outlier 
identification for each continuous variable. 
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Table 2.4.  The method of outlier identification for each continuous variable.  
Variable name Outlier definition Comment 
Crown heel length (cm) 
<1st percentile (<33.02) and 
>99th% (>58.105). 19 values 
removed. 438 values removed. 
Variable seemed particularly 
noisy so a smaller range was 
used to identify non-outliers. 
Crown rump length (cm) 
<1st percentile (<24.8) and 
>99th% (>58.42). 168 values 
removed.  
Variable seemed particularly 
noisy so a smaller range was 
used to identify non-outliers. 
Gestation (weeks) 
<23 and >44 weeks. 10 values 
removed. 
Determined using knowledge of 
the usual range of gestational 
ages at delivery. 
Head circumference (cm) 
<1st percentile (<27.5) and 
>99th% (>39.3). 233 values 
removed. 
Variable seemed particularly 
noisy so a smaller range was 
used to identify non-outliers. 
Birth weight (g) 
<0.1 percentile (<623.7) and 
>99.9% (>5274.6). 95 values 
removed. 
 
Discharge weight (g) 
<0.1 percentile (<2012.8) and 
>99.9% (>4918.3). 19 values 
removed. 
 
Paternal age <13 and >72. 9 values removed. 
Determined using an estimate 
of the usual range of paternal 
ages. 
Maternal age 
<13 and >60. 17 values 
removed. 
Determined using an estimate 
of the usual range of maternal 
ages. 
Paternal height (cm) 
<0.1 percentile (<149.86) and 
>99.9% (>194.74). 18 values 
removed. 
 
Maternal height (cm) 
<0.1 percentile (<135.255) and 
>99.9% (>180.34). 44 values 
removed. 
 
Placenta weight (g) 
<0.1 percentile (<141.75) and 
>99.9% (>3316.9). 18 values 
removed. 
 
2.3.2.3  CONVERTING CONTINUOUS  DATA TO BINARY  
Variables containing imperial measurements were first converted to metric.  Continuous 
variables were then converted to binary variables according to ranges of values. For 
example, information in the continuous variable “B_BIRTHWEIGHT_G” (birth weight in 
grams) was used to create two discrete variables “B_BIRTHWEIGHT_OVER4KG” (birth 
weight over 4kg) and “B_BIRTHWEIGHT_UNDER2.5kg” (birth weight under 2.5kg). This 
discretising of continuous variables was necessary to ensure all variables were in the same 
register. If not converted, a continuous variable would have a disproportionately high 
influence on the overall topology of the network graph. 
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The methods used to create binary variables from continuous variables are explained in 
the table in Appendix 5.  
2.3.3  OBSTETRIC CHARACTERISTIC GRAPH  
A graph was produced in which each node represented a Walker variable (i.e. an obstetric 
characteristic such as small placenta weight or extreme preterm birth). The aim of this 
was to produce a graph to visualise how variables are associated with each other, and 
explore how informative MCL clusters might be in generating hypotheses about these 
relationships. 
To create this graph, the prepared Walker data (48985 births, 148 variables) was loaded 
into R and converted to a correlation matrix using the cor() function (Appendix 3). The 
correlation matrix contains Pearson correlation values for each pairwise comparison of 
variables. The matrix was exported from R to MS Excel where missing values (where it 
was impossible to calculate a Pearson correlation value due to there being no cases with 
information on both variables) were assigned a correlation coefficient of 0. It was also 
necessary to convert negative values to 0 to avoid crashing Biolayout Express3D. Pairwise 
comparisons for which all correlated values were 0 were deleted, leaving 108 variables. 
The matrix was saved as a .matrix file and loaded into Biolayout Express3D. Graphs were 
inspected visually at varying correlation coefficient threshold levels to assess their 
informativeness. Eventually a threshold value of 0.2 was chosen. Any correlation values 
below this were not incorporated into the graph. This produced a graph in which the 
structure could be viewed easily and the number of meaningful (higher) correlations was 
maximised while less meaningful (lower) correlations were not included. 
The MCL algorithm was run with an inflation value of 2.2 and a minimum cluster size of 3 
to define the boundaries of clusters in an objective, unbiased manner. Other values were 
explored, but these produced the cleanest, most informative clusters. 
2.3.4  DELIVERY EPISODE GRAPH  
Larger graphs were also produced in which each node represented a different delivery 
episode (case). The aim of this was to produce graphs to visualise how deliveries cluster 
according to certain similar characteristics. Again, this allows exploration of how variables 
are associated with each other. 
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Data was loaded into Biolayout Express3D as .expression files, which cannot contain any 
missing values. In .expression files, each row represents a different delivery episode and 
each column contains data on a different variable. Missing values cannot simply be 
replaced with zeros because this would skew the binary data. Replacing all 0 values 
(characteristic absent) with -1 and changing all missing values to 0 also skewed the data. 
Therefore, because some variables were unique to certain cards, missing values were 
minimised by splitting the data by card number. For each card, complete variables were 
retained and incomplete and/or less informative variables were formatted as “class sets”, 
whereby the information can be overlaid onto the graph by colouring nodes by class, but 
the information does not influence the graph topology. Data for each card was saved as a 
separate .expression file and loaded separately into Biolayout Express3D. 
A threshold value of 0.8 was set. Any correlations below this value were not incorporated 
into the graph. The MCL algorithm was run with an inflation value of 2.2 and a minimum 
cluster size of 3. Again, graphs were explored at a variety of threshold, inflation and 
minimum cluster size values, but these values provided the most informative, clear graphs. 
2.4 THE EPIDEMIOLOGY OF POSTPARTUM HAEMORRHAGE 
The results of these analyses are discussed in Chapter 6. 
The historical nature of the Walker cohort allows birth information to be linked with a 
large number of current health-outcome databases and allows linkage of records across 
siblings and over generations. For this PhD, the Walker cohort was linked to a current 
database of maternity information, SMR02, to investigate intergenerational transmission 
of postpartum haemorrhage. 
2.4.1  THE COMMUNITY HEALTH IDENTIFIER (CHI) 
Since the 1970’s, people living in Scotland have been allocated a unique Community Health 
Identification (CHI) number, which is used on all their health records. This allows record 
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2.4.2  THE WALKER COHORT  
The Walker cohort is described above in section 2.31.  34183 (73%) of Walker babies can 
be identified through their CHI number, and this presents the opportunity to link this birth 
information with a large number of current health-outcome datasets covering both 
primary and secondary care.  
2.4.3  SCOTTISH MORBIDITY RE CORDS –  MATERNITY ADMISSIONS  (SMR02) 
The Information Services Division (ISD) Scotland provides SMR02 data to HIC. 
The Scottish Morbidity Records Maternity Admissions dataset (SMR02) contains detailed 
information on hospital maternity admissions in Tayside, Scotland collected from January 
1975 to present.  
2.4.4  DATA EXTRACTION AND R ECORD LINKAGE 
The Health Informatics Centre (HIC) at the University of Dundee provided anonymised 
data from Walker and SMR02 in separate delimited text files. I then used the CHI number 
to record-link between the two datasets using the merge function in SPSS. 
From Walker, HIC extracted data on the births of all Walker babies who could be identified 
in SMR02 as having had a child themselves. Each Walker record was identified by the 
baby’s CHI, with 65.5% (n=2532) also having information about the mother’s CHI. From 
SMR02, HIC extracted all records that could be linked to the extracted Walker records 
using the CHI number. Each birth was identified by the mother’s CHI, with 70% (n=15043) 
of births also having information about the baby’s CHI. They extracted all records 
matching the CHI number of the Walker babies, and records matching the CHI number of 
the daughters of the Walker babies. 
HIC also provided a separate delimited text file containing demographic information for 
each CHI number. This file was also record linked to the birth information. 
2.4.5  THE GENERATIONS 
I identified data on three generations of women, defined as follows: 
 Generation 1 - Walker Mothers – Women who appear in the Walker cohort as 
mothers. 
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 Generation 2 - SMR02 Mothers – Women who appear in the Walker cohort as 
babies, and the SMR02 cohort as mothers. 
 Generation 3 - SMR02 Daughters – Women who appear in the SMR02 cohort as 
babies, and also as mothers if they have had children themselves. 
2.4.6  CLASSIFICATION OF POS TPARTUM HAEMORRHAGE  
In the Walker dataset, there is information about postpartum haemorrhage (PPH) stored 
as a dichotomous variable (no PPH = 0, PPH = 1) for the earliest Walker births only (born 
1952-1958). For later Walker births, there exists a variable called “RET_PLAC_PPH”. 
Unfortunately no further information was available to define this variable. It could be 
interpreted as indicating the occurrence of PPH associated with retained placenta, 
however the prevalence would have been much higher than that reported in the literature 
and in SMR02. Because of this ambiguity, this variable was not used to classify PPH. This 
greatly reduced the number of records that could be included in the analyses. 
In SMR02, outcomes are coded according to the International Classification of Diseases 
(ICD9 and ICD10). Table 2.5 shows the codes used to indicate PPH as an outcome.  These 
were used to create a dichotomous variable to indicate PPH in the same way as in the 
Walker cohort. 
Table 2.5.  International Classification of Diseases (ICD) 9 and 10 codes used to identify 
postpartum haemorrhage (PPH) in SMR02 birth records.  
Cause of PPH ICD-9 code ICD-10 code 
Third stage (associated with retained, trapped or adherent placenta) 666.0 O72.0 
Atonic (after placenta delivery) 666.1 O72.1 
Delayed and secondary PPH (associated with retained portions of 
placenta) 
666.2 O72.2 
Coagulation defects 666.3 O72.3 
2.4.7   DATA CLEANING  
It was necessary to prepare the data before analysis to remove records and datapoints 
that would otherwise have introduced bias. All data preparation was performed using 
SPSS version 19 (IBM).  
In SMR02, admissions that did not result in delivery of a child (for example, abortions or 
early miscarriages) were removed. Stillbirths of a baby >500g were included. Deliveries 
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where no further information about the delivery was provided were also excluded, 
because it was impossible to determine whether or not the delivery was associated with 
PPH. Variables were checked, and unlikely values were changed to missing values (for 
example, missing data was often coded as 99, and therefore at risk of being analysed as a 
real value). For continuous variables, any value falling outside a ‘sensible’ range based on 
clinical knowledge. Outliers were changed to missing values. 
In Walker, 13 duplicate baby CHIs with differing birth information were identified and 
deleted. Variables containing imperial measurements were converted to metric.  For 
continuous variables, again any data under the 1% percentile or over the 99th percentile 
were changed to missing values. 
2.4.8  CONVERTING CONTINUOUS  VARIABLES TO CATEGOR ICAL VARIABLES  
Continuous variables were converted to categorical variables to aid interpretation of 
results. This was performed to create the following categorical variables: 
 PPH in a previous pregnancy – calculated by identifying all deliveries by the same 
mother and using the date of birth of the child and the PPH status for previous 
deliveries. 
 High birth weight – all birth weights recorded as ≥4kg = yes (1), all birth weights 
recorded as <4kg but not <2.5kg = no (0). <2.5kg = blank. 
 Low birth weight – all birth weights recorded as <2.5kg = yes (1), all birth weights 
recorded as ≥2.5kg but not ≥4kg = no (0). ≥4kg = blank. 
 Maternal age under 20-years-old – all maternal ages recorded as <20 = yes(1), all 
maternal ages recorded as ≥20 but not ≥40 = no (0). ≥40 = blank. 
 Maternal age over 40-years-old – all maternal ages recorded as ≥40 = yes(1), all 
maternal ages recorded as <40 but not <20 = no (0). <20 = blank. 
 Nulliparity – all deliveries where parity is 0 = yes (1), all deliveries where parity is 
>0 = no (0). 
 Preterm birth – all deliveries where gestation is ≤37 weeks = yes (1), all deliveries 
where gestation is >37 weeks but not ≥42 weeks = no (0). ≥42 = blank. 
 Post-term birth – all deliveries where gestation is ≥42 weeks = yes (1), all 
deliveries where gestation is <42 weeks but not ≤37 weeks = no (0). ≤37 = blank. 
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 Caesarean delivery – all deliveries via Caesarean section = yes (1), all normal, 
vaginal deliveries = 0, all other modes of delivery = blank. 
 Instrumental delivery – all deliveries by ventouse or forceps = yes (1), all normal, 
vaginal deliveries = 0, all other modes of delivery = blank. 
2.4.9  DATA ANALYSIS  
2.4.9.1  THE ODDS RATIO  
Estimates of the size of the effect of exposure variables on occurrence of PPH were 
reported as odds ratios (OR), which describe the ratio of odds of PPH given exposure 
status. The precision (an indication of the degree of random error in the estimate) of these 
ORs was indicated using 95% confidence intervals. 
The OR was favoured over the relative risk (RR) because the OR is deducible from the R 
output of multivariate logistic regression models. 
2.4.9.2  UNLINKED DATA  
Obstetric and demographic risk factors for PPH were assessed in the Walker and SMR02 
datasets, separately and as a pooled dataset. 
IBM SPSS Statistics version 19 (IBM Corp., Armonk NY), was used to perform a univariate 
analysis of the data. Unadjusted ORs were calculated to assess the effects of each of: PPH in 
a previous pregnancy, multiple pregnancy, high birth weight (using the World Health 
Organisation (WHO) definition of ≥4kg), low birth weight (using the WHO definition of 
<2.5kg), maternal age under 20-years-old (previously identified as a risk factor for PPH 
(64)), maternal age over 40-years-old (previously identified as a risk factor for PPH (64)), 
parity, preterm birth (using the WHO definition of ≤37 weeks’ gestation), post-term birth 
(using the WHO definition of ≥42 weeks’ gestation), delivery by Caesarean section, 
instrumental delivery and smoking status on risk of PPH in the index pregnancy. 95% 
confidence intervals were reported in the output from SPSS. 
To calculate adjusted ORs, factors identified as significant in the univariate analyses were 
built into a multivariate logistic regression model. The function glm() in the R package 
lme4 (214) (see Appendix 3) was used to run these models. The ORs were calculated as 
the exponential of the fixed effects coefficients reported in the R output, and 95% 
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confidence intervals were calculated as the exponential of these coefficients ± 1.96 
multiplied by the standard error (see Appendix 3). 
Results from the separate and pooled analyses were compared for differences that might 
indicate a cohort effect. 
2.4.9.3  L INKED DATA  
To assess intergenerational transmission of PPH, the CHI number was used to link records 
across generations as follows:  
 Generation 1 was linked to Generation 2 
 Generation 2 was linked to Generation 3 
 Generation 1 was linked to  Generation 3 
 Pooled mother-daughter analysis: mothers from Generations 1 and 2 were linked 
to daughters in Generations 2 and 3. 
For each of these comparisons, unadjusted ORs were calculated through logistic 
regression models using glm() in R package lme4 (214). These models assess the 
relationship between PPH in the younger generation (the dependent variable) and PPH in 
the older generation (the independent variable) without adjusting for any other potential 
covariates.   
A particular challenge was presented when statistically analysing this data, because the 
mother-daughter units were not independent of each other. The same women can appear 
in different mother-daughter/grandmother-granddaughter pairs (for example a woman 
could be a mother in the comparison of generations 2 and 3, but a daughter in the 
comparison in generations 1 and 2. Additionally, one woman could be a mother to more 
than one daughter). It is important to adjust for this non-independence, because  non 
independence invalidates the assumptions of many statistical tests and can introduce bias 
that can mask exposure effects. Therefore,  generalised linear mixed models (GLMMs) 
were built using the glmer() in R package lme4 (214). These models incorporated any 
other covariates found to be significantly associated with PPH in the univariate analyses, 
and also adjusted for the ‘random effects’ introduced through non-independence of the 
mother-daughter units. These random effects were included by building younger and 
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older generation CHI numbers into the model. The models follow a binomial distribution 
with a logit link because the presence of PPH is a dichotomous variable. 
Again, the ORs were calculated as the exponential of the fixed effects coefficients reported 
in the R output, and 95% confidence intervals were calculated as the exponential of these 
coefficients ± 1.96* the standard error. 
Professor Graham Horgan of Biomathematics and Biostatistics Scotland, and Daniel 
Ayoubkhani of the UK Office for National Statistics provided advice during model design. 
2.4.10  POWER ANALYSIS  
Where low power was suspected, the fe.mdor() function in the R package clinfun (215) 
was used to calculate the smallest effect size (OR) that the analyses would have been able 
to detect at 80% power based on the actual sample sizes. This is more correct than 
carrying out a ‘post-hoc’ power calculation using results generated through the analysis. 
Such analyses are misleading – if an effect is not significant, then by definition the power 
to detect that effect is very low. No new information is gained from carrying out the power 
analysis (216). 
2.5 A  COCHRANE SYSTEMATIC REVIEW  
The results of these analyses are discussed in Chapter 7. 
The Cochrane Collaboration Pregnancy and Childbirth Group publishes systematic reviews 
of health interventions and diagnostic tests involving the mother or baby during and after 
pregnancy and childbirth. For this PhD, I carried out a Cochrane systematic review of fetal 
assessment methods to improve neonatal and maternal outcomes following preterm 
prelabour rupture of membranes (PPROM).  
2.5.1  COCHRANE WORKFLOW  
The Cochrane Collaboration have precise guidelines on the process of preparing and 
maintaining Cochrane systematic reviews. These help to standardise reviews to make 
them easier to interpret and compare. The guidelines also act to minimise bias and 
improve the reliability of the review findings. Authors wishing to conduct a review are 
asked to choose from a list of available titles. They then complete a title registration form 
(Appendix 6), outlining the background, interventions and outcomes of the proposed 
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review, and giving details of the team of authors. There must be at least two authors, at 
least one of whom should be experienced at writing Cochrane reviews. For this PhD, the 
review team consisted of myself, and two experienced Cochrane reviewers, Dr Sarah Stock 
and Professor Jane Norman. Considering the expertise of this team and the other data 
presented in this thesis, the title “Fetal assessment methods for improving neonatal and 
maternal outcomes in preterm prelabour rupture of membranes” was chosen from the list 
as the most appropriate title to address. 
2.5.1.1  AUTHOR CONTRIBUTIONS  
I wrote the title registration form, protocol and review. I also performed all data extraction 
and analysis. In accordance with the Cochrane guidelines, Sarah Stock also independently 
extracted data, and I assessed our results for any differences. Sarah Stock and Jane 
Norman provided a clinical perspective and revised the protocol and review before 
submission. 
2.5.2  PROTOCOL  
In order to minimise the potential for bias in the review process, Cochrane require authors 
to produce a detailed protocol prior to conducting the review. This protocol outlines the 
methods to be used, which promotes transparency of methods and processes and reduces 
the impact of review authors’ bias. The protocol undergoes peer review and is published 
in the Cochrane Library. Any changes to the protocol must be justified in the final review. 
The published protocol(217) for the review carried out here is available at 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010209/full. The methods 
used to conduct the review are outlined below. 
2.5.3  CRITERIA FOR CONSIDER ING STUDIES FOR THIS  REVIEW   
2.5.3.1  TYPES  OF STUDIES    
All relevant published and unpublished randomised controlled trials (RCTs), quasi-RCTs 
and cluster-randomised trials were included. Crossover trials were excluded because this 
is an unsuitable design to study fetal assessment during pregnancy. It was planned that 
abstracts would be included if sufficient details were available and authors of abstracts 
would be contacted to obtain further information where necessary. 
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2.5.3.2  TYPES  OF PARTICIPANTS    
Women with PPROM before 37+0 weeks' gestation with no specific maternal or fetal 
contraindications to expectant management (defined by trialists). 
2.5.3.3  TYPES  OF INTERVENTION S   
All methods of fetal assessment that could detect fetal compromise and provide indication 
for early delivery. These include fetal movement counting, fetal cardiotocography, 
biophysical profiling, fetal and umbilical artery or venous Doppler ultrasound, fetal MRI 
lung volumetrics and amniocentesis for fetal lung maturity. Comparisons were made of 
any intervention versus no intervention and one intervention versus another intervention. 
2.5.3.4  TYPES  OF OUTCOME MEAS URES   
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Table 2.6.  Primary and secondary outcomes addressed in the review.  
Primary outcomes   
Fetal death (antenatal). 
Neonatal death (in the first 28 days of life). 
Maternal death. 
Serious maternal morbidity defined as: 1) septicaemia, 2) need for intensive care, 3) organ 
failure/need for ventilation, 4) need for hysterectomy. 
Secondary outcomes   
Maternal                          
Maternal chorioamnionitis (as defined by trialists). 
Major postpartum haemorrhage. 
Maternal endometritis (as defined by trialists). 
Mode of delivery. 
Induction of labour.                         
Postpartum maternal pyrexia (as defined by trialists).                            
Days of antenatal hospitalisation.                           
Days of postnatal hospitalisation. 
Total days hospitalisation.                            
Breastfeeding initiated in hospital.                           
Breastfeeding at hospital discharge.                            
Maternal satisfaction. 
Caesarean delivery. 
Spontaneous labour before 34+0 weeks. 
Maternal antibiotics after delivery. 
Time of maternal antibiotic treatment before labour (hours). 
Fetal                            
Gestational age at birth.                        
Days from randomisation/rupture of membrane to birth.                            
Birth within 48 hours after rupture of membranes.                            
Birth within seven days of rupture of membranes.                            
Birth before 37+0 weeks' gestation. 
Birth before 34+0 weeks' gestation. 
Birth before 28+0 weeks' gestation. 
Use of corticosteroids. 
Fetal sepsis. 
Neonatal                           
Postneonatal mortality - death after 28 days of life but before one year. 
Infant mortality - death at or after 12 months of age.     
Respiratory distress syndrome.                        
Use of surfactant.                            
Use of mechanical ventilation.                            
Days of mechanical ventilation.                            
Days of oxygen therapy.                           
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Oxygen treatment greater than 28 days.                           
Oxygen therapy at 36+0 weeks' gestation.                        
Birthweight. 
Birthweight less than 10th centile for gestational age.                       
Birthweight less than 2500 grams.                           
Birthweight less than 1500 grams.  
Admission to neonatal intensive care unit.                           
Length of stay in neonatal intensive care unit.                           
Days from birth to discharge home from hospital.                           
Major cerebral abnormalities on ultrasound prior to discharge.                           
Necrotising enterocolitis.         
Neonatal encephalopathy (as described by trialists).                      
Postural deformities (as defined by trialists).                        
Disability at time of childhood follow up (as defined by trialists).                    
Serious disability (as defined by trialists) after two years. 
Diagnosis of fetal distress in labour (as defined by trialists). 
Cardiotocographic abnormality in labour (as defined by trialists). 
Cord pH less than 7.00. 
Apgar scores less than seven at five minutes. 
Apgar scores over five at five minutes. 
Apgar scores. 
Intraventricular haemorrhage. 
Use of antibiotics. 
Days of antibiotic use. 
Neonatal infection. 
Neonatal sepsis. 










Days of postnatal hospitalisation (after discharge of mother). 
Retinopathy of prematurity. 
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2.5.4  SEARCH METHODS FOR ID ENTIFICATION OF STUD IES   
2.5.4.1  ELECTRONIC SEARCHES   
The Cochrane Trials Search Co-ordinator searched the Cochrane Pregnancy and Childbirth 
Group's Trials Register on 28th November 2012. The Trials Register is maintained by the 
Trials Search Co-ordinator and contains trials identified from: 
 monthly searches of the Cochrane Central Register of Controlled Trials 
(CENTRAL); 
 weekly searches of MEDLINE; 
 weekly searches of EMBASE; 
 handsearches of 30 journals and the proceedings of major conferences; 
 weekly current awareness alerts for a further 44 journals plus monthly BioMed 
Central email alerts. 
Trials identified through these searches are each assigned to a review topic (or topics). 
The Trials Search Co-ordinator searches the register for each review using the topic list 
rather than keywords. No language restrictions were applied. 
2.5.5  DATA COLLECTION AND A NALYSIS   
2.5.5.1  SELECTION OF STUDIES    
Two review authors (GS, SS) independently assessed for inclusion all the potential studies 
identified as a result of the search strategy. Any disagreement was resolved through 
discussion or, if required, consultation with a third person (JEN). 
2.5.5.2  DATA EXTRACTION AND M ANAGEMENT   
A data extraction form was designed (Appendix 7) and used to extract data from the 
studies. For eligible studies, two review authors (GS, SS) extracted the data independently. 
Discrepancies were resolved through discussion or, if required, consultation with a third 
author (JEN). Data was entered into The Cochrane Collaboration's statistical software, 
Review Manager, and checked for accuracy. 
2.5.5.3  ASSESSMENT OF RISK OF BIAS  IN INCLUDED STU DIES    
2 – Methodology 
 
72 
Two review authors (GS and SS) independently assessed risk of bias for each study using 
the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(218). Any disagreement was resolved by discussion or by involving a third author (JEN). 
2.5.5.3.1 1.  RAND O M S EQUENCE GENER ATIO N (CHEC KING F O R PO S S IBL E  S ELECT IO N BIAS )  
For each included study, the review describes the method used to generate the allocation 
sequence in sufficient detail to allow an assessment of whether it should produce 
comparable groups. 
The method was assessed as: 
 low risk of bias (any truly random process, e.g. random number table; computer 
random number generator); 
 high risk of bias (any non-random process, e.g. odd or even date of birth; hospital 
or clinic record number); or 
 unclear risk of bias.    
2.5.5.3.2 2.  ALLO CATIO N CO NCEALMEN T  (CHECKING F O R PO S S IBL E  S ELECT IO N BIAS )  
For each included study, the review describes the method used to conceal allocation to 
interventions prior to assignment and assesses whether intervention allocation could have 
been foreseen in advance of, or during recruitment, or changed after assignment. 
The methods were assessed as: 
 low risk of bias (e.g. telephone or central randomisation; consecutively numbered 
sealed opaque envelopes); 
 high risk of bias (open random allocation; unsealed or non-opaque envelopes, 
alternation; date of birth); or 
 unclear risk of bias.    
2.5.5.3.3 3.1.  BL IND ING O F  PARTIC IPA NTS  AND  PERS O NNEL  (CHECKING F O R PO S S IBL E  
PERF O RMANCE BIAS )  
For each included study, the review describes the methods used, if any, to blind study 
participants and personnel from knowledge of which intervention a participant received. 
Studies were considered to be at low risk of bias if they were blinded, or if it was judged 
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that the lack of blinding would be unlikely to affect results. Blinding was assessed 
separately for different outcomes or classes of outcomes. 
The methods were assessed as: 
 low, high or unclear risk of bias for participants; 
 low, high or unclear risk of bias for personnel. 
2.5.5.3.4 3.2.  BL IND ING O F  O UTCO ME A S S ES S MENT (CHECKING F O R PO S S IBL E  D ETECTIO N  
BIAS )  
For each included study, the review describes the methods used, if any, to blind outcome 
assessors from knowledge of which intervention a participant received.  Blinding was 
assessed separately for different outcomes or classes of outcomes. The method of outcome 
assessor blinding was assessed as low, high or unclear risk of bias. 
2.5.5.3.5 4.  INCO MPLETE  O UTCO ME D A TA (CHECKING F O R PO S S IBL E  ATTRIT IO N BIAS  D UE  
TO  THE  AMO UNT ,  NATURE AND  HAND LING O F  IN CO MPLETE  O UTCO ME D AT A)  
For each included study, and for each outcome or class of outcomes, the review describes 
the completeness of data including attrition and exclusions from the analysis. The review 
states whether attrition and exclusions were reported and the numbers included in the 
analysis at each stage (compared with the total randomised participants), reasons for 
attrition or exclusion where reported, and whether missing data were balanced across 
groups or were related to outcomes. Where sufficient information was reported, or could 
be supplied by the trial authors, it was planned that missing data would be re-included in 
the analyses. 
Methods were assessed as: 
 low risk of bias (e.g. no missing outcome data; missing outcome data balanced 
across groups); 
 high risk of bias (e.g. numbers or reasons for missing data imbalanced across 
groups; 'as treated' analysis done with substantial departure of intervention 
received from that assigned at randomisation); or 
 unclear risk of bias. 
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2.5.5.3.6 5.  SELECT IV E  REPO RTIN G (CHECKIN G F O R RE PO RTI NG BIAS )  
For each included study, the possibility of selective reporting bias was assessed by 
comparing outcomes reported in the results section with those mentioned in the methods 
section. 
We assessed the methods as: 
 low risk of bias (where it is clear that all of the study's pre-specified outcomes and 
all expected outcomes of interest to the review have been reported); 
 high risk of bias (where not all the study's pre-specified outcomes have been 
reported; one or more reported primary outcomes were not pre-specified; 
outcomes of interest are reported incompletely and so cannot be used; study fails 
to include results of a key outcome that would have been expected to have been 
reported); or 
 unclear risk of bias. 
2.5.5.3.7 6.  OT HER B IAS  
Any important concerns about other possible sources of bias were considered, and the risk 
was assessed as: 
 low risk of other bias; 
 high risk of other bias; or 
 unclear whether there is risk of other bias. 
2.5.5.3.8 7.  OV ERALL  RIS K O F  B IAS  
Explicit judgements were made about whether studies were at high risk of bias, according 
to the Cochrane guidelines (218). The likely magnitude and direction of the bias and 
whether it was likely to impact on the findings was considered.  It was planned that the 
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2.5.5.4  MEASURES OF TREATMENT  EFFECT   
2.5.5.4.1 D ICHO TO MO US  D ATA  
For dichotomous data, results are presented as summary risk ratios (RRs) with 95% 
confidence intervals (CIs).  
2.5.5.4.2 CO NTINU O US  D ATA  
For continuous data, the mean difference (MD) was used if outcomes are measured in the 
same way between trials. The standardised mean difference (SMD) was used to combine 
trials that measure the same outcome, but using different methods.   
2.5.5.5  DEALING  W ITH MISSING DATA   
For included studies, levels of attrition were noted. It was planned that the impact of 
including studies with high levels of missing data in the overall assessment of treatment 
effect would be explored using sensitivity analysis. 
For all outcomes, analyses were carried out, as far as possible, on an intention-to-treat 
basis, i.e. all participants randomised to each group in the analyses were included, and all 
participants were analysed in the group to which they were allocated, regardless of 
whether or not they received the allocated intervention. The denominator for each 
outcome in each trial was the number randomised minus any participants whose 
outcomes are known to be missing. 
2.5.5.6  ASSESSMENT OF HETEROG ENEITY   
Heterogeneity of treatment effects was measured between trials using the T2, I2 and Chi2 
statistics. Heterogeneity was regarded as substantial if I2 was greater than 30% and either 
T2 was greater than zero, or there was a low P value (less than 0.10) in the Chi2 test for 
heterogeneity.  
2.5.5.7  DATA SYNTHESIS    
Statistical analysis was carried out using the Review Manager software. Fixed-effect meta-
analysis was used for combining data where it was reasonable to assume that studies were 
estimating the same underlying treatment effect: i.e. where trials were examining the 
same intervention, and the trials' populations and methods were judged sufficiently 
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similar. If there was clinical heterogeneity sufficient to expect that the underlying 
treatment effects differed between trials, or if substantial statistical heterogeneity was 
detected, a random-effects meta-analysis would have been used to produce an overall 
summary.  
2.5.6  WRITING THE REVIEW  
The review was produced using the Review Manager software developed by The Cochrane 
Collaboration for preparing and maintaining Cochrane reviews. Review Manager 
facilitates the preparation of protocols and full reviews, including text, characteristics of 
studies, comparison tables and study data. It can perform meta-analysis of the data 
entered and present the results graphically. 
Once written, the review was submitted to the Cochrane Collaboration for peer review and 
publication. 
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3 USING MICROARRAY DATA TO STUDY THE MYOMETRIAL 
TRANSCRIPTOME IN PREGNANCY AND PARTURITION 
3.1 INTRODUCTION  
Over the past decade, microarray technology has been increasingly applied to study 
parturition (219). Such experiments provide large amounts of gene expression data, which 
is combined with existing knowledge of molecular pathways to study the molecular 
mechanisms underlying the initiation of labour and labour complications. The 
myometrium is arguably the most relevant tissue in which to conduct such studies, being 
the tissue that contracts to expel the baby. Several research groups have published 
microarray data comparing gene expression in labouring and non-labouring myometrium 
(55,112,114,115,119,120,140,141). Although there is some agreement between these 
studies on the general mechanisms that appear to underlie the initiation of labour, no 
clear agreed labour-associated myometrial gene expression signature has been identified. 
This may be partly due to variation introduced by the use of different microarray 
platforms. It may also be attributable to the small number of samples used in these studies 
- a problem that often arises due to the relative inaccessibility of myometrial tissue and  
efforts to select only those patients with similar key characteristics (such as gestational 
age, parity, BMI, maternal age and indication for Caesarean delivery). Although the ideal 
experimental design would control for these characteristics in this way, perhaps excluding 
gestational age (115), there is little evidence to suggest that the molecular mechanisms 
initiating parturition are affected by these factors. Therefore, it may be more useful to 
prioritise maximising the number of samples over minimising inter-patient variability. 
This chapter describes the results of the largest-to-date microarray experiment to 
compare gene expression in labouring and non-labouring myometrium. All labouring 
samples in the Edinburgh Reproductive Tissue BioBank (ERTBB) were selected regardless 
of patient characteristics and then loosely matched to similar non-labouring samples (of 
which there were far more). The data is analysed using robust statistical techniques and a 
modern unbiased network graph approach, before functional enrichment to provide 
further insight into the biological meaning. To further increase the statistical power and 
allow inter-study heterogeneity to be assessed, a meta-analysis of similar published 
microarray raw data is also conducted. This is the first time such a meta-analysis has been 
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carried out. This approach will likely lead to more robust, accurate and generalisable 
conclusions and could be widely adopted. 
3.2 SUMMARY OF METHODS  
The methods used in this chapter are described in detail in Chapter 2. Briefly, 22 labouring 
and 26 non-labouring lower segment myometrium samples were selected from the 
Edinburgh Reproductive Tissue Biobank (described in section 2.1.1). RNA was isolated, 
amplified and labelled with biotin (described in section 2.1.2). The microarray experiment 
was conducted at the Wellcome Trust Clinical Research Facility using the Illumina HT-12 
v4 Expression BeadChip platform (described in section 2.1.3). Raw data was subjected to 
RMA background correction and quantile normalisation to remove non-biological 
systemic variation (described in section 2.1.4). Probes were annotated and genes 
expressed, on average, below background in both labouring and non-labouring groups 
were removed (described in section 2.1.5 and 2.1.6). Expression over all probes was used 
to assess relationships between samples (described in section 2.1.7). Differential 
expression between groups was explored by observing fold-changes and P- or RP-PFP 
values as a measure of statistical significance (described in section 2.1.8). Biolayout 
Express3D was also used to visualise the data and provide further insights (described in 
section 2.1.10). Functional analysis was performed by uploading gene lists to DAVID and 
comparing biological GO terms and KEGG pathways (described in section 2.1.11). The 
microarray was validated using TaqMan qRT-PCR for selected up-, down- and non-
differentially regulated genes (described in section 2.1.13). The relative abundance of 
leukocytes in labouring and non-labouring tissue was assessed by staining myometrial 
tissue sections for CD45 (described in section 2.1.12). In addition to the wet-lab validation 
of this microarray, a meta-analysis of the complete data from previously published similar 
microarray experiments was conducted (described in section 2.1.14). A systematic search 
of the literature identified comparable studies and data was preprocessed and analysed 
using similar methods to those described above. Differential expression between 
labouring and non-labouring groups was assessed for individual studies, and agreement 
between studies was also investigated visually and using Forrest plots of the standardised 
mean difference. 
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3.3 RESULTS  
3.3.1  RNA  QUALITY  
Before including RNA samples in the microarray experiment, the quality was assessed. 
Total RNA extracted from myometrium samples was analysed using a NanoDrop 1000. 
Pure RNA is expected to show a 260nm/280nm ratio of around 2.0. The samples assessed 
for use in this study had a mean 260nm/280nm ratio of 2.07 (standard deviation = 0.04), 
so the quality of the RNA was considered high enough to undergo biotin labelling in 
preparation for the array. After biotin labelling, the Wellcome Trust Clinical Research 
Facility used a Bioanalyzer 2100 to assess the quality of the RNA again. For biotin-labelled 
mRNA, Bioanalyzer traces are not associated with an RNA Integrity Number (RIN), 
however the experienced staff at the WTCRF confirmed that all the traces suggested the 
samples were of satisfactory quality so all samples were included on the chips. The CD 
accompanying this thesis contains all the Bioanalyzer results obtained by the WTCRF. 
Using data obtained from the microarray experiment, Figure 3.1 shows boxplots and 
intensity plots to visualise the distribution of expression values across all probes and all 
samples before (Figure 3.1a and Figure 3.1c) and after (Figure 3.1b and Figure 3.1d) 
quantile normalisation. There are no large variations in expression values between 
samples, which indicates that the RNA was of acceptable quality. 




Figure 3.1.  Boxplots and density plots of s ignal intensity (expression value) before (A, C) 
and after (B,D) quantile normalisation.  
3.3.2  SAMPLE CHARACTERISTICS   
Table 3.1 shows the patient characteristics for the samples included in the microarray. 
There are 22 labouring and 26 non-labouring samples. Table 3.2 summarises patient 
characteristics (e.g. BMI, maternal age, etc.) for both groups. The samples were not 
selected to minimise inter-patient variability, so there is a reasonably high degree of 
variation in patient characteristics within both groups. Within the labouring group, there 
is a high degree of variation in cervical dilation, suggesting that the women range from 
early to late stages of labour. There are no significant between-group differences at P<0.05 
in mean/median values of parity, maternal age, maternal BMI or gestational age at 
delivery, so the groups are reasonably well matched and any difference in gene expression 
between the groups is likely to be the result of labour status rather than variation in these 
characteristics.  
3 - The myometrial transcriptome at labour 
 
81 
Key for Tables 3.1 and 3.2: 
RL = RNA later 
FD = Fetal distress 
FTP = Failure to progress 
N/R = Not recorded 
PPROM = Preterm prelabour rupture of membranes 
B = Breech 
PP = Placenta praevia 
O/H = Obstetric history 
IUGR = intrauterine growth restriction 
PIH = Pregnancy-induced hypertension 
PCS = Previous Caesarean section 
Hip = Hip problems 
PG = Prostaglandin 
S = Syntocinon 
 
3 - The myometrial transcriptome at labour 
 
82 











   














































































L0190 RL FD 44 42.4 PG & S 40+3 0+2 9 
L0242 RL FTP 37 21.6 S 41+3 0+0 N/R 
L0353 RL N/R 32 39.8 PG 39+0 1+0 N/R 
L0356 No RL N/R 21 43.7 PG 39+6 0+0 N/R 
L0381 No RL N/R 28 20.7 None 36+4 N/R N/R 
L2567 RL FD 28 30.1 None 41+2 0+0 10 
L2649 RL FTP 39 22.2 None 40+5 1+1 6 
L2688 RL PPROM/B 36 25.8 None 35+0 1+2 1 
L3132 RL FTP 32 22.7 S 40+4 0+0 4.5 
L3140 RL B 28 19.1 None 33+4 0+0 5 
L3168 RL N/R 32 39.3 S 39+2 0+0 8 
L3171 RL FTP 34 20.7 None 41+0 1+0 1 
L3179 RL FTP 22 26.2 None 40+6 1+0 3 
L3189 RL FTP 28 21.2 S 40+3 0+0 5 
L3195 RL B 28 25.7 None 41+3 0+1 N/R 
L3196 RL FTP 29 21.6 S 39+6 0+0 5.6 
L3197 RL B 39 21.7 None 40+1 0+0 2 
L3216 RL FTP 23 23.1 S 41+4 0+0 9 
L3224 RL FTP 33 27 None 41+6 0+0 8 
L3226 RL FD 36 25.6 None 42+2 0+1 4 
L3232 No RL FTP 39 40.3 PG 41+6 2+0 8 
L3236 RL FTP 30 36 S 36+6 N/R 9 
NL0072 RL N/R 30 23.9 None 39+0 ≥1 n/a 
NL2006 RL B 33 23.4 None 39+1 0+1 n/a 
NL2064 RL PP 43 27.2 None 38+4 0+0 n/a 
NL2088 RL B 31 20.5 None 39+5 0+0 n/a 
NL2090 RL O/H 32 27.7 None 39+5 2+0 n/a 
NL2093 RL B 33 41.2 None 39+0 1+1 n/a 
NL2098 RL B 30 22 None 39+3 0+0 n/a 
NL2133 RL N/R 35 29.4 None 41+4 0+0 n/a 
NL2158 RL B 23 21.1 None 40+1 0+1 n/a 
NL2161 RL O/H 36 23 None 37+0 2+0 n/a 
NL2275 RL B 38 23.2 None 39+1 0+0 n/a 
NL2285 RL B 34 22.8 None 40+0 0+2 n/a 
NL2410 RL PP 32 23.1 None 38+5 0+0 n/a 
NL2474 RL IUGR 36 38.1 None 31+2 0+1 n/a 
NL2504 RL PIH 34 26.6 None 36+4 1+0 n/a 
NL3007 RL B 34 46.8 None 39+3 0+0 n/a 
NL3015 RL B 40 26.5 None 39+2 0+1 n/a 
NL3087 RL PCS 31 43 None 39+4 1+2 n/a 
NL3095 RL PCS 26 26.3 None 39+1 1+1 n/a 
NL3114 RL PCS 33 32.3 None 39+2 1+0 n/a 
NL3127 RL B 31 31.7 None 39+3 0+0 n/a 
NL3133 RL N/R 35 44.4 None 39+4 0+0 n/a 
NL3142 RL N/R 38 24.6 None 39+5 1+0 n/a 
NL3148 RL Hip 22 24.3 None 39+2 0+0 n/a 
NL3198 RL B 29 23.9 None 39+5 2+0 n/a 
NL3247 RL O/H 32 22.2 None 39+0 1+0 n/a 
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Table 3.2.  Summary of patient characteristics for the labouring and non -labouring 
groups. P-values represent the significance of the difference between the groups.95% 
confidence intervals are shown in parentheses.  






















RL = 19 
No RL = 3 
FD = 3 
FTP = 11 
B = 3 
CS/OH = 0 
Other = 1 








PG = 3 
S = 7 
Both = 1 








RL = 26 
No RL = 0 
FD = 0 
FTP = 0 
B = 11 
CS/OH = 6 
Other = 5 














n/a n/a 0.52 0.86 n/a 0.15 0.45 n/a 
3.3.3  SAMPLE RELATIONS  
Expression values for all probes were used to calculate Pearson’s correlation values to 
describe how the gene expression values of each sample correlate with those of each of the 
other samples. Figure 3.2 shows the mean correlation values for three comparisons: 
labouring versus labouring samples, non-labouring versus non-labouring samples, and 
non-labouring versus labouring samples.  Non-labouring samples are significantly more 
highly correlated with other non-labouring samples than they are with labouring samples 
(one way ANOVA with Tukey’s multiple comparisons test P<0.0001). Labouring samples 
are not more highly correlated with each other than they are with non-labouring samples 
(one way ANOVA with Tukey’s multiple comparisons test P=0.12). The error bars show 
that the standard deviation for labouring samples is also higher than that for non-
labouring samples. This suggests that non-labouring samples show a similar gene 
expression signature, but that labouring samples are more varied. 
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Mean between sample correlation values



























Figure 3.2.  Mean between-sample Pearson ’s correlation values.  Non-labouring samples 
(NL) are significantly more highly correla ted with each other than with labouring samples 
(L) (P<0.0001).  Labouring samples are not s ignificantly more or less correlated  with each 
other than they are with non-labouring samples (P=0.12).  Error bars indicate standard 
deviation. 
Figure 3.3 shows a heatmap that illustrates this further by indicating the strength of the 
correlation between each sample. Non-labouring samples show high correlation with each 
other (indicated by lighter colours), and lower correlation with labouring samples 
(indicated by darker colours). When compared with each other, labouring samples show a 
degree of correlation similar to that observed in comparison to non-labouring samples, in 
other words, in contrast to the scenario with non-labouring samples, labouring samples 
are not more correlated to each other than they are to non-labouring samples. 




Figure 3.3.  A heatmap illustrating the degree of correlation of gene expression between 
each sample on the array.  The lighter the colour, the stronger the correlation. Samples 
are listed along the axes by their IDs.  Samples beginning with L are from labouring 
women and samples beginning with NL are from non -labouring women. 
In the network graph shown in Figure 3.4, the nodes represent samples and the edges are 
weighted according to the strength of the correlation. Only Pearson’s correlation values 
above 0.95 are included when building the graph. Markov Chain clustering (MCL) was 
performed to assess how the samples cluster into groups. It produced two clusters. When 
nodes are coloured according to labour status it is clear that MCL cluster 1 (42 samples) 
contains all 26 of the non-labouring samples and MCL cluster 2 (5 samples) contains 
labouring samples only. A Chi-squared test confirms that this association is significant 
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(P=0.01). This suggests that the samples cluster by labour status, and the appearance of 
labouring samples in both clusters supports the above finding that labouring samples 
show more variation than non-labouring samples.  
 
Figure 3.4.  A network graph in which each node represents a different sample on the 
array.  The thickness of the edges indicates the strength of the correlation. The same 
graph is  coloured according to Markov chain (MCL) cluster number and labour status.   
3.3.4  ASSESSING DIFFERENTIA L EXPRESSION BETWEEN  LABOURING AND NON -
LABOURING SAMPLES  
A complete list of differentially expressed genes at a fold change of <- or > 1.2 and a RP-
PFP value of <0.05 is presented on the CD accompanying this thesis. There are 960 genes 
upregulated and 801 genes downregulated in labour. The 40 most significant differentially 
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Change             
(NL to L) 
Adjusted 
P-value 
IL8 ILMN_2184373 interleukin 8 9.6 4.2E-05 
MT2A ILMN_1686664 metallothionein 2A 6.9 8.1E-08 
MT1A ILMN_1691156 metallothionein 1A 6.9 6.3E-08 
RARRES1 ILMN_1800091 retinoic acid receptor responder (tazarotene 
induced) 1 
4.2 3.8E-07 
CCL2 ILMN_1720048 chemokine (C-C motif) ligand 2 4.0 3.8E-05 
ANGPTL4 ILMN_1707727 angiopoietin-like 4 3.7 6.9E-07 
MT1G ILMN_1715401 metallothionein 1G 3.3 2.8E-07 
MT1X ILMN_1775170 metallothionein 1X 3.2 1.8E-06 
C19orf59 ILMN_1762713 chromosome 19 open reading frame 59 3.1 1.0E-05 
CHI3L1 ILMN_3307868 chitinase 3-like 1 (cartilage glycoprotein-39) 3.0 4.3E-05 
MT1IP ILMN_2136089 metallothionein 1I pseudogene 3.0 1.8E-06 
IL6 ILMN_1699651 interleukin 6 (interferon beta 2) 2.9 2.3E-06 
LILRA5 ILMN_2266595 leukocyte immunoglobulin-like receptor 
subfamily A (with TM domain) member 5 
2.8 6.6E-07 
FCN1 ILMN_1668063 ficolin (collagen/fibrinogen domain containing) 1 2.8 3.1E-05 
AQP9 ILMN_1715068 aquaporin 9 2.8 1.5E-04 
LILRA3 ILMN_1661631 leukocyte immunoglobulin-like receptor 
subfamily A (without TM domain) member 3 
2.7 1.2E-04 
MMP3 ILMN_1784459 matrix metallopeptidase 3 (stromelysin 1 
progelatinase) 
2.7 6.0E-04 
CCL23 ILMN_1686109 chemokine (C-C motif) ligand 23 2.7 1.8E-06 
SLC11A1 ILMN_1741165 solute carrier family 11 (proton-coupled divalent 
metal ion transporters) member 1 
2.6 4.2E-06 
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Change             
(NL to L) 
Adjusted 
P-value 
MAMDC2 ILMN_1679391 MAM domain containing 2 -2.1 9.8E-06 
APCDD1L ILMN_1689431 adenomatosis polyposis coli down-regulated 1-
like 
-2.1 2.7E-04 
FABP4 ILMN_1773006 fatty acid binding protein 4 adipocyte -2.0 2.5E-05 
SVIL ILMN_1690754 supervillin -1.9 2.6E-06 
HCFC1R1 ILMN_1757877 host cell factor C1 regulator 1 (XPO1 dependent) -1.9 4.8E-06 
SEPP1 ILMN_1785071 selenoprotein P plasma 1 -1.8 9.3E-05 
CD34 ILMN_1732799 CD34 molecule -1.8 2.8E-06 
GPR161 ILMN_1773940 G protein-coupled receptor 161 -1.8 2.8E-06 
RERG ILMN_1746359 RAS-like estrogen-regulated growth inhibitor -1.8 8.0E-06 
CD34 ILMN_2341229 CD34 molecule -1.8 2.3E-04 
SORBS1 ILMN_1749792 sorbin and SH3 domain containing 1 -1.8 4.4E-05 
PPP1R3C ILMN_1736670 protein phosphatase 1 regulatory (inhibitor) 
subunit 3C 
-1.8 8.7E-05 
LMOD1 ILMN_1680948 leiomodin 1 (smooth muscle) -1.7 7.1E-07 
DAAM1 ILMN_1787251 dishevelled associated activator of 
morphogenesis 1 
-1.7 1.2E-06 
MYH11 ILMN_2368834 myosin heavy chain 11 smooth muscle -1.7 2.9E-06 
SNORD13 ILMN_1892403 small nucleolar RNA C/D box 13 -1.7 3.5E-07 
PLCL1 ILMN_2206953 phospholipase C-like 1 -1.7 6.3E-06 
LINGO2 ILMN_1695978 leucine rich repeat and Ig domain containing 2 -1.7 2.6E-07 
KLRAQ1 ILMN_1667356 KLRAQ motif containing 1 -1.7 5.5E-05 
C7orf58 ILMN_1677038 chromosome 7 open reading frame 58 -1.6 6.0E-08 
Differentially expressed genes are visualised in Figure 3.5. This heatmap represents 
expression values as colours on a scale. Columns represent samples and rows represent 
differentially expressed genes. To make the list small enough to enable clear visualisation, 
a fold change cut-off of >2 or <-2 and an RP-PFP cut-off of ≤0.0001 were used. The 
heatmap shows that most genes are upregulated at labour. Additionally samples cluster 
almost perfectly according to labour status. 




Figure 3.5.  A heatmap to show how genes and samples cluster based on similar 
expression levels.  The bar at the top indicates the sample group (dark purple = labouring, 
light purple = non-labouring).  Normalised expression values are indicated on a colour 
scale with red indicating high expression and blue indicating low expression. Genes with 
a non-labour to labour fold change of >2 or < -2 and an RP-PFP ≤0.0001 are included in 
the heatmap. 
3.3.4.1  NETW ORK GRAPH ANALYSI S  
Further analysis and visualisation of the data was conducted using a network graph 
approach. In Figure 3.6a each node is a gene probe and the edges connecting them are 
based on similarity of expression profiles across the samples. Probes with a correlation 
value above 0.8 were included in the graph. The graph is comprised of 2304 nodes and 
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20984 edges. The nodes are coloured according to the MCL cluster they belong to. There 
are 227 clusters in total (calculated using an inflation value of 2.2). To aid visualisation of 
the graph, Figure 3.6b shows a 2D view where each cluster is condensed to a single node. 
The size of the node is proportional to the size of the cluster. The largest clusters are 
numbered. 
 
Figure 3.6.  (A) A network graph of the microarray data coloured according to MCL 
cluster.  (B) A 2D condensed view of the graph, where each cluster is  represented as a 
s ingle node. 
MCL clusters are formed based on similar probe expression profiles. Figure 3.7 shows four 
example cluster expression profiles. Figure 3.7a shows a cluster comprising probes that 
are generally upregulated in labouring samples. Figure 3.7b shows a cluster of probes that 
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are not differentially expressed according to any patient characteristics. Figure 3.7c shows 
a cluster of probes that are generally downregulated in labouring samples. Figure 3.7d 
shows a cluster of probes that are generally upregulated in labouring samples, but only for 
first deliveries (para=0). 




Figure 3.7.  Expression profiles for four clusters.  Error bars indicate 95% confidence 
intervals. 
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3.3.5  QRT-PCR  VALIDATION  
qRT-PCR was performed using all samples in the array to validate the expression of ten 
genes. I chose a selection of genes based on specific changes or no change in labour, as 
identified from the microarray and/or the literature (the rationale behind choosing these 
genes is explained in Chapter 2, Table 2.2).  
The standard curve method was used to assess gene expression relative to an endogenous 
control (18s). Standard curve slopes should be between -3.6 and -3.3 to confirm reactions 
are 90-100% efficient. The mean standard curve slope for these experiments was -3.46 
(standard deviation= 0.16). Despite repeating reactions, one target gene (RBM42) was 
consistently around -3.63, and another target gene (FABP4) was consistently around 3.06, 
indicating issues with the reaction. Therefore the results for these target genes should be 
considered less reliable than the other results. 
For each target gene, three samples (L0353, L2649 and NL2504) were excluded from 
analysis because CT values were over 35 or undetermined. Values over 35 are considered 
unreliable. All samples were run in technical duplicate (standard curves were run in 
triplicate). Where the mean CT values of technical duplicates had a standard deviation 
over 0.2, the reaction was repeated. This did not resolve the difference for MTE1, so the 
results were included in further analysis but the implications of this are noted. After the 
three exclusions there were 25 non-labouring biological replicates and 20 labouring 
biological replicates. 
A table showing the mean raw, normalised and delta CT and quantity values for each gene, 
as well as the fold change in gene expression between non-labouring and labouring 
samples is provided in Appendix 2. T-tests were used to analyse whether the delta CT 
values (raw CT value for the target gene minus the raw CT value for 18s) were 
significantly different in labouring and non-labouring samples. This data is plotted 
alongside results from the microarray experiment in figures 3.8-3.10. 
Interleukin-8 (IL-8), Interleukin-6 (IL-6) and Metallothionein1E (MT1E) were confirmed 
to be upregulated in labour (Figure 3.8). RNA binding motif protein 42 (RBM42) and 
Shroom family member 4 (SHROOM4) were confirmed to be not differentially expressed 
between groups (Figure 3.9). Oxytocin receptor (OXTR), Myosin heavy chain 11 (MYH11) 
and Fatty acid binding protein 4 (FABP4) were confirmed to be downregulated in labour. 
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However, contrary to the microarray results, Tropomyosin 1 (TPM1) and Insulin-like 
growth factor binding protein 5 (IGFBP5) were not significantly downregulated in 
labouring samples (Figure 3.10). 
 
Figure 3.8.  qRT-PCR validation of Interleukin-8, Interleukin-6 and Metallothionein 1E.  
PCR results are shown in red and microarray results are shown in black.  Error bars 
indicate 95% confidence intervals of fold changes. Stars indicate the level of s ignificance 
according to t -tests of the delta CT values.  




Figure 3.9.  qRT-PCR validation of RNA binding motif protein 42 and S hroom family 
member 4.  PCR results are shown in red and microarray results are shown in black.  Error 
bars indicate 95% confidence intervals of fold changes.  Stars indicate the level of 
s ignificance according to t -tests of the delta CT values.  




Figure 3.10.  qRT-PCR validation of Tropomyosin 1, Oxytocin receptor, Fatty acid binding 
protein 4, Insulin-like growth factor binding protein 5 and Myosin heavy chain 11.  PCR 
results are shown in red and microarray resu lts are shown in black.  Error bars indicate 
95% confidence intervals  of fold changes.  Stars indicate the level of s ignificance 
according to t -tests of the delta CT values.  
3.3.6  FUNCTIONAL ANALYSIS  
The Functional Classification Tool within DAVID was used to assess whether the up and 
down regulated gene lists (on the accompanying CD) were enriched for any biological 
process gene ontology (GO) terms and KEGG pathways. The same method was also used to 
analyse lists of genes comprising each MCL cluster in the network graph. 
3.3.6.1  GENE ONTOLOGY  
3.3.6.1.1 FULL  GENE L IS TS  
Table 3.5 shows the top five clusters of GO terms associated with the genes upregulated in 
labour. Upregulated biological processes are mainly associated with inflammation, cell 
(probably leukocyte) movement/migration, response to hormone stimulus, regulation of 
cell death and angiogenesis. Table 3.6 shows the top five clusters of GO terms associated 
with the genes downregulated in labour. Downregulated biological processes are mainly 
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associated with the response to hormone stimulus, muscle development, cytoskeleton 
organisation, ion homeostasis, neuron development and cell adhesion. 
Table 3.5.  The top five clusters of GO terms associated with genes found to be 





















GO:0006952~defense response 91 9.86 7E-18 
GO:0009611~response to wounding 78 8.45 4E-15 
GO:0006954~inflammatory response 57 6.18 2E-14 
2 8.5 
GO:0042330~taxis 35 3.79 8E-12 
GO:0006935~chemotaxis 35 3.79 8E-12 
GO:0007626~locomotory behavior 38 4.12 5E-07 
GO:0007610~behavior 52 5.63 3E-06 
3 5.87 
GO:0010033~response to organic substance 96 10.40 1E-15 
GO:0048545~response to steroid hormone 
stimulus 
28 3.03 8E-06 
GO:0009719~response to endogenous 
stimulus 
41 4.44 3E-04 
GO:0009725~response to hormone stimulus 38 4.12 3E-04 
GO:0043627~response to estrogen stimulus 14 1.52 5E-03 
4 5.16 
GO:0043066~negative regulation of apoptosis 51 5.53 9E-10 
GO:0043069~negative regulation of 
programmed cell death 
51 5.53 2E-09 
GO:0060548~negative regulation of cell death 51 5.53 2E-09 
GO:0042981~regulation of apoptosis 81 8.78 2E-07 
GO:0043067~regulation of programmed cell 
death 
81 8.78 3E-07 
GO:0010941~regulation of cell death 81 8.78 3E-07 
GO:0006916~anti-apoptosis 31 3.36 1E-06 
GO:0043065~positive regulation of apoptosis 38 4.12 5E-03 
GO:0043068~positive regulation of 
programmed cell death 
38 4.12 6E-03 
GO:0010942~positive regulation of cell death 38 4.12 6E-03 
GO:0006917~induction of apoptosis 27 2.93 3E-02 
GO:0012502~induction of programmed cell 
death 
27 2.93 3E-02 
5 4.92 
GO:0046651~lymphocyte proliferation 13 1.41 2E-06 
GO:0070661~leukocyte proliferation 13 1.41 3E-06 
GO:0032943~mononuclear cell proliferation 13 1.41 3E-06 
GO:0045321~leukocyte activation 33 3.58 4E-06 
GO:0046649~lymphocyte activation 29 3.14 5E-06 
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GO:0001775~cell activation 36 3.90 1E-05 
GO:0042110~T cell activation 19 2.06 2E-04 
GO:0042098~T cell proliferation 8 0.87 5E-04 
Table 3.6.  The top five clusters of GO terms associated with genes found to be 




















GO:0048545~response to steroid hormone 
stimulus 
26 3.47 2.5E-07 
GO:0031960~response to corticosteroid 
stimulus 
12 1.60 6.2E-04 
GO:0051384~response to glucocorticoid 
stimulus 
11 1.47 1.2E-03 
2 4.09 
GO:0009725~response to hormone stimulus 40 5.34 3.7E-08 
GO:0009719~response to endogenous 
stimulus 
41 5.47 1.8E-07 
GO:0048545~response to steroid hormone 
stimulus 
26 3.47 2.5E-07 
GO:0043627~response to estrogen stimulus 17 2.27 4.8E-06 
GO:0010033~response to organic substance 55 7.34 9.3E-06 
GO:0032355~response to estradiol stimulus 11 1.47 5.3E-05 
GO:0032870~cellular response to hormone 
stimulus 
16 2.14 3.2E-04 
GO:0043434~response to peptide hormone 
stimulus 
16 2.14 1.5E-03 
GO:0032868~response to insulin stimulus 9 1.20 5.0E-02 
GO:0032869~cellular response to insulin 
stimulus 
7 0.93 5.7E-02 
GO:0008286~insulin receptor signaling 
pathway 
4 0.53 1.9E-01 
3 3.67 
GO:0007517~muscle organ development 26 3.47 1.5E-06 
GO:0014706~striated muscle tissue 
development 
15 2.00 3.3E-04 
GO:0060537~muscle tissue development 15 2.00 5.4E-04 
GO:0007519~skeletal muscle tissue 
development 
10 1.34 1.3E-03 
GO:0060538~skeletal muscle organ 
development 
10 1.34 1.3E-03 
4 3.67 
GO:0007517~muscle organ development 26 3.47 1.5E-06 
GO:0014706~striated muscle tissue 
development 
15 2.00 3.3E-04 
GO:0060537~muscle tissue development 15 2.00 5.4E-04 
GO:0007519~skeletal muscle tissue 
development 
10 1.34 1.3E-03 
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GO:0060538~skeletal muscle organ 
development 
10 1.34 1.3E-03 
5 3.67 
GO:0007010~cytoskeleton organization 37 4.94 4.2E-05 
GO:0030036~actin cytoskeleton organization 24 3.20 4.8E-05 
GO:0030029~actin filament-based process 24 3.20 1.3E-04 
GO:0007015~actin filament organization 9 1.20 8.5E-03 
3.3.6.1.2 NETWO RK GRAPH  MCL  CLUS TERS  
MCL clusters (from Figure 3.6) and the main GO terms describing their functions are 
summarised in Table 3.7. One of the largest clusters (MCL2) is composed mostly of genes 
upregulated in labour and associated with inflammation. MCL14, MCL17, MCL21 and all 
further MCL clusters were too small to undergo functional enrichment. 












category based on 















1 209 205 RNA processing   
2 147 147 Inflammation   
3 80 70 Transcription 
  
4 53 53 RNA processing   
5 44 44 Cell death   
6 42 33 Transcription   
7 42 35 Transcription   
8 40 39 Protein transport 
  
9 38 37 Transcription   
10 37 36 Steroid biosynthesis   
11 31 31 RNA processing 
  
12 31 31 Cell cycle   
13 30 30 Cell cycle   
15 25 21 Cell death 
  
16 24 24 Inflammation   
18 23 23 Inflammation   
19 21 21 Protein 
phosphorylation 
  
20 20 20 Cell death   
22 17 17 RNA processing   
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3.3.6.2  KEGG  PATHW AYS  
Pathways upregulated in labour include NOD-like receptor signalling (Figure 3.11), MAPK 
activation and cytokine-cytokine receptor signalling. These are all important inflammatory 
pathways. Pathways downregulated in labour include vascular smooth muscle contraction 
(Figure 3.12) and calcium signalling. This may represent a change in the composition 
(effectively dilution in quantity) of the myometrial tissue due to leukocyte infiltration at 
labour. 




Figure 3.11. The KEGG diagram for the Nod-like Receptor Signalling Pathway. Red stars 
indicate genes found to be upregulated in labour.  




Figure 3.12.  The KEGG pathway diagram for (vascular) smooth muscle contraction. Red 
stars indicate genes found to be downregulated in labour.  
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3.3.7  ASSESSING CHANGES IN TISSUE COMPOSITION  
Functional analysis showed that labour is associated with an upregulation of inflammatory 
genes/processes and a downregulation of genes/processes involved in smooth muscle 
contraction. It was hypothesised that both of these observations may be in part due to a 
change in the myometrial tissue; specifically that more leukocytes are present in  
labouring compared to non-labouring tissue and this “dilutes” the relative contribution of 
the smooth muscle cells. To illustrate this argument, the log2 mean ratio of labouring to 
non-labouring expression (including confidence intervals calculated using Fieller’s 
theorem) was plotted for: 
 Smooth muscle markers (Figure 3.13a)    Calponin 1 (CNN1), Desmin (DES), 
Transgelin (TAGLN), Tropomyosin 1 (TPM1) and Myosin heavy chain 11 (MYH11) 
are all considered classical markers of smooth muscle myofilament.(220) If there 
is a large influx of leukocytes into the myometrium at labour, these smooth muscle 
markers are expected to be downregulated. 
 Leukocyte markers (Figure 3.13b)   CD14, CD68 and CD163 were the only Cluster 
of Differentiation genes expressed above background level. These are all 
macrophage markers.(221) The classic pan-leukocyte marker, CD45, was not 
expressed above background level (using 4/4 probes), although this does not 
suggest that leukocytes are absent. If there is a large increase in the number of 
leukocytes in the myometrium at labour, these leukocyte markers are expected to 
be upregulated. 
 Genes reported in the literature as associated with smooth muscle 
contraction (Figure 3.13c)   Caldesmon 1 (CALD1), Calmodulin 1 (CALM1), and 
Myosin light chain kinase (MYLK) are key proteins in smooth muscle contraction 
and Protein phosphatase 1 regulatory subunit 12A (PPP1R12A) is a subunit of 
myosin phosphatase, which plays a key role in smooth muscle relaxation.(222) 
Expression of these contraction-associated proteins might be expected to increase 
in labour. Connexin43 (Cx43), is a component of gap junctions and important for 
synchronised contraction. Cx43 transcript increases dramatically in labour in the 
rat, but no such increase is seen in humans.(56)  
 Inflammatory cytokines (Figure 3.13d)   Interleukin 1β (IL-1β), Interleukin 6 (IL-
6), Interleukin 8 (IL-8), Interleukin 10 (IL-10). Expression of the pro-inflammatory 
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cytokines IL-1β , IL-6 and IL-8 have all been previously identified in the 
myometrium, largely restricted to leukocytes,(5) and upregulated in labour 
compared to non-labour.(6,55,115,142,223) The anti-inflammatory cytokine, IL-
10, has previously been identified as upregulated in labour in the choriodecidua 
and amniotic fluid,(224,225) but not the myometrium.(115)  
 Genes reported in the literature as associated with myometrial activation 
(Figure 3.13e)   Estrogen receptor alpha (ERα), Oxytocin receptor (OXTR), 
Prostaglandin E synthase 2 (PTGES2), and Cyclooxygenase 2 (COX2), have all been 
shown to be upregulated in the myometrium at labour.(26,33,226,227) 
This analysis showed that leukocyte markers are upregulated and smooth muscle cell 
markers are downregulated at labour. Pro-inflammatory cytokines are highly upregulated, 
but genes classically associated with smooth muscle contraction are downregulated. Most 
genes classically associated with myometrial activation or stimulation are apparently not 
differentially expressed, which may be an effect of myocyte dilution (in other words, the 
myocytes do express greater amounts of activation stimulation markers, but their 
apparent density is diluted by the larger number of leukocytes in labouring samples, 
leading to an apparent lack of change in marker expression). 




Figure 3.13. Microarray results to illustrate changes in gene expression between 
labouring and non-labouring groups. Error bars indicate 95% confidence intervals  of the 
gene expression ratio between groups . Stars indicate the strength of statistical 
s ignificance, calculated using t -tests on labouring and non-labouring expression values.  
Higher numbers of leukocytes in labouring compared to non-labouring myometrium has 
been demonstrated previously (4). To confirm this in these samples, 
immunohistochemistry was carried out on 10 randomly selected myometrial samples (5 
labouring, 5 non-labouring) from the same patients who were included in the microarray. 
Samples were stained for the leukocyte marker CD45 as described in Chapter 2. Although 
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there was a high level of variation between samples, there tended to be more leukocytes in 
labouring samples compared to non-labouring samples (Figure 3.14).  
 
Figure 3.14. Staining for CD45 (brown) in myometrial t issue from (A) five labouring 
patients, and (B)  five non-labouring patients.  Pictures obtained using a 10x objective.  
3.3.8  ASSESSING CONFOUNDING  BY OTHER PATIENT CHA RACTERISTICS  
When observing the network graph in which nodes represent samples (previously shown 
in Figure 3.4), there are no significant associations between MCL cluster assignment and 
BMI category (P=0.2), gestation category (P=1, calculated with a Fishers exact test because 
cell numbers are low), and maternal age category (P=0.6, the 40+ group was combined 
with the 35-39 year old group to avoid invalidating the Chi-squared test due to low 
counts) (Figure 3.5). This suggests that these characteristics have little effect on 
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myometrial gene expression, however this technique is dependent on values assigned to 
the MCL clustering algorithm, so it does not provide strong evidence. 
 
Figure 3.15.  A network graph in which each node represents a different sample on the 
array.  The same graph is  coloured according to Markov chain (MCL) cluster number and 
several patient characteristics.  
The association between MCL cluster assignment and parity category (para=0/para≥1) 
was not significant (P=0.1 calculated using a Fishers exact test), however all 15 para≥1 
patients included on the graph appear in MCL cluster 1. This suggests that further work to 
confirm whether parity plays a small role in shaping the myometrial gene expression 
signature would be useful. In order to do this, lists of genes significantly associated only 
with first delivery (para=0) and only with subsequent deliveries (para≥1) were created. 
There were 246 genes associated with para=0 and 175 genes associated with para≥1 (the 
full list appears on the CD accompanying this thesis). 
 
 
3 - The myometrial transcriptome at labour 
 
108 
The number of genes that were significantly associated with parity and labour status was 
assessed (Figure 3.16). Although most genes are not associated with parity (i.e. they are 
not differentially expressed with a fold change of >1.2 or <-1.2, and an RP-PFP <0.05 
between para=0 and para≥1 samples), 150 genes that are upregulated in labour are 
associated only with first deliveries (para=0) and 38 are associated only with subsequent 
(para≥1) deliveries. 24 genes that are downregulated in labour are associated with para=0 



































Number of genes associated
with parity and labour status
 
Figure 3.16. The number of genes significantly associated with parity and labour status.  
Lists of genes upregulated in labour and para=0, and in labour and para≥1, were uploaded 
to DAVID to perform functional analyses. Table 3.8 shows the top five clusters of GO terms 
associated with the genes upregulated in labour and para=0. According to this, first labour 
is mainly associated with biological processes involved in inflammation, cell (probably 
leukocyte) movement/migration, responses to hormone stimulus, cytoskeleton 
organisation and the cell cycle. These are very similar to the biological processes 
associated with labour, regardless of parity (Table 3.5).  
 
Table 3.9 shows the top 10 clusters of GO terms associated with the genes upregulated in 
labour and para≥1. Again, the biological processes are similar to those identified as 
associated with labour regardless of parity. There are also no clear differences in the 
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biological processes identified as associated with para=0 and those identified as 
associated with para≥1. 
Table 3.8.  The top five clusters of GO terms associated with genes found to be 





















GO:0006952~defense response 39 26.17 1.8E-20 
GO:0006954~inflammatory response 23 15.44 9.2E-13 
GO:0009611~response to wounding 27 18.12 1.0E-11 
2 3.30 
GO:0006909~phagocytosis 6 4.03 1.1E-04 
GO:0006897~endocytosis 10 6.71 3.4E-04 
GO:0010324~membrane invagination 10 6.71 3.4E-04 
GO:0016044~membrane organization 12 8.05 1.4E-03 
GO:0016192~vesicle-mediated transport 15 10.07 1.7E-03 
3 3.10 
GO:0010033~response to organic substance 23 15.44 2.2E-06 
GO:0048545~response to steroid hormone 
stimulus 
10 6.71 1.2E-04 
GO:0009719~response to endogenous stimulus 14 9.40 1.9E-04 
GO:0009725~response to hormone stimulus 13 8.72 2.9E-04 
GO:0031960~response to corticosteroid 
stimulus 
5 3.36 1.0E-02 
GO:0014070~response to organic cyclic 
substance 
5 3.36 3.2E-02 
GO:0051384~response to glucocorticoid 
stimulus 
4 2.68 4.2E-02 
4 3.09 
GO:0009617~response to bacterium 9 6.04 6.7E-04 
GO:0042742~defense response to bacterium 7 4.70 8.6E-04 
GO:0050830~defense response to Gram-
positive bacterium 
4 2.68 9.6E-04 
5 2.68 
GO:0007010~cytoskeleton organization 15 10.07 1.1E-04 
GO:0030036~actin cytoskeleton organization 9 6.04 1.8E-03 
GO:0030029~actin filament-based process 9 6.04 2.7E-03 
GO:0007015~actin filament organization 4 2.68 3.5E-02 
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Table 3.9.  The top five clusters of GO terms assoc iated with genes found to be 





















GO:0030334~regulation of cell migration 4 10.81 6.7E-03 
GO:0040012~regulation of locomotion 4 10.81 9.4E-03 
GO:0051270~regulation of cell motion 4 10.81 9.6E-03 
GO:0001558~regulation of cell growth 4 10.81 9.7E-03 
GO:0042127~regulation of cell proliferation 6 16.22 3.2E-02 
GO:0040008~regulation of growth 4 10.81 4.2E-02 
2 1.68 
GO:0009617~response to bacterium 4 10.81 9.6E-03 
GO:0006955~immune response 6 16.22 1.9E-02 
GO:0006952~defense response 5 13.51 5.0E-02 
3 1.54 
GO:0007204~elevation of cytosolic calcium ion 
concentration 
4 10.81 2.0E-03 
GO:0010627~regulation of protein kinase 
cascade 
5 13.51 2.4E-03 
GO:0051480~cytosolic calcium ion homeostasis 4 10.81 2.4E-03 
GO:0006874~cellular calcium ion homeostasis 4 10.81 8.3E-03 
GO:0055074~calcium ion homeostasis 4 10.81 8.9E-03 
GO:0006875~cellular metal ion homeostasis 4 10.81 1.0E-02 
GO:0055065~metal ion homeostasis 4 10.81 1.1E-02 
GO:0008284~positive regulation of cell 
proliferation 
5 13.51 1.4E-02 
GO:0030005~cellular di-, tri-valent inorganic 
cation homeostasis 
4 10.81 1.5E-02 
GO:0055066~di-, tri-valent inorganic cation 
homeostasis 
4 10.81 1.7E-02 
GO:0030003~cellular cation homeostasis 4 10.81 2.0E-02 
GO:0019725~cellular homeostasis 5 13.51 2.1E-02 
GO:0055080~cation homeostasis 4 10.81 2.7E-02 
GO:0009967~positive regulation of signal 
transduction 
4 10.81 2.9E-02 
GO:0042127~regulation of cell proliferation 6 16.22 3.2E-02 
GO:0010647~positive regulation of cell 
communication 
4 10.81 3.9E-02 
GO:0007166~cell surface receptor linked signal 
transduction 
9 24.32 5.3E-02 
GO:0006873~cellular ion homeostasis 4 10.81 5.3E-02 
GO:0055082~cellular chemical homeostasis 4 10.81 5.5E-02 
GO:0050801~ion homeostasis 4 10.81 6.6E-02 
GO:0042592~homeostatic process 5 13.51 9.0E-02 
GO:0007186~G-protein coupled receptor 6 16.22 1.1E-01 
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protein signaling pathway 
GO:0048878~chemical homeostasis 4 10.81 1.1E-01 
GO:0043085~positive regulation of catalytic 
activity 
4 10.81 1.2E-01 
GO:0044093~positive regulation of molecular 
function 
4 10.81 1.5E-01 
GO:0030030~cell projection organization 3 8.11 2.1E-01 
GO:0007242~intracellular signaling cascade 4 10.81 5.6E-01 
4 1.28 
GO:0007610~behavior 5 13.51 2.1E-02 
GO:0042330~taxis 3 8.11 5.2E-02 
GO:0006935~chemotaxis 3 8.11 5.2E-02 
GO:0007626~locomotory behavior 3 8.11 1.3E-01 
5 1.26 
GO:0010627~regulation of protein kinase 
cascade 
5 13.51 2.4E-03 
GO:0032101~regulation of response to external 
stimulus 
4 10.81 5.6E-03 
GO:0032103~positive regulation of response to 
external stimulus 
3 8.11 9.4E-03 
GO:0012501~programmed cell death 6 16.22 1.2E-02 
GO:0008284~positive regulation of cell 
proliferation 
5 13.51 1.4E-02 
GO:0008219~cell death 6 16.22 2.3E-02 
GO:0016265~death 6 16.22 2.3E-02 
GO:0009967~positive regulation of signal 
transduction 
4 10.81 2.9E-02 
GO:0009611~response to wounding 5 13.51 3.2E-02 
GO:0042127~regulation of cell proliferation 6 16.22 3.2E-02 
GO:0010647~positive regulation of cell 
communication 
4 10.81 3.9E-02 
GO:0006915~apoptosis 5 13.51 4.7E-02 
GO:0010740~positive regulation of protein 
kinase cascade 
3 8.11 5.6E-02 
GO:0051345~positive regulation of hydrolase 
activity 
3 8.11 6.3E-02 
GO:0048584~positive regulation of response to 
stimulus 
3 8.11 1.0E-01 
GO:0042981~regulation of apoptosis 5 13.51 1.1E-01 
GO:0043067~regulation of programmed cell 
death 
5 13.51 1.1E-01 
GO:0010941~regulation of cell death 5 13.51 1.1E-01 
GO:0043085~positive regulation of catalytic 
activity 
4 10.81 1.2E-01 
GO:0044093~positive regulation of molecular 
function 
4 10.81 1.5E-01 
GO:0051336~regulation of hydrolase activity 3 8.11 1.8E-01 
GO:0043066~negative regulation of apoptosis 3 8.11 1.9E-01 
GO:0043069~negative regulation of 
programmed cell death 
3 8.11 2.0E-01 
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GO:0060548~negative regulation of cell death 3 8.11 2.0E-01 
GO:0043065~positive regulation of apoptosis 3 8.11 2.6E-01 
GO:0043068~positive regulation of 
programmed cell death 
3 8.11 2.6E-01 
GO:0010942~positive regulation of cell death 3 8.11 2.6E-01 
3.3.8.1  ASSESSING CONFOUNDING  W ITHIN  THE LABOURING GROUP  
Another network graph was produced using only the labouring samples. This allows 
assessment of the impact on myometrial gene expression of patient characteristics that 
are only relevant to the labouring group. Figure 3.17 shows the network graph coloured 
according to MCL cluster number, whether the patient was administered 
prostaglandins/syntocinon, and rough stage of labour (assessed as ‘early’ if cervical 
dilation was ≤3cm, and ‘late’ if cervical dilation was ≥6cm). Fisher’s exact or χ2 tests 
showed no significant association between MCL cluster membership and either stage of 
labour (P=0.6) or induction/augmentation status (P=0.7). 
 
Figure 3.17.  A network graph in which each node represents a different  labouring  sample 
on the array.  The same graph is  coloured according to Ma rkov chain (MCL) cluster 
number and two patient character istics: induction/augmentation of labour status and 
rough stage of labour.  There appears to be fewer nodes in the ‘Stage of labour’ graph 
because nodes representing patients with cervical dilation between 3 and 6cm are 
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3.3.9  M ICROARRAY META-ANALYSIS 
3.3.9.1  L ITERATURE SEARCH  
A literature search was conducted to identify microarrays comparing labouring and non-
labouring myometrial gene expression.  
Table 3.10 shows the number of results for keyword searches in online literature 
repositories.  
Table 3.10. Number of results for keyword searches in online repositories of abstracts 
and microarray data.  
 
Abstract repositories Microarray data repositories 











76 3790 145 123   
"uterine smooth muscle" 
+ microarray 
6 659 15 11   
myometrium     31 37 
myometrial     17 3 
“uterine smooth muscle”     31 2 
3.3.9.2  SELECTED STUDIES  
The 10 eligible studies are outlined in Table 3.11. Although ten studies were identified, 
raw data was only available for three: Bukowski 2006 (55), O’Brien 2008 (119), and 
Weiner 2010 (115). These studies were included in the meta-analysis, along with the 
study conducted as part of this PhD, referred to as “Sharp 2013”. This would equate to 27 
extra (not including Sharp 2013) samples,  however when the authors of the O’Brien study 
(119) supplied the data files, they confirmed that two samples (one term in labour and one 
term not in labour) had been removed from their analysis because they “deviated from the 
others”. These samples were also omitted from the meta-analysis. Therefore the meta-
analysis used 29 samples (15 labouring, 14 non-labouring), plus the 48 used in Sharp 
2013, giving a total of 77 samples (37 labouring, 40 non-labouring). 
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Table 3.11. Studies eligible for the meta-analysis. 
First author Microarray platform 
Groups compared 
(number of LS 
myometrial 
samples) 
Inclusion in meta-analysis 
Aguan 
(2000)(112) 
Atlas Human cDNA array blots 
TNIL (3) 
TIL (3) 
 No reply from authors 




 No reply from authors 
Charpigny 
(2003)(114) 
Atlas Human 1.2 and 1.2II 











Incyte Human UniGEM V .14 
NIL (6) 
TIL (4) 
 No reply from authors 
Bukowski 
(2006)(55) 




Raw data available in 
online repository 
Esplin (2005)(141) 
Unknown (cDNA hybridized to 
two glass chips and imaged 
using the Molecular Dynamics 









Applied 130 Biosystems 

































Raw data available in 
online repository 
TNIL, Term not in labour; TIL, Term in labour; PTNIL, Preterm not in labour; PTIL, Preter m 
in labour; NIL, Not  in labour; LS, lower segment.  
3.3.9.3  PREPROCESSING  
The Weiner and Bukowski datasets were preprocessed in the same way as Sharp 2013 – 
by subjecting the data to RMA background correction before quantile normalisation to 
remove non-biological variation. Figure 3.18 shows boxplots to visualise the distribution 
of expression values across all probes and all samples before (A and C) and after (B and D) 
normalisation for both studies. Compared with Sharp 2013 (Figure 3.1) there are large 
variations in the raw data, indicating a large amount of inter-patient variation and perhaps 
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lower RNA quality. O’Brien 2008 did not undergo consistent preprocessing because the 
authors did not supply raw data.  
 
Figure 3.18. Boxplots to show the distribution of expression values across all samples in 
Weiner 2010 and Bukowski 2006 before and after quantile normalisation.  
3.3.9.4  ASSESSING DIFFERENTIA L EXPRESSION  
Figure 3.19 shows the number of significantly (RP-PFP<0.05) differentially expressed (fold 
change of >1.2, <-1.2) genes in Sharp 2013, Weiner 2010 and Bukowski 2006, and the 
number of genes in agreement between studies. There are only 42 genes agreed to be 
differentially expressed (regardless of the direction of the change) in all three studies. 
These are listed along with their fold changes in Table 3.12. 




Figure 3.19. The number of genes significantly differentially expressed (regardless of the 
direction of the change) between non -labouring and labouring samples in three 
microarray studies.  
Table 3.12. Fold changes of genes agreed to be significantly differentially expressed in all 
three studies considered in the microarray meta -analysis. 












ABP1 amiloride binding protein 1 2.96 -1.47 2.92 No 
AHNAK2 AHNAK nucleoprotein 2 -1.32 -1.55 -1.54 Yes 
ALDH1A2 
aldehyde dehydrogenase 1 family, member 
A2 
-1.35 -1.88 -1.49 Yes 
AP3S1 
adaptor-related protein complex 3, sigma 1 
subunit 
-1.24 -1.26 -1.91 Yes 
ATP2B4 
ATPase, Ca++ transporting, plasma 
membrane 4 
-1.24 -1.44 -1.70 Yes 
CALD1 caldesmon 1 -1.44 -1.32 -1.50 Yes 
CAV1 caveolin 1, caveolae protein, 22kDa -1.29 -1.28 -1.45 Yes 
CCL2 chemokine (C-C motif) ligand 2 4.01 3.41 1.32 Yes 
CCT2 
chaperonin containing TCP1, subunit 2 
(beta) 
1.32 1.25 -1.41 No 
COL1A2 collagen, type I, alpha 2 -1.20 -1.48 -1.22 Yes 
DAAM1 
dishevelled associated activator of 
morphogenesis 1 
-1.54 -1.86 -2.80 Yes 
FHL1 four and a half LIM domains 1 -1.44 -1.46 -1.34 Yes 
GAS1 growth arrest-specific 1 -1.26 -1.42 -1.39 Yes 
HSP90AA1 
heat shock protein 90kDa alpha (cytosolic), 
class A member 1 
1.22 1.24 -1.49 No 
ISCU iron-sulfur cluster scaffold homolog (E. coli) -1.26 -1.23 -1.67 Yes 
LAMA2 laminin, alpha 2 -1.26 -1.65 -1.87 Yes 
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LDHA lactate dehydrogenase A 1.38 1.38 -1.22 No 
LITAF lipopolysaccharide-induced TNF factor 1.31 1.52 -2.01 No 
METTL7A methyltransferase like 7A -1.40 -1.57 -2.26 Yes 
MFAP5 microfibrillar associated protein 5 -1.32 -1.44 -2.05 Yes 
NR2F2 
nuclear receptor subfamily 2, group F, 
member 2 
-1.52 -1.46 -1.87 Yes 
PARVA parvin, alpha -1.46 -1.31 -1.23 Yes 
PGK1 phosphoglycerate kinase 1 1.35 1.35 -1.35 No 
PLA2G2A 
phospholipase A2, group IIA (platelets, 
synovial fluid) 
1.64 2.71 1.49 Yes 
PRG2 proteoglycan 2 2.14 1.62 4.24 Yes 
PRKAR1A 
protein kinase, cAMP-dependent, 
regulatory, type I, alpha 
-1.28 -1.30 -2.27 Yes 
PRSS23 protease, serine, 23 -1.21 -1.61 -1.36 Yes 
RASSF2 
Ras association (RalGDS/AF-6) domain 
family member 2 
-1.41 -1.58 -2.00 Yes 
RNASE1 ribonuclease, RNase A family, 1 (pancreatic) -1.32 -1.25 -1.35 Yes 
S100A8 S100 calcium binding protein A8 3.33 3.58 1.27 Yes 
SPP1 secreted phosphoprotein 1 2.00 1.88 1.71 Yes 
STAT3 
signal transducer and activator of 
transcription 3 
1.27 1.41 -1.66 No 
SVIL supervillin -1.86 -1.38 -1.85 Yes 
SYNM synemin, intermediate filament protein -1.52 -1.32 -1.89 Yes 
TCEAL1 transcription elongation factor A (SII)-like 1 -1.51 -1.44 -1.63 Yes 
TCEAL4 transcription elongation factor A (SII)-like 4 -1.63 -1.38 -1.28 Yes 
TMEM123 transmembrane protein 123 -1.34 -1.22 -1.96 Yes 
TMEM59 transmembrane protein 59 -1.21 -1.42 -1.82 Yes 
TPM1 tropomyosin 1 (alpha) -1.47 -1.22 -1.20 Yes 
TUBB2A tubulin, beta 2A -1.44 -1.23 -1.60 Yes 
VCL vinculin -1.44 -1.22 -1.52 Yes 
ZFP36 
zinc finger protein 36, C3H type, homolog 
(mouse) 
1.71 1.24 -1.21 No 
Figure 3.20 and Figure 3.21  show Forrest plots of the standardised mean difference in 
gene expression between labouring and non-labouring groups for each study for smooth 
muscle markers (markers of myofilament (220) Figure 3.20) and leukocyte markers 
(macrophage markers (221) Figure 3.21). In general, studies agree on the direction of the 
changes and heterogeneity (assessed using Tau2 and significance of the Chi2 statistics) is 
low. 
 




Figure 3.20. Forrest plots of the mean standardised  difference in smooth muscle marker 
gene expression between labouring and non -labouring groups in each study.  




Figure 3.21.  Forrest plots of the mean standardised difference in leukocyte marker gene 
expression between labouring and non-labouring groups in each study.  
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3.3.9.5  FUNCTIONAL ANALYSIS  
As described above for Sharp 2013, functional analysis was performed on lists of official 
gene identifiers representing 1) down-regulated genes (fold change <-1.2 and RP-PFP 
≤0.05) and 2) up-regulated genes (fold change >1.2 and RP-PFP ≤0.05) for each study 
individually (Again, O’Brien 2008 could not be used to perform these analyses). Figure 
3.22 shows the number of GO terms up and down regulated in labour according to each 
study, and each combination of studies. 25 GO terms were agreed to be upregulated by all 
three studies and 52 were agreed to be downregulated. The main classes of these GO 
terms are summarised in Table 3.13. 
 
Figure 3.22. Venn diagrams to illustrate the number of GO terms upregulated and 
downregulated in labour according to each study.  
Table 3.13. Summarised classes of the main GO terms agreed to be up or down regulated 
in labour by Sharp 2013, Weiner 2010 and Bukowski 2006.  
Upregulated in labour Downregulated in labour 
Defense response Response to hormone stimulus 
Response to organic substance Response to endogenous stimulus 
Response to wounding Response to steroid hormone stimulus 
Inflammatory response Response to estrogen stimulus 
Regulation of cell proliferation Muscle organ development 
3.4 DISCUSSION  
The myometrial transcriptome of labouring women differed considerably from that of 
non-labouring women. In terms of overall gene expression, non-labouring samples were 
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very similar to each other and different from labouring samples, but labouring samples 
were more varied. This suggests that we can be confident that the women supplying non-
labouring samples were not in labour, and the women supplying the labouring samples 
were in labour but likely to be at different stages. 1761 genes were differentially 
expressed between the two groups, which is considerably more than identified by 
previous microarray experiments of this kind (115,140). Network graph and Gene 
Ontology analysis showed that labour was associated with an upregulation of biological 
processes such as inflammation and cell movement/migration, and a downregulation of 
muscle-specific processes and pathways such as muscle development, smooth muscle 
contraction and calcium signalling. The main protein pathways identified as associated 
with labour (Nod-like receptor signalling, MAPK activation and cytokine-cytokine receptor 
signalling) are all downstream or involved in crosstalk with pathways to NF-kappa B (NF-
κB) activation.  These observations are in agreement with the results of previous human 
microarray studies (115,130,140,155,228), might provide further evidence to support the 
hypothesis that the initiation of parturition is associated with inflammation. However, it 
was also hypothesised that these observations may be in part due to a change in the 
composition of the myometrial tissue at labour. It has previously been demonstrated that 
more leukocytes are present in labouring myometrium compared to non-labouring 
myometrium. This has been interpreted as evidence of leukocytes infiltrating the 
myometrium at labour (4), but an alternative explanation is that labouring samples 
contain more blood than non-labouring samples due to the trauma of emergency 
Caesarean delivery. Staining for the leukocyte marker CD45 confirmed the presence of 
more leukocytes in labouring compared to non-labour samples in this study. The 
microarray data showed that leukocyte markers were “upregulated” and smooth muscle 
cell markers were “downregulated” in labouring compared to non-labouring samples. 
Some genes that have been implicated in the initiation of labour by previous studies were 
not differentially expressed in this study, suggesting the contribution of myometrial 
smooth muscle cells may be diluted by the greater leukocyte composition. The feasibility 
of adjusting for this effect (for example, by normalising gene expression values to the 
expression of leukocyte markers) was considered. However, this was unlikely to be useful 
or reliable in noisy data. 
The patient samples were selected to maximise the number of samples in the experiment, 
rather than minimise interpatient variation. Therefore, there was a high degree of patient 
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variation within (but not between) each group on BMI, maternal age, gestational age, 
parity and stage of labour (in the labouring group, assessed by cervical dilation). Network 
graph analysis suggested that these factors were unlikely to have a significant impact on 
the results; samples appeared to cluster by labour status rather than any other 
characteristic. However, this does not provide definitive evidence of no significant 
confounding. Previous studies have shown a significant difference in the myometrial gene 
expression signature of women in preterm and term labour (115,229). Our results did not 
support this finding, but the number of preterm samples in our analysis was small (4 
labouring, 2 non-labouring). Parity appeared to have a small effect on myometrial gene 
expression, with 421 genes being significantly differentially expressed in first deliveries 
(para=0) compared to subsequent deliveries (para≥1). However, functional analysis did 
not show any clear differences in the biological processes identified as associated with 
para=0 and those identified as associated with para≥1. 
The results were compared to the published results of similar microarrays using a meta-
analysis. This is the first time microarray data to study parturition has been meta-analysed 
using raw, complete data. The meta-analysis showed that although different studies show 
limited agreement on the precise myometrial gene signature associated with labour, 
studies do agree that labour is associated with an “upregulation” of inflammatory 
processes and a “downregulation” of muscle-specific processes. No microarray study can 
suggest whether these results are due to leukocyte infiltration into the myometrium as a 
mechanism initiating labour, or due to larger numbers of leukocytes in labouring 
myometrium as a consequence of the trauma of emergency Caesarean section. 
The main strengths of this study are its size and the comprehensive, novel methods used 
to analyse the data. In studies of parturition, gene expression is likely to show a 
particularly high degree of variation between individuals. This is not only due to genetic 
and environmental effects, but also because the time to the onset of spontaneous labour in 
non-labouring samples is unknown (55). The large sample size used in this study helps to 
reduce some of this bias by increasing the power of the study to detect real changes in 
gene expression. Additionally, network graph and meta-analytical approaches have been 
used for the first time to study the myometrial transcriptome at labour. The network 
graph approach offered new insights into the effect of patient variability on gene 
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expression signatures, and the meta-analysis further increased the statistical power, 
reliability and generalizability of results. 
There are, however, some limitations to this study that must be considered when 
interpreting the results.  
1) No “control” sample was included on all of the four microarray chips. If such a control 
had been included, a more accurate estimation of any batch-effect could have been made 
and adjusted for.  
2) The qRT-PCR validation of the microarray results was conducted on the same samples 
used in the array. More reliable validation could have been achieved using samples from 
different patients, but this was impossible due to lack of availability of such samples. The 
large number of samples used in this study means this is less of a limitation than it is for 
smaller microarray experiments.  
3) IHC confirmed the presence of the CD45 protein in non-labouring and labouring 
samples, so it is surprising that the mRNA transcript was not expressed above 
background. qRT-PCR for CD45 would have been useful for validating this result.   
Furthermore, the IHC results show a lot of variation between patients. More compelling 
evidence of a difference between non-labouring and labouring samples could have been 
achieved by examining more than one tissue section per patient, counting CD45-stained 
cells to give a quantitative measure of differential protein expression, and staining for 
other leukocyte markers. 
4) The non-labouring samples were collected during elective Caesarean section that was 
sometimes performed because the woman had previously delivered via Caesarean section 
due to an underlying uterine pathology. Additionally, the labouring samples were collected 
during emergency Caesarean section, performed for reasons such as breech presentation, 
failure to progress in labour and fetal distress. Therefore, many of the patients in the study 
cannot be considered physiologically “normal”, which raises the question of whether or 
not the results can be generalised to a normal population.  
5) Many of the women had undergone treatment with syntocinon, prostaglandins or both 
to induce or augment labour. It is unclear how these treatments may effect global gene 
expression in the myometrium, but they are likely to contribute to the upregulation of 
3 - The myometrial transcriptome at labour 
 
124 
genes with an inflammatory role. Network graph analysis of labouring samples suggested 
this effect was small.  
6) Parity has been categorised as para=0 for women with no previous children and para≥1 
for women with one or more children, however, this information is insufficient to state 
that women in the para=0 group have never undergone labour before or that women in 
the para≥1 group have.  
7) Due to time restrictions, no protein-level analyses were conducted, which would have 
validated the gene-level results. Some similar microarray studies have confirmed 
differential expression using ELISA and Western blots (119,120,140). However, when 
published, our data will be available in full online, providing the possibility for results to 
be validated at the protein-level by any other researcher. 
8) The network graph approach is useful for offering insights into the effect of patient 
variability on gene expression and for providing useful visualisations of the data, however 
the MCL clustering algorithm is dependent on values assigned to its parameters. These 
values are defined through empirical testing to achieve a result the researcher believes to 
be most informative and useful. However, this introduces a level of bias and subjectivity, 
that should be considered when interpreting these graphs. 
9) Tissue was collected from the upper flap of the lower transverse incision through the 
uterine wall, which is the most convenient location at the time of Caesarean. However, the 
upper segment is known to show increased contractility relative to the lower segment 
(55,230,231), making it arguably a more appropriate tissue to study. Furthermore, 
previous studies have shown significant differences in gene expression and molecular 
pathways associated with the initiation of labour between the upper and lower uterine 
segments (55,56), so the results of this study cannot be assumed to be relevant to the 
molecular events taking place throughout the whole organ (54). 
10) Finally, although microarray experiments can highlight differences in gene expression 
between non-labouring and labouring samples, they are not able to prove that these 
differences cause a progression towards labour, and other hypothesised explanations 
(such as greater blood content of labouring samples due to the trauma of emergency 
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Caesarean section, or inflammation caused by vigorous myometrial contraction) remain 
possibilities.  
In conclusion, labour appears to be characterised by an “upregulation” of inflammatory 
genes and a “downregulation” of muscle-specific processes in human lower segment 
myometrium. Both the large sample size and the meta-analysis with previous studies 
improve the reliability and generalisability of these results. Our results suggest that other 
patient characteristics such as gestational age, BMI, maternal age and parity do not to have 
a large effect on the myometrial transcriptome. Appropriate analysis of high throughput 
studies such as this are essential for improving our understanding of the molecular 
mechanisms underlying parturition, and will provide a basis for understanding differences 
between normal and dysfunctional or preterm labour. 
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4 A COMPUTATIONAL MODEL OF A KEY SIGNALLING 
PATHWAY IN INFECTION-INDUCED PRETERM LABOUR 
4.1 INTRODUCTION  
In addition to the high throughput data generation and analysis described in chapter two, 
the novel approach of systems biology also provides useful strategies to integrate complex 
interactions within biological systems through building computational models. Such 
models can be used to develop comprehensive in silico reproductions of “pregnant” tissues  
that demonstrate “emergent” properties, not obvious by conventional analysis (156). 
Computational models of the molecular mechanisms initiating parturition could (i) 
identify gaps in knowledge where additional wet lab experiments are required, and (ii) 
provide the basis for an in silico model of parturition for “testing” novel drugs to treat or 
prevent preterm labour. For example, a model could predict how a myometrial smooth 
muscle cell might respond to the inhibition of an intracellular pathway and used to inform 
the design of further in vitro experiments in the initial stages of drug design. 
This chapter describes the use of published data to develop a comprehensive model of an 
important candidate signalling pathway in infection-induced preterm labour: that of 
lipopolysaccharide (LPS) -induced activation of nuclear factor kappa B (NF-κB). This is an 
important candidate signalling pathway in infection-induced preterm labour. The actions 
of LPS and NF-κB are well characterised: LPS is a gram negative bacterial endotoxin that 
triggers an inflammatory response in many cells including uterine smooth muscle cells 
(232). LPS is often used in animal and culture studies to mimic intrauterine infection 
which subsequently induces preterm labour (228,233–235), therefore the actions of LPS 
could be considered to replicate the actions of the initiator of some cases of infection-
induced preterm labour. LPS binds to its receptor, Toll-Like Receptor 4 (TLR4) to trigger 
an innate immune response. TLR4 is expressed in the decidua, amnion and myometrium, 
and expression is higher at term compared to preterm (236,237). TLR4-neutralising 
monoclonal antibody and TLR4 antagonists have been shown to inhibit LPS- and 
inflammation-induced preterm labour in a mouse (238) and a primate model These 
studies suggest that TLR4 plays an important role in the induction of  gram-negative 
bacteria infection-induced uterine contractility. Other toll-like receptors (such as TLR2) 
also appear to play a key role in parturition (236,237,239,240). TLR2 recognises 
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endotoxins associated with gram-positive bacteria and shows increased expression in 
chorion, amnion and myometrium at labour (237). 
All toll-like receptor signalling pathways culminate in activation of NF-κB (241). NF-κB is a 
protein complex transcription factor with a particular role in the immune response to 
infection. It is activated in response to pro-inflammatory stimuli (242), but also regulates 
the transcription of inflammatory genes (243–245). NF-κB activity increases in human 
labour, particularly in the fetal membranes (246), but also in the myometrium, where 
labour is associated with an increase in the NF-κB p65-p50 herterodimer in pregnancy 
and labouring tissue compared to non-labouring tissue (247). In this way NF-κB may act 
as a feed-forward mechanism for the inflammatory events associated with labour (248). In 
fact, the microarray experiment in the previous chapter (in agreement with other studies 
(130,133,155)) identified several inflammatory pathways associated with labour, all of 
which are downstream of or involved in crosstalk with pathways that activate NF-κB.  
Therefore, in a uterine smooth muscle cell, the LPS/NF-κB signalling pathway is likely to 
be involved in triggering preterm labour in response to intrauterine infection. 
4.2 SUMMARY OF METHODS  
Detailed model development methods are discussed in Chapter 2. Briefly, a literature 
search was conducted to provide specific information on the structure and kinetic 
behaviour of the LPS/ NF-κB signalling pathway (described in section 2.2.3). The reasons 
for selecting this model target are explained in section 2.2.1). Graphical representations of 
the pathway that detail every reaction were drawn using two standardised graphical 
notations (SBGN and mEPN, described in section 2.2.4). The software tool Copasi was used 
to build a kinetic model of the pathway based on ordinary differential equations (ODEs, 
the reasons for selecting this modelling approach are discussed in section 2.2.2 and model 
development is discussed in section 2.2.5). The model was developed through successive 
rounds of running steady-state and time-course simulations, comparing outputs to 
published descriptions of the pathway’s behaviour in vitro, and adjusting the model 
(described in section 2.2.6). An attempt was also made to test the ability of the model to 
recapitulate the in vitro behaviour of the system when either of two upstream proteins 
(MyD88 and TRIF) is knocked-out. 
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4.3 RESULTS  
4.3.1  THE LITERATURE SEARCH  
An extensive literature search (described in Chapter 2) provided information on the LPS-
NF-κB pathway. Figure 4.1 shows a simplified overview of the canonical LPS-NF-κB p65-
p50 pathway, derived from generally accepted interactions in the literature.  
 
Figure 4.1.  A simplified overview of the LPS -induced NF-κB signalling pathway. IκB, 
nuclear factor of kappa light polypeptide gene enhancer in B -cells  inhibitor (alpha, beta 
and epsilon isoforms are incorporated into the model); IKK, IκB kinase; LPS, 
l ipopolysaccharide; MyD88, myeloid differentiation primary response gene 88; NF -κB, 
nuclear factor kappa B; TLR4, toll - like receptor 4; TNFα, tumour necrosis  factor alpha; 
TNFR, tumour necrosis  factor receptor; TRIF, Tir -Domain-Containing Adapter-Inducing 
Interferon-β.  
The pathway can be split into three modules: 1) The MyD88-dependent pathway, 2) The 
TRIF-dependent pathway, 3) IκB-NF-κB signalling.  
The reactions that describe LPS activation of its receptor Toll Like Receptor 4 (TLR4) are 
common to both modules 1 and 2: LPS binds to LPS-binding protein (LBP) (249) and this 
complex binds to and activates CD14 on the cell membrane.(250) CD14 then helps 
transport the LPS-LBP complex to TLR4 where LPS activates the receptor (251–254). 
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Further downstream signalling occurs via two pathways: one dependent on Myeloid 
Differentiation Primary Response Gene 88 (MyD88) and the other dependent on Tir-
Domain-Containing Adapter-Inducing Interferon-β (TRIF). The MyD88-dependent 
pathway is largely responsible for the expression of proinflammatory cytokines (255–
260), and the main role of the TRIF-dependent pathway is to induce expression of co-
stimulatory molecules and IFN-inducible genes (261–264). NF-κB can be activated via 
either pathway, and in vivo the two pathways probably interact to maximise expression of 
inflammatory cytokines (265). 
Module 1) The MyD88-dependent pathway 
The MyD88-dependent pathway begins when TIRAP (toll-interleukin 1 receptor 
domain containing adaptor protein) is recruited to the cytoplasmic domain of 
TLR4 (266,267). TIRAP recruits MyD88,(266–268) which binds IRAK4 
(interleukin-1 receptor-associated kinase 4) (269,270), IRAK1 (interleukin-1 
receptor-associated kinase 1) (271) and TRAF6 (TNF receptor associated factor 
6)(272,273). IRAK1 is phosphorylated by IRAK4 (269,274,275) and then the 
IRAK1/TRAF6 complex dissociates from the receptor (271,275). TRAF6 then 
interacts with a complex consisting of the MAPK kinase kinase transforming 
growth factor-beta-activated kinase 1 (TAK1) and its binding proteins TAB1 and 
TAB2 (276). The TRAF6/IRAK1/TAK1/TAB1/TAB2 complex is inactive until it 
translocates to the cytoplasm and forms a larger complex with the ubiquitin-
conjugating enzymes Ubc13 and Uev1A. This ubiquitination activates TAK1 and 
marks IRAK1 for degradation by the proteasome (276,277). TAK1 phosphorylates 
an IκB kinase (IKK) complex consisting of two catalytic subunits (IKKα and IKKβ) 
and a regulatory subunit (IKKγ) (278–281). This phosphorylated IKK complex 
feeds into the IκB-NF-κB signalling module of the pathway. 
Module 2) The TRIF-dependent pathway 
Compared to the MyD88-dependent pathway, less is known about the TRIF-dependent 
module. Here we have modelled the pathway according to the suggestions put forward 
by Covert et al. (205). They observed delayed NF-κB activation in MyD88-deficient 
mouse embryo fibroblasts (MEFs) treated with LPS. They hypothesised that the delay 
occurs because the TRIF-dependent pathway requires protein synthesis before NF-κB 
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can be activated via a secondary signal in an autocrine manner.  Microarray analysis of 
LPS stimulated MyD88-deficient MEFs showed significant upregulation of the tumour 
necrosis factor alpha (TNFα) transcript, which (along with the findings of additional 
validation experiments) led them to suggest that TNFα is the autocrine signal 
responsible for the late-phase activation of NF-κB in response to LPS. 
The pathway they put forward begins when TRIF-related adapter molecule (TRAM) 
binds to active TLR4 (282–284) and acts as a bridging adaptor connecting TLR4 to 
TRIF (283,285). This complex activates two non-canonical IKKs, TANK-binding kinase 
1(TBK1) and IKKε (286–288), which phosphorylate Interferon Regulatory Factor 3 
(IRF3) (286,287,289). IRF3 then translocates to the nucleus and regulates 
transcription of TNFα. TNFα is secreted into the extracellular space where it binds to 
its membrane receptor TNFR1 (290). This leads to the recruitment of TRAF2, TRADD 
and RIP1. TRAF2 then recruits the IKK complex, which allows it to be phosphorylated 
by RIP1 (291–295). 
Module 3) IκB-NF-κB signalling 
In resting cells, NF-κB is sequestered in an inactive state in the cytoplasm by 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IκB). 
Active IKK can bind to and phosphorylate IκB, which causes it to degrade and 
therefore release NF-κB (288,296). Free NF-κB then translocates to the nucleus 
where it regulates transcription of target genes, including the IκB isoform IκBα 
(297–299). The production of IκBα results in a negative feedback loop that causes 
oscillations in NF-κB activity (204,206). Two other IκB isoforms (IκBβ and IκBε) 
are also included in the model. They act in the same way as IκBα, but their 
production is not modelled as NF-κB-dependent and their activity is in antiphase 
with IκBα activity. This antiphase activity acts to dampen NF-κB oscillations. 
Much of the above information was derived from cell types other than uterine smooth 
muscle cells. There was insufficient data in the literature to confirm whether any 
deviations of this standard pathway occur in uterine smooth muscle cells and in the 
scenario of pregnancy. 
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4.3.2  GRAPHICAL DEPICTION  
The details of the individual molecular interactions of the pathway, which are well 
characterised in the experimental literature, were built into a single detailed graphical 
depiction of the canonical pathway. These present the topographical model according to 
two standardised graphical notations, Systems Biology Graphical Notation (SBGN) and 
Modified Edinburgh Pathway Notation (mEPN).. A key to these notations is provided in 
Appendix 4). These graphical representations detail every entity used in the final model, 
the reactions they are involved in, and in what way they react (binding, phosphorylation, 
etc.). They act as blueprints to the static structure of the model. Although SBGN and mEPN 
each have their own merits, arguably mEPN provides a clearer depiction of the model 
structure in this case. These are the first standardised graphical depictions of this 
pathway. High resolution images of these graphical depictions are included on the CD 
accompanying this thesis. 
4.3.3  THE KINETIC MODEL  
4.3.3.1  STRUCTURE AND KINETIC  PARAMETERS  
A kinetic model was built using known parameters for each of the processes shown in the 
graphical depiction. The model reaction and kinetic equations used in the final model are 
listed in Table 4.1. Table 4.2 lists the initial concentrations of molecular species used in the 
model. The full model, encoded in SBML format, is available in the Biomodels database 
(http://www.ebi.ac.uk/biomodels-main/MODEL1303230000). 
 An extensive search of the literature retrieved no data on time course behaviour or kinetic 
parameter values specific to uterine smooth muscle cells, so for the IKK-NF-κB portion of 
the model, kinetic values were taken from the model of Hoffmann et. al which was derived 
from experiments on mouse embryo fibroblasts (MEFs)(204). Kinetic values for the novel 
reactions that we included upstream of NF-κB activation (for example LPS to IKK, and 
production and actions of TNFα) were not available in the literature and were therefore 
imputed to fit the time course NF-κB activity profile observed by Covert et al. (205) in LPS-
treated MEFs. Data-fitting is a standard technique in computational modelling and can be 
achieved automatically through algorithms that find optimal values (203), however in this 
case, parameters were adjusted manually because data were sparse. 
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Table 4.1.  Summary of reactions and reaction parameters used in the model.  
 
Red italics  = parameters derived during model fitt ing to experimental data from 
Covert et al.  (205); all other values  = parameters used in Hoffmann et al. ’s  model of 
NF-κB signalling (204).  v= reaction rate, kf= rate of the forward reaction, kr  = rate 
of the reverse reaction.  
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Table 4.1 continued. 
 
Red italics  = parameters derived during model fitt ing to experimental data from 
Covert et al.  (205); all other values  = parameters used in Hoffmann et al. ’s  model of 
NF-κB signalling (204).  v= reaction rate, kf= rate of the forward reaction, kr  = rate 
of the reverse reaction.  
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Table 4.1 continued. 
 
Red italics  = parameters derived during model fitt ing to experimental data from 
Covert et al.  (205); all other values  = parameters used in Hoffmann et al. ’s  model of 
NF-κB signalling (204).  v= reaction rate, kf= rate of the forward reaction, kr  = rate 
of the reverse reaction.  
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Table 4.2.  .  Init ial (pre-steady state) concentrations of species used in the model.   
Species Initial concentration (µmol/ml) 
CD14  1* 
IkBa  0 
IkBa(nuc)  0 
IkBa:NFkB  0 
IkBa:NFkB(nuc)  0 
IkBa_mRNA  0 
IkBb  0 
IkBb(nuc)  0 
IkBb:NFkB  0 
IkBb:NFkB(nuc)  0 
IkBb_mRNA  0 
IkBe  0 
IkBe(nuc)  0 
IkBe:NFkB  0 
IkBe:NFkB(nuc)  0 
IkBe_mRNA  0 
IKK  0.1 
IKK[P]  0 
IKK[P]:IkBa  0 
IKK[P]:IkBa:NFkB  0 
IKK[P]:IkBb  0 
IKK[P]:IkBb:NFkB  0 
IKK[P]:IkBe  0 
IKK[P]:IkBe:NFkB  0 
IRAK1  1 
IRAK4  1* 
IRF3  1 
IRF3[P]  0 
IRF3[P](nuc)  0 
LBP  1* 
LPS  1* 
LPS:LBP:CD14:TLR4:RIP1:TRAM:TRIF:TBK/IKKe  0 
LPS:LBP:CD14:TLR4:TIRAP:MyD88:IRAK4  0 
MyD88  1* 
NFkB  0.1 
NFkB(nuc)  0 
RIP1  1* 
sink  0* 
source  1* 
TAK1:TAB1:TAB2  1* 
TAK1:TAB1:TAB2:TRAF6  0 
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TBK1/IKKe  1* 
TIRAP  1* 
TLR4  1* 
TNFa  0 
TNFa:TNFR1:TRAF2:TRADD:RIP1  0 
TNFR1  1* 
TRADD  1* 
TRAF2  1* 
TRAF6  1* 
TRAF6:IRAK1[P]  0 
TRAM  1* 
TRIF  1* 
All values were set to 1µmol/ml if  they were assumed to be present at t ime=0s and 0µM 
if they were assumed to be absent. NF -κB was set to 0.1µmol/ml as in Hoffmann et 
al. (204).  Concentrations marked with an asterisk were ‘fixed’ at their init ial 
concentrations to avoid overcomplicating the  model by modelling synthesis and 
degradation of these species.  
4.3.3.2  STEADY STATE BEHAVIOU R 
The model was run to steady state (i.e. when there were no further changes in 
concentrations over time) using different concentrations of LPS. This showed that both 
IKK (active and inactive) and free NF-κB (nuclear and cytoplasmic) show a dose response 
(Figure 4.2). At LPS doses over 0.4, there is a switch from the majority of IKK being 
inactive at steady state, to the majority being phosphorylated at steady state. 
Concentrations of nuclear and cytoplasmic NF-κB both increase with higher doses of LPS 
because LPS treatment leads to an increase in free cytoplasmic NF-κB via phosphorylated 
IKK, and this free cytoplasmic NF-κB then translocates to the nucleus.  




Figure 4.2.  Steady state concentrations at different doses of LPS.  A.  In silico  s imulation of 
steady state concentrations of inactive and phosphorylated IKK, and B .  In silico  
s imulation of steady  state concentrations of free nuclear and cytoplasmic NF -κB.  
4.3.3.3  T IME COURSE BEHAVIOUR  
The model mimics in silico the activation of NF-κB over time that Covert et al.(205) 
described in vitro in time course experiments on LPS-treated wild-type MEFs, and in silico 
in their model of IKK-NF-κB signalling (Figure 4.3). Nuclear (active) concentration of NF-
κB shows damped oscillatory behaviour.  The model also mimics in silico the time-course 
concentration of phosphorylated IKK found by Covert et al. (205) in vitro (Figure 4.4). The 
in silico model presented here mimics the pattern of these behaviours, although not to the 
exact degree; the timing, number of oscillations and exact concentrations are not the same 
as found by Covert et al. (205) in vitro. The model predicts that the concentration of the 
phosphorylated (active) form of IKK should increase with a small amount of oscillation 
and reach a maximum around 4 hours after LPS treatment. Covert et al.’s (205) Western 
blot analysis suggests a similar pattern, but with a faster and steadier increase in 
phosphorylated IKK, reaching a maximum at around two hours after treatment.  




Figure 4.3.  NF-κB time course behaviour of A.  Concentrations of nuclear NF -κB over t ime, 
simulated using the in silico  model described here, B.  Concentrations of nuclear NF -κB 
over t ime, s imulated using the in silico  model described by Covert et al. , C.  Experimental 
data from LPS-treated mouse embryo fibroblasts as described by Covert et al.  (205) 
 
Figure 4.4.  IKK time course behaviour.  A.  Concentrations of nuclear IKK over time, 
s imulated using the in silico  model described here, B.  Experimental data from LPS-
treated mouse embryo fibroblasts as described by Covert et al. (205) 
The model mimics in silico the activation of NF-κB over time that Covert et al. (205) found 
in TRIF (Tir-Domain-Containing Adapter-Inducing Interferon-β) and MyD88 (Myeloid 
Differentiation Primary Response Gene 88) knock-out cells in vitro (Figure 4.5). After LPS 
treatment of both knock-out cells, the time-course experiments of Covert et al. (205) 
showed increased oscillatory NF-κB activation compared to wild-type cells, and the 
initiation of NF-κB activation was delayed by around 30 minutes in MyD88 knock-out 
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compared to wild-type cells. Covert et al. (205) argued that this 30 minute delay occurs 
because the TRIF-dependent pathway relies on the synthesis and actions of TNFα. 
Whereas Covert et al. (205) could only mimic this behaviour in silico by introducing an 
artificial delay to mimic MyD88 knock-out, the extended model presented here allows 
MyD88 or TRIF to be ‘knocked-out’ directly, by fixing their concentrations at 0 before 
running steady state and time course simulations as described above. The model 
described here also includes the reactions involved in the synthesis of TNFα and its 
autocrine actions on the cell. Therefore it can be used to test the downstream effects of 
MyD88 and TRIF knock-out more naturally. The model successfully predicts increased 
oscillations in NF-κB activation when TRIF or MyD88 is ‘knocked-out’, and there is a 
simulated delay in NF-κB activation when MyD88 is ‘knocked-out’. Again, although the 
model captures the general pattern of the in vitro data, it is not quantitatively accurate. 
 
Figure 4.5.  NF-κB time course behaviour  in TRIF and MyD88 knock-out conditions.  A. 
Concentrations of nuclear NF -κB over t ime, s imulated using TRIF and MyD88 knock -out 
versions of the in silico  model described here, B.  Concentrations of nuclear NF-κB over 
time, s imulated using TRIF and MyD88 knock -out versions of  the in silico  model described 
by Covert et al. , C. Experimental in vitro  data from LPS-treated TRIF or MyD88 knock-out 
mouse embryo fibroblasts as described by Covert et al.  (205) 
4.4 DISCUSSION  
Using only published data, a graphical depiction and kinetic model of LPS-induced NF-κB 
activation has been produced. The model successfully recapitulates in silico the published 
behaviour of the system in vitro in MEFs. 
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Computational modelling is a major growth area in biomedical research, but has only 
rarely been applied to pregnancy physiology or pathology. The model described here is 
the first kinetic model of a signalling pathway involved in parturition. The LPS-NF-kB 
pathway is an important candidate signalling pathway in infection-induced preterm 
labour.  There is only one report of another computational model to study the molecular 
events initiating labour (121). This model by Equils et al. uses published data to model the 
immune-endocrine interactions in a uterine smooth muscle cell with an increase in the 
ratio of progesterone receptor A (PR-A) to progesterone receptor B (PR-B) as an endpoint. 
It showed that NF-κB increased the PR-A:PR-B ratio, and that higher doses of NF-κB 
shortened the time to reach the PR-A:PR-B ratio observed in labour. The model assumes 
that NF-κB is a marker of infection so these results reflect the known association between 
infection and preterm birth. This is an encouraging and useful first step towards modelling 
preterm labour, however the model does not include the molecular interactions upstream 
of NF-κB activation that initiate the whole pathway, and so does not allow in silico 
exploration of the importance of these interactions to the system. Additionally, the model 
does not include the complex interactions between molecules at an intracellular level and 
therefore risks oversimplifying the system. The model described here extends this work 
by comprehensively including interactions upstream of NF- κB activation. 
Models of NF-κB activity have previously been published in scenarios outwith pregnancy. 
These generally use IKK as an input to allow the model to be adapted to simulate NF-κB 
activity following any treatment (204–206). However, in a pregnancy scenario, LPS is a 
more appropriate input than IKK because LPS could be considered the initiator of some 
cases of infection-induced preterm labour. Therefore, the model described here extends 
previous models by using LPS as an input and explicitly modelling molecular interactions 
upstream of IKK activation, including LPS to IKK and the production and action of TNFα. 
This allows closer analysis of the interactions that activate IKK and therefore affect 
downstream NF-kB activity. After validation using cells from human uterine smooth 
muscle cells, this will allow in silico testing of drugs targeting these upstream interactions. 
This is the first attempt to explicitly model these upstream events appropriately. One 
previous attempt by Selvarajoo (300) was flawed because although the kinetic rate 
equations were based on mass action kinetics, they did not describe physical interactions 
between individual entities. For example, the first reaction in the Selvarajoo model (300), 
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“TLR4 <-> MyD88” (rate equation: Kf [TLR4] – Kr[MyD88]), describes a reaction where 
TLR4 is reversibly converted to MyD88, which does not represent the true physical 
interaction between these two molecules. 
Explicitly modelling the upstream events produces a more complete model that is able to 
reproduce in silico the published behaviour of the system in vitro in wild-type, MyD88 
knock-out and TRIF knock-out MEFs. However, it should be noted that, to an extent, the 
model was built for this purpose. At the time of model development, we were aware of the 
behaviour of NF-κB in LPS-treated MyD88 and TRIF knock-outs that Covert et al. (205) 
reported, but we did not develop the model under knock-out conditions. Instead, we built 
the “wild-type” model and used MyD88- and TRIF- “knock-out” conditions to test the 
model in silico. Several “tests” and subsequent changes to the wild-type model were made 
during model development. A true test of the model would be to “knock-out” or inhibit 
another component of the pathway and compare the in silico behaviour to that achieved in 
vitro. We are unaware of any published data that would allow us to make this comparison. 
Although the model described here can simulate the pattern of the in vitro behaviour, the 
exact timing, number of oscillations and exact concentrations were different. However, 
this is unlikely to invalidate the model because the kinetics of the pathway are also likely 
to alter in different experimental conditions and in different cell types. There are 
undoubtedly more LPS targets that could be incorporated into extended versions of the 
model to make it more comprehensive and improve its potential to make predictions 
about the relative importance of different parts of the pathway. In particular, it would be 
interesting to expand the model to include more inflammatory cytokines aside from TNFα. 
Inflammatory cytokines (such as IL-8 and IL-6) have been shown to induce preterm labour 
and uterine contractions in animal models (301,302), and their expression is also 
regulated by NF-κB (243–245), therefore a model of inflammatory cytokine-induced NF-
κB activation would be useful in the context of parturition. In the early model described 
here, a decision was made to use LPS as a model input, because it is exogenous to the cell 
and could therefore be modelled with a fixed concentration. Future, more complex, 
versions of the model could use other inputs that are also produced by the cell. A model of 
NF-κB activation via TLR2 would also be useful, because TLR2 is activated by naturally 
occurring endotoxins in vivo. 
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 No published data was found to describe the structure or kinetics of the LPS-NF-κB 
pathway in uterine smooth muscle cells and therefore it cannot be confirmed that the 
pathway does not deviate from that described in MEFs. Although this is a major limitation 
of the model, it is unlikely that there would be any large deviations because the pathway 
appears to be well conserved (303) and  the main components of the pathway (NF-κB, 
TLR4, TNFα and IκBα) have been shown to be expressed in uterine smooth muscle 
(232,304). However, wet lab experiments using uterine smooth muscle cells should be 
conducted to validate the model in uterine smooth muscle cells. For example, quantitative 
western blots and/or ELISAs could be used to quantitate the levels of active and inactive 
proteins in the pathway at short time intervals up to around two hours. The most 
important parameters to define would be those describing the behaviour of TLR4, IKK, NF-
κB, IκBα and TNFα in response to LPS stimulation. NF-κB activation may be best measured 
using electromobility shift assay (EMSA). PCR to measure mRNA transcripts of IκBα and 
TNFα would also be useful.  The lack of available published data also highlights the need 
for the publication of detailed data from time course experiments to aid with model 
building. More data in the literature would have been useful for validating the model. For 
example, detailed results of in vitro experiments on IKK knock-out cells would have 
allowed us to test if our model could predict changes to NF-κB activation under these 
circumstances. The SBML version of this model has been uploaded to PloSONE (as 
supplementary material to the paper) and the Biomodels database (305) to encourage 
other researchers to use it. This is an important next step in validating the model and 
confirming its usefulness. 
This work provides proof of concept that it is possible to build computational models of 
signalling pathways relevant to labour. When validated using wet lab experiments on cells 
derived from human gestational tissue (for example, uterine smooth muscle cells), such 
models could be used for drug testing in silico, providing a rapid, safe, economical and 
ethical strategy to identify candidate effective therapies for further testing. Thus, these 
models have the potential to improve our understanding of parturition and translate into 
improved pregnancy outcomes. 
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5 A NETWORK GRAPH APPROACH TO EXPLORE 
EPIDEMIOLOGICAL DATA 
5.1 INTRODUCTION  
Chapters 3 and 4 describe applications of data-driven, systems biology approaches to 
study the molecular biology of parturition. This chapter explores the use of a systems 
approach to study the epidemiology of parturition-related events. 
Conventional data analysis in epidemiology involves testing specific hypotheses generated 
by the researcher. Although undoubtedly useful, this approach risks overlooking 
interesting and confounding associations the researcher does not expect to see. A similar 
limitation has been described of the reductionist approach in molecular biology. In that 
field, systems biology has been proposed as a complementary approach that can help 
overcome this limitation through hypothesis-free data-driven analyses. For the work 
described in this thesis, it was proposed that a similar, systems approach could be applied 
in epidemiology, to complement traditional methods. Specifically, this chapter describes 
the use of 3D, interactive, unbiased network graphs to visually explore the Walker Cohort 
– a database of nearly 50,000 birth records collected from 1952 to 1966 in Dundee. To our 
knowledge, this is the first time network graphs have been used to explore 
epidemiological data. BioLayout Express3D (which is most commonly used to analyse gene 
expression data (150,151,153,306–308), and was used for this purpose in Chapter 3) was 
used to build three dimensional network graphs in which each ‘node’ represents either a 
clinical characteristic or a delivery episode, and these are connected by weighted ‘edges’ 
based on Pearson’s correlation coefficients.  
5.2 SUMMARY OF METHODS  
The detailed methods for this chapter are described in Chapter 2. Briefly, the Walker 
Cohort of 48985 births (described in section 2.3.1) was prepared by removing erroneous 
values and converting continuous variables to discrete, binary variables (described in 
section 2.3.2). The data was then used to build an “obstetric characteristic graph”, in which 
nodes represent obstetric characteristics such as small placental weight (described in 
section 2.3.3), and “delivery episode graphs”, in which nodes represent delivery episodes 
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(described in section 2.3.4). An outline of the final protocol is provided in Figure 5.1. A 
description of all the variables available in the Walker dataset is provided in Appendix 5. 
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5.3 RESULTS  
5.3.1  EFFECT OF DATA CLEANI NG  
Data stored as continuous variables were ‘cleaned’ to remove potentially inaccurate data. 
This affected the distribution of the data, in most cases making it more consistent with 
what would be expected (Figure 5.2 and Figure 5.3). For example, birth weight was more 
normally distributed after cleaning and maternal age was more clearly skewed to the left 
(younger mothers).  
The two sub-populations that appear to exist in variables such as maternal/paternal 
height and head circumference are likely to have arisen because some values were 
recorded in centimetres and some were converted from imperial measurements. If the 
recorded value was metric, it is more likely to be an integer to the nearest centimetre, 
whereas converted values are more likely to be fractions.  Therefore, there are unlikely to 
be two clear sub-populations in reality. 
The bimodal distribution of crown-heel and crown-rump length suggests that these 
measurements were more likely to have been recorded if they deviated from a “normal” 
range of values. This bias is important to consider when interpreting data on any variable. 
Cleaning removed many erroneous 0 values that were possibly used when data was 
missing. It also removed extreme low or high values that might have arisen through 
recording or typing errors. Table 5.1 shows key statistics describing the distribution of 
continuous data before and after cleaning. The procedure successfully removes the 
relatively small number of values that might introduce bias, without substantially altering 
the median and 25th and 75th centiles (except  in variables such as paternal age and height, 
which contained many erroneous 0 values). 




Figure 5.2.  Histograms to show the distribution of data for continuous variables before 
data cleaning. 




Figure 5.3.  Histograms to show the distribution of data for continuous variables  after 
data cleaning. 
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5.3.2  NETWORK GRAPHS  
BioLayout Express3D worked well with binary data and produced informative network 
graphs that could be used to dynamically explore relationships between patient health 
characteristics, obstetric complications and fetal and maternal outcomes following 
delivery.  
5.3.2.1  OBSTETRIC CHARACTERIS TIC GRAPH  
A network graph in which each node represents a variable was produced. The edges 
denote the strengths of the correlations between variables according to size (thicker edges 
show stronger correlations) and colour (from blue (weak correlation) to red (strong 
correlation)). Pearson’s correlation coefficients are shown for each edge. The graph 
consisted of 54 nodes and 51 edges making up 14 small, unconnected graphs. Markov 
Chain (MCL) clustering revealed the four clusters shown in Figure 5.4. These clusters 
confirmed known associations between certain obstetric characteristics, and could 
therefore be categorised according to the main condition/characteristic likely to be linking 
them.  




Figure 5.4.  The four MCL clusters identified in the obstetric characteristic graph. Each 
cluster confirms known associations between certain obstetric characteristics.  Large 
weight at discharge: ≥3912.2cm ; Small weight at discharge: ≤2749.9cm ; Small placenta 
weight: ≤481.94g ; Heavy placenta weight: ≥830g ; Small crown-rump length: ≤28.6cm ; 
Small head circumference: ≤32.9cm ; Large head circumference: ≥36.8cm ; Large crown-
heel length: ≥53.34cm. 
5.3.2.2  DELIVERY EPISODE GRAP H 
A larger network graph in which each node represents a different delivery episode was 
also produced. Over the study period, Walker data was collected on three different cards, 
which collected data on slightly different variables. Therefore, it was necessary to split the 
dataset by card number and create a separate graph using data from each card. After 
preparation, card 0 contained 6478 complete records over 39 variables, card 1 contained 
10046 complete records over 36 variables, and card 2 contained 7982 complete records 
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over 24 variables. Here, only the graph built using data from card 0 is shown, because this 
is representative of the graphs built using data from the other cards. Card 0 also contained 
the most data (6478 delivery episodes * 39 variables = 252642 values). 
The graphs consisted of a large main graph including most patients, and several smaller 
graphs including patients with very similar, but rarer types of delivery. Figure 5.5 shows 
the main graph built using data from card 0. Similar deliveries form MCL clusters that can 
be explored in more detail by viewing a chart of average values for every obstetric 
characteristic on the card (Figure 5.6). Although each individual delivery has a value of 1 
(present) or 0 (absent) for each characteristic, the average is calculated across all 
deliveries, giving a value between 0 and 1. The clusters confirm known associations 
between risk factors and outcomes. For example, cluster 1 confirms known associations 
between preeclampsia and surgical induction of labour and cluster 8 confirms known 
associations between pelvic deformity, cephalopelvic disproportion and delivery by 
Caesarean section, 




Figure 5.5.  The main delivery episode network graph built  using data from card 0.Edges 
have been hidden to aid visualisation.  




Figure 5.6.  Examples of charts of average values for each obstetric characteristic in two 
MCL clusters. The charts show all obstetric characteristics used to create the network 
graph of data on Walker card 0. 
The network graphs were overlain with additional information about each birth to explore 
how certain obstetric characteristics influence the data. This was particularly useful for 
highlighting key associations between risk factors and outcomes. For example, Figure 5.7 
shows that nodes clearly cluster according to mode of delivery, and a higher incidence of 
pelvic deformity, uterine dysfunction and cephalopelvic disproportion are associated with 
assisted (surgical or instrumental) delivery compared to vaginal delivery.  Figure 5.8 
shows that nodes also cluster according to the duration of labour, with longer durations 
being associated with uterine dysfunction and assisted delivery. Figure 5.9 shows that 
fetal position is associated with different types of delivery, with right/left occiput 
posterior and lateral positions being associated with a higher risk of Caesarean section 
compared to the normal position (right/left occiput anterior). 
 








Figure 5.8.  The main delivery episode graph for card 0  coloured according to duration of 
labour. 




Figure 5.9.  The main delivery episode graph for card 0 coloured according  to fetal 
position. 
5.4 DISCUSSION  
Biolayout Express3D was used to produce network graphs to explore epidemiological birth 
record data. The network graphs confirmed known associations between risk factors and 
pregnancy outcomes.  
Networks have previously been used to explore the transmission of communicable disease 
throughout populations (154,309–311), however, this is the first time a 3D network graph 
has been used to explore epidemiological data on non-communicable health outcomes. 
The large size of the Walker project provided an ideal dataset in which to develop this 
technique. It contains over 48000 records, representing around 75% of births of all babies 
in Dundee during the 15-year period it was conducted (212). The relatively recent study 
period means the deliveries are more comparable to the present generation’s deliveries 
than some other historical cohorts. The main limitation of the Walker data is the lack of 
information on maternal smoking, parental diet and BMI, which are likely to be important 
factors influencing pregnancy outcome. 
When using nodes to represent each variable (as in the obstetric characteristic graph), 
relationships can be visualised and traced to a wider network to generate hypotheses 
5 – A network graph approach to epidemiology 
 
156 
about covariates. The graph formed four MCL clusters that confirmed known associations 
between obstetric characteristics. The largest cluster (Figure 5.4a) contained nodes 
representing characteristics of small, compromised premature babies (fetal death, low 
birth weight, small crown-rump, small head circumference, light placenta weight), 
preterm birth (at 28-32 weeks and 32-37 weeks) and consequences of preterm birth 
(neonatal death) (66–68). Large weight at discharge also appears in this cluster, which 
initially seemed counterintuitive. However, we have hypothesised that the relatively high 
correlation between large discharge weight and low birthweight might be explained by 
neonatal growth occurring during a prolonged postnatal hospital stay. It is interesting to 
note that not all known associations cluster together, for example extreme prematurity 
(under 28 weeks) did not occur in this cluster. In fact, this characteristic did not appear in 
any cluster because it only correlated with one other characteristic (small crown-heel 
length) above the 0.08 Pearson’s correlation value cut-off. This is likely to be due to the 
low prevalence of extreme prematurity in the Walker data (34 cases out of 12457 
deliveries with information on this variable, 0.27%). The second largest cluster (Figure 
5.4b) contained nodes characteristic of larger babies (large birthweight, large crown heel 
length and large head circumference). Small weight at discharge also appeared in this 
cluster, which we have hypothesised to be a result of a shorter postnatal hospital stay. 
Interestingly, these nodes do not connect to nodes representing obstetric complications 
classically related to macrosomia such as cephalopelvic disproportion or delivery by 
Caesarean section (312). Instead, these characteristics formed a different cluster (Figure 
5.4d), along with two other common indications for Caesarean section – pelvic deformity 
(which was historically more common due to the higher prevalence of rickets(313)) and 
maternal history of Caesarean section (314). The final cluster (Figure 5.4c) contained 
nodes representing methods of inducing or augmenting labour (artificial rupture of 
membranes, pharmaceutical induction of labour, Pitocin (oxytocin) drip), along with 
antenatal admission to hospital, which is necessary to receive such treatment. This is as 
expected, because women often receive two or more interventions to induce/augment 
labour if initial attempts fail (315). 
The “obstetric characteristic” graph approach copes well with missing data and allows 
discovery of ‘emergent’ relationships that could not be identified using a purely statistical 
approach. For example, the largest MCL cluster (Figure 5.4a) confirms associations 
between preterm birth and fetal and neonatal death. However, if we were to have used a 
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more traditional logistic modelling approach, it would have been impossible to infer the 
relationship between these variables because no Walker births have information on both 
gestation and fetal or neonatal death. 
When using nodes to represent cases (as in the “delivery episode” graph), larger, more 
informative graphs can be explored to reveal factors that often occur together in different 
deliveries. This is useful for highlighting pregnancy risk factors for parturition 
complications. For example, in the delivery episode network graph for card 0, MCL cluster 
1 comprises mostly deliveries in which women had pre-eclampsia and were subsequently 
surgically induced, this is in line with NICE guidelines on management of pre-eclampsia 
(316). Many of the women in this cluster also underwent episiotomy and experienced 
morbidity in the puerperal period. MCL cluster 8 comprises deliveries in which women 
tended to have pelvic deformities, experience cephalopelvic disproportion and, probably 
consequently, deliver via Caesarean section (313,317). Many of these women also 
experienced uterine dysfunction and/or underwent external version suggesting that the 
fetus was in an abnormal position. These are also both indications for Caesarean section 
(99,318–321). 
Information that does not influence the structure of the delivery episode graph can be 
used to colour nodes to highlight more relationships in the data. The main (largest) graph 
created using data from Walker card 0 was overlaid with information on the mode of 
delivery, which showed that deliveries cluster according to whether they were assisted 
(Caesarean or instrumental deliveries) or unassisted (normal, vaginal deliveries). The 
graph was then overlaid with information on the duration of labour, which showed that 
labours lasting over 24 hours tend to cluster. Observing the chart of average values for 
each obstetric characteristic shows that long labours are more often associated with 
uterine dysfunction, which is a well-known association (38). By comparing with the graph 
overlaid with information on mode of delivery, it is also clear that long labour is more 
often associated with assisted rather than unassisted deliveries, which reflects the 
common clinical practice to resort to instrumental or surgical delivery in cases of difficult 
prolonged labour (99,322,323). Finally, the graph was overlaid with information on the 
position of the fetus, which showed that deliveries in which the fetus was in the most 
common “normal” left/right occiput anterior position clustered separately from deliveries 
in which the fetus was in a less common occiput lateral or posterior position. Charting 
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average values for each obstetric characteristic shows that abnormal positions are more 
commonly associated with pelvic deformity and cephalopelvic disproportion. By 
comparing with the other graphs, it is also possible to visually observe that the occiput 
lateral or posterior position is more frequently associated with labour over 24 hours and 
assisted delivery, as shown previously (319,320). 
Although the network graph approach did not highlight any novel associations, it provided 
a way to quickly view relationships within the data and was particularly useful in 
identifying non-informative variables. For example, data on maternal and paternal blood 
group was initially included in the analyses, but was removed after observation of the 
resulting ‘obstetric characteristic’ network graphs suggested the data contained errors. 
The graphs showed that all maternal and paternal blood groups were forming two 
clusters, separate from any other characteristic. This would suggest that the blood groups 
were correlated (i.e. that it is possible for one patient to have more than one blood group). 
Further observation of the data showed that many mothers/fathers had been erroneously 
recorded as having two or more blood groups. Therefore, information on blood group was 
judged to be meaningless and was removed. The network graph approach may be more 
successful at highlighting novel associations if applied to a dataset in which less is known 
about the associations between its variables. In pregnancy research, such a dataset might 
contain variables on pregnancy exposures such as over/under the recommended 
gestational weight gain, gestational diabetes and preeclampsia, and the occurrence of each 
of these in their own daughters’ pregnancies. In this way, the network graph approach 
could be used to highlight trends in intergenerational transmission of several obstetric 
complications simultaneously. Alternatively, epigenetic effects of pregnancy exposures 
could be investigated using this approach and a dataset of methylation of specific CpG sites 
in neonatal cord blood samples and pregnancy exposures such as those previously 
mentioned. 
The network graph approach aims to create graphs that are informative and 
comprehensive, therefore a number of considerations should be made to optimise the size 
and amount of useful information included in the graph. Clearly, the graphs are dependent 
on the data used to build them, so care should be taken to prepare the input files 
appropriately. Omission of a key variable, or inclusion of a less useful/meaningless 
variable (such as parental blood groups in this example) can potentially mask interesting, 
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real associations. Similarly, selecting a Pearson’s correlation cut-off value that is too 
stringent or too relaxed can lead to interesting associations not appearing in the graphs, or 
being hidden by weaker associations. Additionally, once the graph has been loaded, MCL 
clustering is highly dependent on the “inflation value” selected to run the algorithm. Lower 
inflation values result in fewer, larger, noisier clusters and higher inflation values result in 
many, smaller, cleaner clusters. As was the case in the development of the graphs shown 
here, a range of inflation and Pearson’s correlation cut-off values should be explored when 
building network graphs. The size of the dataset is a key factor in producing useful 
network graphs. The obstetric complication graph was built using data on 48985 patients 
for 108 variables, but low correlation between most of the variables meant the final graph 
contained only 54 nodes (variables), and only 22 of these were assigned to MCL clusters. 
Therefore, we do not think this approach would be useful in smaller datasets, unless 
variables within the datasets correlate strongly.  
Within Biolayout Express3D, network graphs are interactive; they can be viewed from any 
angle or zoom level and clicking on a node will reveal more information about how it 
relates to the rest of the data. Since network graphs are best viewed in this way, there are 
clear advantages to publishing the graphs online. Currently, the obstetric characteristic 
graph could potentially be made available to download to run in Biolayout Express3D 
(which is free and available to anyone). This would allow other researchers to experiment 
with other Pearson value thresholds and inflation values and therefore facilitate validation 
of the approach. The .matrix file (a correlation matrix) used to build the obstetric 
characteristic graph contains no patient-level data, so publishing it online would not 
breach the data protection rules set out by HIC. However, the delivery episode graph is 
built using a .expression file that can be opened in a program such as MS Excel to reveal 
the raw data. Therefore, HIC (who own the data, but also have a duty to protect the privacy 
of the cohort participants) would not currently permit this.  
In conclusion, network graphs provide a quick and effective way to preliminarily explore 
relationships between risk factors, outcomes and confounders in an unbiased data-driven 
manner, but require large datasets of over or around 50,000 cases
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6 INTERGENERATIONAL TRANSMISSION OF POSTPARTUM 
HAEMORRHAGE RISK – ANALYSIS OF TWO SCOTTISH BIRTH 
COHORTS 
6.1 INTRODUCTION  
The previous chapter describes analyses of birth record data from the Walker cohort. The 
historical nature of this dataset allows these records to be linked with a large number of 
current health-outcome databases, and allows linkage of records over generations. This 
chapter describes the results of a record-linkage study in which the Walker cohort was 
linked to a current database of maternity information, SMR02, to investigate 
intergenerational transmission of postpartum haemorrhage (PPH). 
PPH is defined as ≥500ml blood loss from the genital tract in the first 24 hours after 
childbirth. It is the leading cause of maternal death worldwide, occurring in around 7-26% 
of all deliveries (63) and contributing to the deaths of an estimated 125,000 women each 
year (324).  The annual incidence of PPH appear to be rising steadily, even in high 
resource countries (100). Known risk factors, causes and consequences of PPH are 
summarised in Figure 6.1, however the aetiology is often unclear and PPH may occur in 
women with no identifiable risk factors. PPH can be associated with a failure of the uterus 
to contract adequately after birth (atonic PPH; 90% of cases), trauma to the genital tract 
(traumatic PPH; 7% of cases), or bleeding due to retention of placental tissue or failure in 
the coagulation system (3% of cases) (101). Given the large percentage of PPH cases 
attributed to uterine atony and the focus on myometrial function in previous chapters, we 
also considered investigating intergenerational transmission of dystocia. However, 
dystocia was only defined as “labour over 24 hours” in the Walker cohort, and too few 
cases could be linked to SMR02 to provide adequate power to conduct this analysis. 
Therefore, we focussed our analyses on PPH. 




Figure 6.1.  Causes, risk factors and consequences of postpartum haemorrhage, as 
identified previously.  
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Previous PPH is a significant risk factor for subsequent PPH, with several studies finding 
women two to three times more likely to have PPH in their second pregnancy if they had 
PPH in their first (325–328). If individual women are at increased risk, it is possible that 
this predisposition could be heritable, but no studies have previously addressed this. 
Understanding the biological and potentially heritable basis to PPH could be useful in 
understanding the aetiology of this important obstetric complication and developing 
better predictive and preventive tools. Additionally, it would help in the counselling of 
pregnant women, who are often aware of their family history of pregnancy related adverse 
events, including PPH. 
Here, Scottish population data was used in which quality and consistency has previously 
been confirmed, and where database linkage is possible. This allowed patient-based 
analysis and analysis of intergenerational transmission over three generations of women. 
6.2 SUMMARY OF METHODS  
The methods for this chapter are described in detail in Chapter 2. Briefly, the Walker 
dataset of birth records collected between 1952-1966 was linked via the Community 
Health Identifier (CHI number) to the Scottish Morbidity Records Maternity Admissions 
dataset (SMR02) collected from 1975 to present (described in sections 2.4.1 to 2.4.4).  
Data was cleaned and continuous variables were used to create categorical variables 
(described in sections 2.4.7 and 2.4.8). Obstetric and demographic risk factors for PPH 
were assessed in the Walker and SMR02 datasets separately and as a pooled dataset by 
calculating unadjusted and adjusted odds ratios (described in section 2.4.9.2).  To assess 
intergenerational transmission of PPH, generations were linked as follows: 
 Generation 1 (Walker Mothers – Women who appear in the Walker cohort as 
mothers) was linked to Generation 2 (SMR02 Mothers – Women who appear in the 
Walker cohort as babies, and the SMR02 cohort as mothers). 
 Generation 2 was linked to Generation 3 (SMR02 Daughters – Women who appear 
in the SMR02 cohort as babies, and also as mothers if they have had children 
themselves) 
 Generation 1 was linked to Generation 3. 
 Pooled mother-daughter analysis: mothers from Generations 1 and 2 were linked 
to daughters in Generations 2 and 3. 
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For each of these comparisons, logistic regression models were used to calculate 
unadjusted ORs to describe the relationship between PPH in the younger generation and 
PPH in the older generation. Generalised linear mixed models (GLMMs) were used to 
adjust for the non-independence arising from the appearance of the same woman in 
different (grand)mother-(grand) daughter pairs, as well as known risk factors for PPH 
identified through the unlinked analyses (described in section 2.4.9.3). In SMR02 only, ICD 
codes made it possible to determine which type of PPH a woman experienced, however 
there were too few cases to allow us to conduct subgroup analyses with adequate power. 
Furthermore, the Walker data did not contain information on the type of PPH. Therefore, 
in all analyses PPH was defined as “any type of PPH”. 
6.3 RESULTS  
6.3.1  PREVALENCE OF PPH 
Figure 6.2 outlines how records were linked in this study and the number of records used 
in the final analysis. 
The overall prevalence of PPH (1089/25322, 4.3%) was similar in both the Walker 
(176/3847, 4.6%) and SMR02 (913/21475, 4.3%) cohorts. 82.3% (751) of cases of PPH in 
SMR02 deliveries were caused by uterine atony. PPH was diagnosed as delayed or 
secondary in 8.9% (81) of SMR02 cases and associated with retained placenta (third 
stage) in 8.4% (77). Coagulation defect was the least common recorded cause of PPH 
(0.4%, 4 cases). 




Figure 6.2.  Method of record linkage and number of records analysed.  
6.3.2  EFFECT OF DATA CLEANI NG  
Data were cleaned as described in Chapter 2, section 2.4.7. Table 6.1 and Table 6.2 show 
the effects of data cleaning on the distribution of three key continuous variables in the 
SMR02 and the Walker dataset, respectively. This shows that data cleaning gave the data 
more ‘reasonable’ distributions, based on clinical knowledge. 
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Table 6.1.  The effects of data cleaning on the distribution of SMR02 variables.  
 Before cleaning After cleaning 
 Mean Median Min. Max. Mean Median Min. Max. 
Birth weight (g) 2244.4 3010 0 9999 3309.4 3340 250 5710 
Maternal age  27 25 14 48 26 25 14 48 
Gestational age (weeks) 31.7 39 0 99 39.6 40 12 44 
Table 6.2.  The effects of data cleaning on the distribution of Walker variables.  
 Before cleaning After cleaning 
 Mean Median Min. Max. Mean Median Min. Max. 
Birth weight (g) 3275.7 3280 907.2 39973.5 3245.5 32319 1332 39974 
Maternal age  26 25 2 228 27 26 16 228 
Gestational age (weeks) 39.7 40 26 48 39.7 40 26 48 
6.3.3  COHORT EFFECT  
Univariate analysis of the data was performed to quantify the effect of known and 
unknown risk factors for PPH. Univariate analysis of the Walker and SMR02 datasets 
separately showed different risk factors for PPH (Table 6.3), with high birth weight being 
the only common risk factor. To maximise the size of the dataset, and therefore statistical 
power, all further analysis was conducted using a ‘pooled’ dataset, combining SMR02 and 
Walker.   
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Table 6.3.  Analysis  of risk factors associated with PPH in separate Walker and SMR02 
dataset analyses.  
Risk factor 
WALKER - unadjusted 
odds ratio* (95% 
confidence interval) 
SMR02 –  
unadjusted odds ratio* 
(95% confidence interval) 
Multiple pregnancy 0.422 (0.06 to 3.08) ns 2.27 (1.72 to 3.01) 
Low birth weight (≤2.5kg) 0.68 (0.34 to 1.34) ns 1.20 (0.94 to 1.53) ns 
High birth weight (≥4kg) 1.73 (1.01 to 2.94) 2.48 (2.09 to 2.94) 
Maternal age ≤20-years-old 1.42 (0.81 to 2.49) ns 13.2 (11.9 to 14.7) 
Maternal age ≥40-years-old 0.82 (0.299 to 2.26) ns 3.62 (2.56 to 5.11) 
Nulliparity 1.03 (0.76 to 1.40) ns 1.20 (1.05 to 1.37) 
Preterm birth (≤37 weeks' gestation) 1.03 (0.52 to 2.07) ns 1.36 (1.12 to 1.66) 
Postterm birth (≥42 weeks' gestation) 1.63 (0.95 to 2.8) ns 0.70 (0.54 to 0.91) 
Delivery by Caesarean section† 1.37 (0.53 to 3.56) ns 7.35 (5.96 to 9.08) 
Instrumental delivery (forceps or ventouse) 0.47 (0.18 to 1.21) ns 0.71 (0.40 to 1.23) ns 
Genital trauma or episiotomy 1.48 (0.91 to 2.39) ns 3.91 (1.50 to 10.20) 
Mother smoked during pregnancy n/a 0.07 (0.06 to 0.09) 
ns: non significant.  
* ratio of the odds of a birth being affected by PPH when the risk factor is  present to the 
odds of a birth being affected by PPH when the risk factor is  absent.  
6.3.4  UNIVARIATE ANALYSIS OF POOLED DATA . 
In univariate analyses of data pooled from Walker and SMR02 (Table 6.4), multiple 
pregnancy, baby birth weight over 4kg, maternal age over 40-years, preterm gestation ≤37 
weeks, Caesarean delivery, nulliparity, genital trauma/episiotomy and smoking during 
pregnancy were significant risk factors for PPH (ORs ranging from 1.17 to 6.02). Delivery 
by forceps or ventouse was associated with a small but significant lower risk of PPH. There 
was insufficient data on PPH in a previous pregnancy to determine if this was a risk factor 
for PPH in a subsequent pregnancy.  
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risk factor is 












Multiple pregnancy 25322 1089 (4.3%) 58 (5.3%) 
2.09 (1.59 to 
2.76) 
1.87 (0.77 to 
4.53) ns 
Low birth weight 
(≤2.5kg) 
24935 1059 (4.2%) 81 (7.6%) 
1.11 (0.88 to 
1.39) ns 
n/a 
High birth weight 
(≥4kg) 
24935 1059 (4.2%) 199 (18.8%) 
2.37 (2.02 to 
2.78) 




20207 1015 (5.0%) 136 (13.4%) 
1.34 (1.12 to 
1.62) 




20207 1015 (5.0%) 44 (4.3%) 
2.73 (1.98 to 
3.77) 
1.32 (0.73 to 
2.38) ns 
Nulliparity 25293 1085 (4.3%) 541 (49.9%) 
1.17 (1.03 to 
1.32) 
1.47 (1.10 to 
1.98) 
Preterm birth (≤37 
weeks' gestation) 
23741 1003 (4.2%) 127 (12.7%) 
1.33 (1.1 to 
1.61) 
0.63 (0.41 to 
0.97) ns 
Postterm birth (≥42 
weeks' gestation) 
23741 1003 (4.2%) 81 (8.1%) 





3872 471 (12.2%) 283 (60.1%) 
6.02 (4.92 to 
7.38) 
8.20 (6.19 to 
10.86) 
Instrumental 
delivery (forceps or 
ventouse) 
3872 471 (12.2%) 21 (4.5%) 
0.42 (0.27 to 
0.66) 
n/a 
Genital trauma or 
episiotomy 
18890 885 (4.7%) 25 (2.8%) 
1.61 (1.07 to 
2.44) 




8833 573 (6.5%) 140 (24.4%) 
1.40 (1.15 to 
1.71) 
0.79 (0.57 to 
1.08) ns 
ns: non significant.  
* ratio of the odds of a birth being affected by PPH when the risk factor is  present to the 
odds of a birth being affected by PPH when the risk factor is  absent.  
†adjusted for all factors identif ied as s ignificant in the univariate (unadjusted) analysis.  
6.3.5 MULTIVARIATE ANALYSIS  OF POOLED DATA  
A logistic regression model incorporating significant risk factors from the univariate 
analysis allowed us to adjust for confounding and revealed that large birth weight, 
Caesarean delivery, nulliparity and genital trauma/episiotomy were significant 
independent risk factors for PPH (Table 6.4). After these adjustments (particularly for 
multiple pregnancy and Caesarean section, which are significant confounders), delivery at 
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≤37 weeks was associated with a significant decreased risk of PPH (OR 0.63 95% CI 0.55-
0.97).  
6.3.6  INTERGENERATIONAL LINKED ANALYSES  
Table 6.5 shows that there is a small increased risk of PPH in women whose mothers 
and/or grandmothers had PPH across generations 1-2 and 1-3, but this trend did not 
reach statistical significance. Comparisons of generations 2 and 3 and pooling of mother 
and daughter comparisons showed a reverse trend, i.e a trend to a protective effect of 
maternal PPH on the risk of PPH in the daughter. This highlights the cohort effect 
observed in the data; generations 2 and 3 are comprised solely of women from SMR02. 
GLMMs were used to adjust for non-independence between related mother-daughter pairs 
and most risk factors identified as significant by the multivariate analysis (analyses could 
not be completely adjusted for delivery by Caesarean section due to incomplete data). 
These analyses again confirmed no statistically significant effect of maternal PPH on the 
risk of PPH in the daughter. These intergenerational analyses had 80% power at an alpha 
of 0.05 to detect the following odds ratios: 2.1 for generation 1 linked to generation 2; 1.3 
for generation 2 linked to generation 3; 2.1 for generation 1 linked to generation 3; and 1.3 
for the pooled mother to daughter analysis. Thus we can be reasonably confident that any 
intergenerational effect of maternal PPH, should it exist, is not greater than an odds ratio 
of PPH in the daughter of 1.3. 


































PPH in generation 1 as a 
risk factor for PPH in 
generation 2 
2543 49 (1.9%) 3 (6.1%) 





PPH in generation 2 as a 
risk factor for PPH in 
generation 3 
2464 290 (11.8%) 4 (1.4%) 
0.68 (0.24 to 
1.90) 
0.58 (8.0x10-
3 to 41.61) 
PPH in generation 1 as a 
risk factor for PPH in 
generation 3 
519 65 (12.5%) 6 (9.2%) 
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PPH in mothers as a risk 
factor for PPH in 
daughters (pooled 
analysis) 
5007 339 (6.8%) 7 (2.1%) 
0.59 (0.27 to 
1.27) 
0.69 (0.06 to 
7.62) 
*calculated using a generalised linear mixed model to adjust for the non -independence 
between linked births and risk factors identified as s ignificant in the multivariate 
analysis  (excluding delivery by Caesarean section because of incomplete data).  
6.4 DISCUSSION  
To our knowledge, this is the first attempt to investigate the intergenerational 
transmission of PPH. The analyses do not support a large increased risk of PPH for women 
whose mothers/grandmothers had PPH. Caesarean delivery, genital trauma or episiotomy, 
high birth weight and nulliparity were identified as risk factors for PPH in univariate and 
multivariate analysis, thus confirming the results of previous studies (64,327,329–331). In 
particular, the odds of PPH in nulliparous women (odds ratio 1.47) was very similar to 
that reported by Combs et al. (odds ratio 1.45) (327).  
Univariate analysis of the Walker and SMR02 datasets separately showed different risk 
factors for PPH. This may be due to the use of different measure and record data in the 
different cohorts. To maximise the size of the dataset and therefore the statistical power, 
analyses were conducted on a ‘pooled’ dataset, which means this ‘cohort effect’ was largely 
ignored. However, it is worth noting that due to its larger size, SMR02 has a greater impact 
on the results of these analyses compared to Walker.  
In both the SMR02 and Walker cohorts, the prevalence of PPH (4.3% and 4.6%, 
respectively) was lower than that reported for other populations. In a meta-analysis of 
104 datasets, Calvert et al. (63) showed that PPH prevalence shows high regional 
variation, ranging from 7.2% in Oceania to 25.7% in Africa. In Europe, they found a 
prevalence of 12.7%, which is similar to the 13.2% incidence reported in the NHS 
maternity records for England and Wales in 2011-12 (60). However, the authors also 
found that the prevalence depends strongly on the method of diagnosis of PPH, with a 
subjective measurement of blood loss resulting in a lower prevalence compared to an 
objective measurement. A subjective measure is likely to have been used for the SMR02 
and Walker cohorts, which may explain the relatively low prevalence of PPH in these 
datasets. 
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In line with previous studies (64,332,333), the most frequent cause of PPH was uterine 
atony (82.3% of cases in SMR02), which prevents constriction of blood vessels during 
placental separation. Unfortunately there was insufficient data to analyse risk factors for 
different types of PPH individually.  
No previous reports have investigated family history of PPH as a risk factor for PPH. The 
historical Walker data linked to the more recent SMR02 data presented a unique 
opportunity to do this. SMR02 data collection began in 1975, so the same comparison 
could be made within this dataset. Special consideration was given to the appearance of 
the same women in more than one mother-daughter/grandmother-granddaughter pair. 
This is further complicated by the tendency for women to experience PPH in repeat 
pregnancies (325–328). This non-independence invalidates the assumptions of many 
statistical tests and can lead to spurious conclusions.  One option for dealing with this 
“clustering” is to restrict analysis to one pregnancy per woman (for example, the first 
pregnancy). However, this reduces statistical power and ignores a lot of potentially 
important information. It also changes the definition of the study population from “all 
births within the dataset” to “all first births within the dataset”, so it may not be possible 
to generalise the results to “all births”(334). Another possible tactic is to include data on 
all pregnancies and ignore the non-independence. This approach was used to calculate the 
“unadjusted odds ratios” for intergenerational transmission of PPH. However, this will 
lead to incorrect standard errors and potentially incorrect conclusions. Therefore, a mixed 
model was used in the final, multivariate analysis to adjust for both covariates (fixed 
effects) and within-woman clustering (random effects). This protects against bias and 
allows estimation of the size of the effect introduced by this clustering (334). 
No significant association was shown between PPH in the mother and the odds of PPH in 
daughters. This study had 80% power to detect an OR of 1.29 for maternal influence on 
PPH in the daughter. This is a lower OR than conferred by birthweight > 4.0kg and 
nulliparity (1.87 and 1.47 respectively) and very much lower than conferred by maternal 
Caesarean section (8.2) and genital tract trauma (2.6). Thus any effect of the pregnant 
woman’s maternal history of PPH is (if it exists) much less significant than those of the 
index pregnancy. These data contrast with the known intergenerational transmission of 
pre-eclampsia and of preterm delivery (335,336). Again, the ‘cohort effect’ was apparent  
in the analyses that involved data from the Walker cohort (generation 1) there was a slight 
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increase in odds of PPH in women whose mothers had experienced PPH. However, these 
observations were not significant so they did not change the overall conclusions of the 
analyses. 
 Pregnant women whose mothers had PPH can be reassured that they are unlikely to be at 
any significantly increased risk, compared to those whose mothers did not have PPH. 
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7 FETAL ASSESSMENT METHODS FOR IMPROVING NEONATAL 
AND MATERNAL OUTCOMES FOLLOWING PRETERM 
PRELABOUR RUPTURE OF MEMBRANES –  A SYSTEMATIC 
REVIEW 
7.1 INTRODUCTION  
The previous two chapters describe how epidemiology can make use of patient health 
records to explore complex relationships between risk factors and outcomes of obstetric 
complications. Epidemiology is also concerned with how clinical interventions affect the 
health of a population. As discussed in Chapter One, the efficacy of medical interventions is 
assessed through randomised controlled trials (RCTs), but the reliability of the evidence is 
greatly increased through meta-analysis of all available data from comparable RCTs. This 
chapter describes a Cochrane systematic review and meta-analysis of RCT data to assess 
the efficacy of different methods of fetal assessment in improving neonatal and maternal 
outcomes following preterm prelabour rupture of membranes (PPROM).  
7.1.1  DESCRIPTION OF THE CONDITION   
Preterm prelabour rupture of membranes (PPROM) is defined as rupture of the 
chorioamniotic membranes before 37 weeks' gestation, where there is at least one hour 
between rupture of membranes and the onset of contractions. It occurs in around 1% to 
2% of pregnancies and is associated with around 30% to 40% of preterm births 
(61,337,338). 
PPROM is often idiopathic, but it has been associated with a number of factors including a 
history of previous preterm delivery or PPROM, vaginal bleeding during pregnancy, 
uterine overdistension (76), black race (74), smoking, cervical cerclage (75) 
amniocentesis, infection, and low socioeconomic status (77). 
The mechanisms responsible for PPROM are largely unknown, but might include excessive 
stretching of the membranes, decreased collagen content, placental abruption or 
programmed amniotic cell death (78). Between one-quarter and one-half of cases are 
associated with intrauterine infection and inflammation (79). 
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PPROM is associated with fetal and maternal morbidity and mortality. Cord prolapse, cord 
compression, placental abruption and maternal/neonatal infection are potential 
complications (79), and many women require interventions to expedite delivery, with 
induction of labour or Caesarean section. The major cause of perinatal morbidity following 
PPROM arises from preterm birth, which is a significant problem because most women 
will go into spontaneous labour within several days of PPROM (66). The neonatal 
morbidity associated with preterm birth includes respiratory distress syndrome, 
intraventricular haemorrhage, and infection (78). 
Several Cochrane reviews have assessed interventions for improving outcomes following 
PPROM:  Kenyon et al. (339) found some evidence that antibiotics may increase time to 
labour and decrease the risk of infection, but appear to have no effect on mortality. 
Mackeen et al. (83) found tocolytics increase time to labour but may also increase risk of 
chorioamnionitis, low Apgar scores and need for ventilation. Hofmeyr et al. (82) found 
transabdominal amnioinfusion decreased risk of neonatal sepsis, infection and death, but 
the evidence was insufficient to recommend routine use. Transcervical amnioinfusion 
improved fetal heart rate patterns and umbilical cord blood pH results but did not 
significantly improve substantive clinical outcomes. Abou El Senoun et al. (340) found 
home care is associated with a lower rate of Caesarean section compared with hospital 
care, although there was only a small effect on outcomes such as perinatal mortality, 
neonatal and maternal infection, latency period and neonatal admission to intensive care. 
7.1.2  DESCRIPTION OF THE FETAL ASSESSMENT AS AN INTERVENTION   
This review focuses on fetal assessment methods following PPROM to improve pregnancy 
outcomes. Although fetal assessment does not aim to “treat” the mother or the fetus, it is a 
way for medical professionals to monitor fetal wellbeing and aid their decisions about how 
to manage cases of PPROM. Fetal assessment may result in earlier delivery due to earlier 
detection of fetal compromise, which could improve neonatal and maternal outcomes. 
However, if the fetal assessment tool is inaccurate, it may cause inappropriate early 
delivery and worsen outcomes. 
There are several methods for assessing fetal wellbeing, including: 
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 Fetal movement counting - mothers count fetal movements over a specified period 
or measure the time it takes for the fetus to make a specified number of 
movements. Reduced frequency of movements can be a sign of fetal compromise. 
 Fetal cardiotocography - allows monitoring of the fetal heart rate over time. 
Changes in heart rate parameters outside of the accepted 'normal' limits can 
identify fetuses at risk of acute or chronic fetal hypoxia. 
 Biophysical profile (BPP) - an assessment of overall fetal wellbeing through the 
combined assessment of fetal cardiotocography along with ultrasonic 
measurement of fetal movements, fetal tone, fetal breathing and estimation of 
amniotic fluid volume. 
 Modified biophysical profile (MBPP) - less time-consuming than the BPP, the MBPP 
is an assessment of overall fetal wellbeing based only on fetal cardiotocography 
and estimation of amniotic fluid volume. 
 Fetal and umbilical artery or venous Doppler ultrasound - ultrasonic measurement 
of blood flow through blood vessels of interest can indicate high vascular 
impedance and possible feto-placental compromise. 
 Fetal MRI lung volumetrics - fetal lung volume is measured by MRI and used as an 
indication of fetal lung development and pulmonary hypoplasia. 
 Amniocentesis for fetal lung maturity - levels of fetal lung surfactant in the 
amniotic fluid are used to gauge fetal lung maturity. 
Several Cochrane reviews have examined the use of some of these tests in improving 
maternal and fetal outcomes in normal and compromised pregnancies (341–345). The 
scope of this review is to examine these assessment methods in improving outcomes in 
pregnancies affected by PPROM. Although some of these methods may be useful in 
identifying intrauterine infection (346–350), their effectiveness in improving outcomes 
following PPROM is uncertain. 
7.1.3  WHY IT IS IMPORTANT T O DO THIS REVIEW   
Following PPROM, accurate methods for assessing fetal wellbeing and prognosis are 
needed to aid obstetrician's decisions in planning the time and mode of delivery. However, 
the value of the various methods of fetal assessment in ultimately improving neonatal and 
maternal outcomes has yet to be established. 
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7.1.4  OBJECTIVES   
This review aims to compare methods of fetal assessment in improving outcomes 
following preterm prelabour rupture of membranes. 
7.2 SUMMARY OF METHODS  
Detailed methods of this review are described in Chapter 2. Briefly, the review was carried 
out according to Cochrane guidelines (described in section 2.5.1).  Firstly, a detailed 
protocol was produced outlining the methods to be used (described in section 2.5.2). The 
Cochrane Trials Search Co-ordinator searched the Cochrane Pregnancy and Childbirth 
Group’s Trials Register on 28th November 2012 (described in section 2.5.4). Criteria for 
considering studies for inclusion are described in section 2.5.3. All relevant randomised 
controlled trials involving women with PPROM before 37+0 weeks’ gestation undergoing 
any method of fetal assessment (including no intervention) were included in the review. 
Primary outcomes of interest were fetal death (antenatal), neonatal death (in the first 28 
days of life), maternal death, and serious maternal morbidity (septicaemia, need for 
intensive care, organ failure/need for ventilation, or need for hysterectomy). A complete 
list of secondary outcomes is provided in Table 2.6. Data was extracted (described in 
section 2.5.5) from the trial reports using a custom data extraction form (Appendix 7). For 
each RCT, the risk of bias was assessed (described in section 2.5.5.3). Statistical analysis 
was carried out using the Review Manager software to provide summary risk ratios (RRs) 
with 95% confidence intervals for dichotomous data, and mean differences for continuous 
data (described in section 2.5.5.4). Heterogeneity of treatment effects was also measured 
between trials (described in section 2.5.5.6). 
This work was conducted by a team of three authors, although my contribution was the 
largest (precise author contributions are described in section 2.5.1.1). 
7.3 RESULTS   
7.3.1  RESULTS OF THE  SEARCH   
The search of the Cochrane Pregnancy and Childbirth Group's Trials Register identified 
four studies in six reports. Three studies (Carlan (1997) (351) Cotton (1984) (352) and 
Lewis (1999) (353)) reporting data on 271 women were included in the review. One study 
(Li et al., 2010 (354)) was excluded from the review because all the patients were over 
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37+0 weeks' gestation. Figure 7.1 shows a summary of information flow in the selection of 
papers for the review. 
 
Figure 7.1.  The summary of information flow in the selection of papers for the review. 
7.3.1.1  INCLUDED STUDIES   
Details of the three included studies are described in Table 7.1, Table 7.2 and Table 7.3. 
Lewis (1999)(353) was associated with three publications: one abstract (355), one 
answer from Lewis et al. in response to a letter regarding the abstract (355), and one full 
article describing the results of the trial (353). 
Table 7.1.  A description of the key features of the Carlan (1997) (351) study. 
Carlan et al. (1997)(351) 
Methods 
A single centre unmasked randomised controlled trial conducted 
from May 1993 until June 1996 (the study was interrupted from 
March 1994 until December 1994 due to technical difficulties with 
the sonography machine). 
Participants 
93 women (92 available for analysis) with a diagnosis of PPROM 
between 24+0 and 34+0 weeks' gestation at Arnold Palmer 
Hospital for Children and Women (Orlando, Florida, USA). 
Interventions 
Weekly endovaginal ultrasound scans versus no endovaginal 
ultrasound scans. 
Outcomes  Neonatal death. 
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 Maternal chorioamnionitis (diagnosed when maternal 
temperature reached 100.4°F, the patient exhibited 
uterine tenderness, and there was fetal or maternal 
tachycardia). 
 Maternal endometritis (diagnosed when maternal 
temperature reached 100.4F on two or more occasions 
during a 6-hour period after the first 24 hours 
postpartum, in association with uterine tenderness and 
no other source of infection). 
 Caesarean delivery. 
 Respiratory distress syndrome (determined by clinical 
presentation (oxygen therapy for more than 24 hours) 
and radiographic findings of a grapund-glass appearance 
with the presence of an air bronchogram). 
 Days of postnatal hospitalisation. 
 Days from randomisation to birth. 
 Birthweight. 
 Days from birth to discharge home. 
 Spontaneous labour before 34+0 weeks. 
 Maternal antibiotics after delivery. 
 Neonatal antibiotics. 
 Neonatal infection (diagnosed if there was fever, 
leukocytosis, or a positive culture of blood, urine, or 
gastric aspirate). 
 Corticosteroid use. 
 Number with Apgar over 5 at 5 minutes. 
 Intraventricular haemorrhage (defined as a haemorrhage 
within the germinal matrix, ventricular system of the 
brain, or intracerebral tissue. Diagnosed using cranial 
ultrasound). 
 Time from rupture to admission (days). 
 Time of maternal antibiotic treatment before labour 
(hours). 
 Cord blood pH. 
Notes 
The trial addressed a further outcome (the relation of cervical 
length to the time of labour in women who went into 
spontaneous labour), but this was not included in the review 
because it did not compare the effect of the intervention. 
Risk of bias associated 
with sequence 
generation 
Unclear risk: sequences were "randomly generated", but the 
method is not described. 
Risk of bias associated 
with allocation 
concealment 
Low risk: allocations were concealed in sealed envelopes. 
Risk of bias associated 
with blinding method 
High risk: the nature of the intervention prohibited participant 
and clinician blinding. It is presumed that the outcome assessor 
was also not blinded, because the outcomes include cervical 
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length measurement, which was only available for the treatment 
group. 
Risk of bias associated 
with incomplete 
outcomes 
Low risk: loss of participants to follow-up and exclusion of 
participants after randomisation are described adequately. Only 
one participant was excluded after randomisation, representing a 
low risk of bias. 
Risk of bias associated 
with selective 
reporting 
Low risk: there is no suggestion of selective reporting of 
outcomes. All main outcomes described in the methods are 
reported in the results. 
Risk of other bias Low risk: no reason to suspect other bias. 
Table 7.2.  A description of the key features of the Cotton (1984) (352) study. 
Cotton et al. (1984) 
Methods A single centre unmasked randomised controlled trial. 
Participants 
47 women (44 available for analysis) with a diagnosis of PPROM 
between 26+0 and 34+0 weeks' gestation at Hermann Hospital 
(Houston, Texas, USA). 
Interventions Amniocentesis versus no amniocentesis. 
Outcomes 
 Latency period (days from rupture of membranes to birth; 
reported as a count of patients in different latency period 
categories). 
 Gestation at birth. 
 Birthweight. 
 Apgar scores. 
 Fetal death. 
 Neonatal death. 
 Neonatal sepsis. 
 Fetal sepsis. 
 Respiratory distress syndrome. 
 Transient tachypnea. 
 Intraventricular haemorrhage. 
 Pneumothorax. 
 Persistent ductus arteriosus. 
 Seizures. 
 Hyperbilirubinaemia. 
 Metabolic problems. 
 Apnea. 
 Feeding difficulties. 
 Days of postnatal hospitalisation (after discharge of 
mother). 
 Cardiotocographic abnormality in labour (fetal distress). 
 Maternal antepartum hospitalisation. 
 Maternal postpartum hospitalisation. 
 Maternal postpartum endometritis. 




Days of postnatal hospitalisation could not be included in the 
review because data was presented as the median and range, 
which was insufficient to calculate the mean difference between 
the groups. 
Risk of bias 
associated with 
sequence generation 
Unclear risk: not described. 




Unclear risk: not described. 
Risk of bias 
associated with 
blinding method 
High risk: the nature of the intervention prohibited participant and 
clinician blinding. Outcome assessor blinding is not described, 
therefore the risk of bias arising from this is unclear. 
Risk of bias 
associated with 
incomplete outcomes 
Low risk: loss of participants to follow-up and exclusion of 
participants after randomisation are described adequately. 
Risk of bias 
associated with 
selective reporting 
High risk: several outcomes listed in the methods section are not 
described in the results section. Some outcomes are reported only 
as showing no difference between the two groups, without any 
quantitative data. 
Risk of other bias 
Unclear risk: the number of patients with multiple gestations is not 
reported .These patients were not excluded from the study, but a 
subgroup analysis of their effect has not been described. 
Therefore the risk of bias arising from the inclusion of patients 
with multiple gestations in the analyses is unclear. 
Table 7.3.  A description of the key features of the Lewis (1999)(353) study. 
Lewis et al. (1999) 
Methods 
A single centre unmasked randomised controlled trial conducted 
during a 36 month period. 
Participants 
135 women with a diagnosis of PPROM ≤34+0 weeks' gestation at 
Louisiana State University School of Medicine, Shreveport, 
Louisiana, USA) and who were stable after 24 hours' monitoring. 
Interventions Daily nonstress test versus daily modified biophysical profile. 
Outcomes 
 Latency period (days from rupture of membranes to 
birth). 
 Days from birth to discharge home. 
 Birthweight 
 Neonatal antibiotic use (days) 
 Respiratory distress syndrome 
 Intraventricular haemorrhage 
 Necrotising enterocolitis 
 Bronchopulmonary dysplasia (interpreted in the review as 
oxygen treatment after 36+0 weeks) 
 Retinopathy of prematurity 
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 Intra-amniotic infection (maternal chorioamnionitis) 
(diagnosed by analysis of amniotic fluid obtained from an 
amniocentesis or by a maternal temperature of 100.4°F, 
foul smelling fluid, and uterine tenderness). 
 Maternal endometritis 
 Neonatal sepsis 
 Presumed neonatal sepsis (diagnosed when there were 
clinical signs of infection with negative culture results and 
an abnormal leukocyte count). 
 Neonatal pneumonia (diagnosed by a positive 
radiographic finding plus evidence of sepsis). 
 Corticosteroid use. 
 Delivery for maturity. 
 Caesarean delivery. 
 Apgar score of 7 or less at 5 minutes. 
Risk of bias 
associated with 
sequence generation 
Low risk: random number tables with a 1:1 match were used to 
generate allocation sequences. 




Low risk: allocation cards were kept in opaque envelopes and not 
opened until after informed consent was obtained. 
Risk of bias 
associated with 
blinding method 
High risk: the nature of the intervention prohibited participant or 
clinician blinding. Outcome assessor blinding is not described, 
therefore the risk of bias arising from this is unclear. 
Risk of bias 
associated with 
incomplete outcomes 
Low risk: no loss of participants to follow-up at each data 
collection point. No exclusion of participants after randomisation. 
Risk of bias 
associated with 
selective reporting 
Low risk: there is no suggestion of selective reporting of 
outcomes. All main outcomes described in the methods are 
reported in the results. 
Risk of other bias 
Unclear risk: the number of patients with multiple gestations is 
not reported. These patients were not excluded from the study, 
but a subgroup analysis of their effect has not been described. 
Therefore the risk of bias arising from the inclusion of patients 
with multiple gestations in the analyses is unclear. 
7.3.1.1.1 STUD Y D ES IGN  
All included studies were unmasked single-centre randomised controlled trials. 
7.3.1.1.2 SAMPLE  S IZES  
Carlan (1997)(351) recruited 93 women (92 available for analysis), 46 were randomised 
to the intervention group and 47 to the control group. Cotton (1984)(352) recruited 47 
women (44 available for analysis), 25 were randomised to the intervention group and 22 
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to the control group. Lewis (1999)(353) recruited 135 women (all 135 available for 
analysis), 66 were randomised to the group receiving daily modified biophysical profiling 
and 69 were randomised to the group receiving a daily nonstress test. 
7.3.1.1.3 STUD Y LO CATIO N  
All included studies were conducted in the USA. 
7.3.1.1.4 PARTIC I PANTS  
All included studies recruited women with a diagnosis of PPROM occurring ≤34+0 weeks. 
Lewis (1999) (353) only recruited women with this diagnosis who were stable after 24 
hours' monitoring. 
Carlan (1997) (351) excluded women with multiple pregnancies, cerclage in place, 
cervical dilatation on admission of more than 4cm, active regular contractions, or any 
indication for delivery. One woman was found to have a funic presentation (the 
appearance of the umbilical cord before the main presenting part of the fetus) and cervical 
dilation at the initial scan and was delivered by Caesarean immediately. This left 92 
patients available for analysis (45 in the intervention group and 47 in the control group). 
Cotton (1984) (352) excluded women with evidence of amnionitis, an indication for 
immediate delivery, sonographic evidence of gross fetal congenital anomalies, active 
labour with a cervical dilation of more than 4cm, or an inadequate amount of amniotic 
fluid for amniocentesis (assessed by real time ultrasound). In the treatment group, 
amniocentesis was unsuccessful in two patients and one patient withrdrew after the initial 
amniocentesis visit. This left 44 patients available for analysis (22 in each group). 
Lewis (1999)(353) excluded women with signs of obvious clinical infection or indications 
for immediate delivery. No patients were excluded from analysis or lost to follow up, so 
135 were available for analysis. 
All three studies reported no significant difference between groups in maternal age 
(Carlan (1997)(351) data not reported; Cotton (1984) (352) data not reported; Lewis 
(1999) (353) mean 24.4 years in the nonstress test group and 25.7 years in the 
biophysical profile group) and parity (Carlan (1997)(351) data not reported; Cotton 
(1984) (352) data not reported; Lewis (1999) (353) 30.4% primigravid in the nonstress 
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test group and 19.7% primigravid in the biophysical profile group). Lewis (1999) (353) 
also reported no significant difference in ethnicity (27.5% White, 72.5% African American 
in the nonstress test group, 21.2% white, 78.8% African American in the modified 
biophysical profile group). Patient ethnicity was not reported for Carlan (1997)(351) or 
Cotton (1984) (352). 
7.3.1.1.5 TYPES  O F  INTERV ENTIO N  
Carlan (1997)(351) compared weekly endovaginal ultrasound scans versus no 
endovaginal ultrasound scans. Both also groups received intravenous antibiotics until 
genital culture results were available. If the culture results were positive, patients in both 
groups received intravenous antibiotics and were offered amniocentesis. Patients in both 
groups were offered steroids to accelerate pulmonary maturation until 31+0 weeks' 
gestation. 
Cotton (1984) (352) compared amniocentesis versus no amniocentesis. Amniocentesis 
was performed at admission, 48 hours later, and then at weekly intervals until pulmonary 
maturity or bacteria in the amniotic fluid was identified, at which point the patient was 
delivered). Both groups also received bi-weekly electronic fetal heart rate monitoring. In 
the abasence of fetal pulmonary maturity, infection or fetal compromise, both groups 
received intravenous tocolysis. Steroids were also administered to both groups at the 
discretion of the managing physician. 
Lewis (1999) (353) compared a daily nonstress test (a measurement of fetal 
cadiotocography) versus daily modified biophysical profile (as described by Chamberlain 
et al.(356)): total score of 10, with points each for tone, amniotic fluid, movement, 
breathing, and a nonstress test). Both groups also received intravenous antibiotics until 
delivery or for a total of seven days. 
7.3.1.1.6 OUTCO ME MEAS URES  
None of the primary outcomes of this review (fetal/neonatal death, maternal death, and 
serious maternal morbidity) were addressed by all trials. Neonatal deaths (in the first 28 
days of life) were reported for Carlan (1997)(351) and Cotton (1984) (352). From this, it 
was inferred that there were no fetal deaths (before birth) in either study. Lewis (1999) 
(353) did not report data for any of the primary outcomes. 
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Of the secondary outcomes, only maternal chorioamnionitis and respiratory distress 
syndrome were addressed by all three trials. Additionally, data on the frequency of 
intraventricular haemorrhage was also reported for all three trials. Accordingly, the 
review protocol was updated to include this as an outcome of interest, along with any 
other relevant outcomes described by each study but not identified in the original 
protocol. Interestingly, no study reported mean gestational age at delivery. 
All addressed outcomes are listed in Table 7.1, Table 7.2 and Table 7.3. 
7.3.2  R ISK OF BIAS  IN INCLUDED STUDIES   
Figure 7.2 summarises judgements about overall risk of bias. 
 
Figure 7.2.  A summary of  judgements about each risk of bias item presented as 
percentages across all included studies.  
7.3.2.1  ALLOCATION (SELECTION BIAS )    
Allocation sequence generation and concealment was not described for Cotton (1984) 
(352), so the risk of selection bias is unclear. For Carlan (1997)(351), the authors state 
that sequences were "randomly generated" but do not describe the method. Therefore the 
risk of bias can only be judged as unclear. However, the allocations were concealed in 
sealed envelopes, which is associated with a low risk of bias. For Lewis (1999) (353), there 
is an overall low risk of selection bias because random number tables were used to 
generate allocation sequences and allocations were concealed in opaque envelopes that 
were not opened until after informed consent was obtained. 
7.3.2.2  BLINDING (PERFORMANCE BIAS  AND  DETECTION BIAS )    
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The nature of the interventions meant that blinding of patients and clinicians was not 
possible. For Carlan (1997)(351) it is assumed that outcome assessors were also not 
blinded because one of the outcomes (cervical dilation) was only recorded for the 
treatment group. For Cotton (1984) (352) and Lewis (1999) (353), outcome assessor 
blinding is not discussed, so the risk of bias arising from this is unclear. 
7.3.2.3  INCOMPLETE OUTCOME DA TA (ATTRITION BIAS )    
The risk of attrition bias was judged to be low, because all three studies adequately 
described any loss of participants to follow up and any exclusion of participants after 
randomisation. Additionally, the level of attrition in all studies was low. 
7.3.2.4  SELECTIVE REPORTING (REPORTING BIAS )    
For Carlan (1997)(351) and Lewis (1999) (353) the risk of reporting bias is low because 
there is no suggestion of selective outcome reporting in either study. For Cotton (1984) 
(352), the risk of reporting bias is high because several outcomes listed in the methods 
section (gestation at delivery, birthweight and Apgar scores) are not described in the 
results section. Other outcomes (maternal antepartum and postpartum hospitalisation 
days, postpartum endometritis and fetal sepsis) are reported only as showing no 
difference between groups, without any quantitative data. 
7.3.2.5  OTHER POTENTIAL SOURC ES  OF BIAS    
For Carlan (1997)(351), there is have no reason to suspect another potential source of 
bias. A potential source of bias in Cotton (1984) (352) and Lewis (1999) (353) arises from 
their treatment of patients with multiple pregnancies. Neither study excludes patients 
with multiple pregnancies but the reports do not mention how many (if any) patients had 
multiple pregnancies. If patients with multiple pregnancies are included in the analyses 
(without a subgroup analysis assessing their effect), then this is a potential source of bias. 
7.3.3  EFFECTS OF INTERVENTI ONS   
Each study considered different comparisons of interventions, so these comparisons were 
considered separately in the review. It was also possible to consider a comparison of any 
assessment method versus no assessment method. This comparison included two studies 
(Carlan (1997)(351) and Cotton (1984) (352)). Lewis (1999) (353) could not be included 
in this comparison because the study did not consider the effect of no intervention. 
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Data on one outcome (days of postnatal hospitalisation) in one (Cotton (1984) (352)) 
study was not reported in a form that could be included in the meta-analysis (only the 
median and range were reported), this data was therefore omitted. 
7.3.3.1  WEEKLY ENDOVAGINAL ULTRASOUND SCAN VERSUS  NO ENDOVAGINAL 
ULTRASOUND SCAN . 
Compared with the group receiving no fetal assessment, Carlan (1997)(351) found a 
significantly decreased relative risk (RR) of maternal endometritis in the group assessed 
by endovaginal ultrasound (RR 0.32, 95% CI 0.11-0.91). There was a non-significant 
decreased RR of maternal chorioamnionitis (RR 0.72, 95% CI 0.34-1.52) and neonatal 
respiratory distress syndrome (RR 0.71, 95% CI 0.4-1.27) in this group. However, there 
was also a non-significant increased RR of neonatal death (RR 7.30, 95% CI 0.39-137.54), 
Caesarean delivery (RR 1.39, 95% CI 0.33-5.88), spontaneous labour before 34+0 weeks 
(RR 1.04, 95% CI 0.75-1.45), corticosteroid use (RR 1.15, 95% CI 0.87-1.52), neonatal 
infection (RR 1.18, 95% CI 0.5-2.78), use of neonatal antibiotics (RR 1.02, 95% CI 0.89-
1.17), neonatal intraventricular haemorrhage (RR 1.31, 95% CI 0.37-4.56), and maternal 
use of antibiotics after delivery (RR 1.34, 95% CI 0.55-3.3) associated with assessment by 
endovaginal ultrasound. There was no significant mean difference (MD) between groups 
in days from randomisation to birth (MD 1.9, 95% CI -11.61-15.41), days of postnatal 
maternal hospitalisation (MD -1, 95% CI -22.03-20.03), duration of maternal antibiotic 
treatment before labour (MD 21, 95% CI -67.6-109.6), birthweight (MD 31, 95% CI -
636.35-698.35), days from birth to discharge home of the neonate (MD 4, 95% CI -45.82-
53.82) or cord blood pH (MD -0.01, 95% CI -0.13-0.11). There was no difference in risk of 
Apgar scores over 5 at 5 minutes between the groups (RR 1, 95% CI 0.91-1.09).  It was also 
inferred that there were no fetal deaths in either the treatment (endovaginal scan) group 
or the control (no scan) group (RR not estimable). 
7.3.3.2  AMNIOCENTESIS  VERSUS NO AMNIOCENTESIS . 
Compared with the group who were not assessed, Cotton (1984) (352) found a 
significantly decreased RR of neonatal apnea in the group assessed by amniocentesis (RR 
0.13, 95% CI 0.02-0.92). Amniocentesis was associated with a non-significant decreased 
RR of maternal chorioamnionitis (RR 0.67, 95% CI 0.12-3.61), respiratory distress 
syndrome (RR 0.67, 95% CI 0.22-2.04), intraventricular haemorrhage (RR 0.75, 95% CI 
0.31-1.8), neonatal sepsis (RR 0.33, 95% CI 0.04-2.96), cardiotocographic abnormality in 
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labour (RR 0.14, 95% CI 0.02-1.07), neonatal transient tachypnea (RR 0.75, 95% CI 0.31-
1.8), hyperbilirubinaemia (RR 0.65, 95% CI 0.4-1.04) and metabolic problems (RR 0.38, 
95% CI 0.11-1.23). However, amniocentesis was also associated with a non-significant 
increased RR of birth within 48 hours after rupture of membranes (RR 1.33, 95% CI 0.71-
2.51), feeding difficulties (RR 2.33, 95% CI 0.69-7.88), seizures (RR 3, 95% CI 0.13-69.87) 
and persistent ductus arteriosus (RR 2, 95% CI 0.2-20.49). There was no difference in risk 
of neonatal death (RR 1, 95% CI 0.07-15) or pneumothorax (RR 1, 95% CI 0.07-15) 
between the groups. It was also inferred that there were no fetal deaths in either group 
(RR not estimable). 
7.3.3.3  DAILY NONSTRESS  TEST VERSUS DAILY MODIFIE D BIOPHYSICAL PROFIL E. 
Compared with the group receiving daily full modified biophysical profiles, Lewis (1999) 
(353) found a significant decreased RR of maternal endometritis  in the group receiving 
the daily nonstress test only (RR 0.25, 95% CI 0.1-0.64). There was also a non-significant 
decreased RR of Caesarean delivery (RR 0.64, 95% CI 0.35-1.15), maternal 
chorioamnionitis (RR 0.55, 95% CI 0.29-1.07), neonatal respiratory distress syndrome (RR 
0.58, 95% CI 0.33-1.03), oxygen therapy after 36+0 weeks (RR 0.77, 95% CI 0.21-2.73), 
intraventricular haemorrhage (RR 0.72, 95% CI 0.17-3.08), necrotising entercolitis (RR 
0.64, 95% CI 0.11-3.7), apgar scores less than 7 at 5 minutes (RR 0.78, 95% CI 0.35-1.77) 
and corticosteroid use (RR 0.88, 95% CI 0.64-1.21) in this comparison. However, there 
was a non-significant increased RR of retinopathy of prematurity (RR 1.34, 95% CI 0.45-
4.01), delivery for maturity (RR 1.57, 95% CI 0.89-2.79), sepsis (RR 2.87, 95% CI 0.31-
26.9) and presumed sepsis (RR 1.05, 95% CI 0.48-2.31). There was no significant mean 
difference (MD) between groups in days of neonatal antibiotic use (MD 0.36, 95% CI -0.26-
0.98), days from birth to discharge home (MD -5.6, 95% CI -16.88-5.68), birthweight (MD 
126.2, 95% CI -56.32-308.72), or days from randomisation to birth (MD 1, 95% CI -2.83-
4.83). 
7.3.3.4  ANY ASSESSMENT METHOD VE RSUS NO ASSESSMENT M ETHOD . 
Where Carlan (1997)(351) and Cotton (1984) (352) reported the same outcomes, it was 
possible to conduct meta-analyses to assess the effect of any assessment method (fetal 
assessment using amniocentesis or endovaginal ultrasound) versus no assessment 
method. These meta-analyses showed no significant differences in risk of any outcome 
between the assessed and non-assessed groups. Compared with no assessment, fetal 
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assessment was associated with a non-significant increased RR of neonatal death (RR 3.07, 
95% CI 0.5-18.83) and a non-significant decreased RR of maternal chorioamnionitis (RR 
0.71, 95% CI 0.36-1.41), respiratory distress syndrome (RR 0.7, 95% CI 0.42-1.17) and 
intraventricular haemorrhage (RR 0.93, 95% CI 0.45-1.91). There were no fetal deaths in 
either group, so the RR is not calculable for this outcome. The two studies included in 
these meta-analyses (Carlan (1997)(351) and Cotton (1984) (352)) roughly agreed on the 
direction and degree of the RR, and statistical measures suggest low heterogeneity (I2 was 
0% for all outcomes, with P-values from Chi2 tests for heterogeneity ranging from 0.32 to 
0.93). The results are summarised in Figure 7.3. 
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7.4 DISCUSSION  
7.4.1  SUMMARY OF MAIN RESUL TS   
This review looked at fetal assessment methods for improving neonatal and maternal 
outcomes in PPROM. The search returned six reports describing four studies. Of the three 
studies that met the inclusion criteria of this review, all were unmasked single-centred 
randomised controlled trials and all investigated different fetal assessment methods. 
Carlan (1997)(351) investigated endovaginal ultrasound versus no assessment, Cotton 
(1984) (352) investigated amniocentesis versus no assessment, and Lewis (1999) (353) 
investigated daily nonstress tests versus daily modified biophysical profiling. Overall, 
there were few significant differences in maternal or fetal outcomes between the two 
groups in any of the studies. There were no significant differences in a meta-analysis of 
any assessment method versus no assessment. None of the included studies addressed all 
of the primary outcomes, although Carlan (1997)(351) and Cotton (1984) (352) found no 
significant difference in neonatal death between the assessed and non-assessed groups. 
7.4.2  OVERALL COMPLETENESS AND APPLICABILITY OF  EVIDENCE   
There are too few trials in this area to provide enough data to draw any firm conclusions. 
Additionally, none of the identified studies reported all of the primary outcomes, and few 
of the secondary outcomes were reported. The “results” of fetal assessment (i.e. the 
decision to intervene to deliver the baby early) were also not reported in any study. None 
of the outcomes that were reported were significantly affected by any of the assessment 
methods, so the evidence cannot be applied in a clinical setting. 
As outlined in the protocol, we planned to meta-analyse the results of trials comparing 
specific, individual assessments versus no assessment. However, only three trials were 
identified and each assessed a different method of fetal assessment, so we were only able 
to conduct a meta-analysis of “any assessment” versus “no assessment”. The combined 
analysis of very different methods of fetal assessment (endovaginal ultrasound and 
amniocentesis) could be considered invalid. 
7.4.3  QUALITY OF THE  EVIDEN CE   
Overall, the quality of the three studies included in this review is mixed. In two (Carlan 
(1997)(351) and Cotton (1984) (352)) out of three studies, the method used to generate 
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allocation sequences was not described and in one study (Cotton (1984) (352)) the 
concealment of these allocations was also not described. Although the nature of the 
interventions prevented patient and clinician blinding, blinding of outcome assessors was 
also not attempted in any study. Two studies were free of selective reporting, but one 
study (Cotton (1984) (352)) did not report data for several outcomes mentioned in the 
methods section. For Cotton (1984) (352) and Lewis (1999) (353) there was an unclear 
risk of bias associated with the failure to perform a subgroup analysis of patients with 
multiple pregnancies. Attrition was not a problem in any of the studies and reasons for any 
patients lost to follow up were also described adequately. 
The small number of studies and limited applicability of the evidence mean that findings of 
these studies and this review may not be generalisable to other populations. 
7.4.3.1  POTENTIAL BIASES  IN T HE REVIEW PROCESS    
The applicability of this review is limited by the small number of high quality studies 
identified. In an effort to reduce biases from other potential sources, study eligibility for 
inclusion, data extraction and risk of bias assessment were independently conducted by 
two review authors. 
7.4.4  AGREEMENTS AND DISAGR EEMENTS WITH OTHER STUDIES OR 
REVIEWS   
No other studies or reviews assessing fetal assessment methods for improving neonatal 
and maternal outcomes in PPROM were identified. 
7.4.5  CONCLUSION  
Currently, there is insufficient evidence on the benefits and harms of any fetal assessment 
method for improving neonatal and maternal outcomes in women with PPROM to make 
firm recommendations to guide clinical practice. However, this is an important clinical 
question and further randomised controlled trials are required. These should collect data 
on a wide range of neonatal and maternal outcomes, including fetal and maternal 
morbidity and mortality and the “results” of the fetal assessment (i.e. time from 
assessment to delivery and whether the delivery was medically indicated or spontaneous) 
and should include subgroup analyses to assess the effect of multiple pregnancies. Future 
systematic reviews in this area should be weary of combining analysis of disparate fetal 
7 - A systematic review of fetal assessment methods in PPROM 
 
191 
assessment methods, and should meta-analyse individual assessment methods versus no 
assessment to provide the most clinically useful evalutaion of their efficacy. 
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8 GENERAL DISCUSSION 
8.1 BACKGROUND AND AIMS OF PHD 
The molecular mechanisms initiating human parturition are complex and difficult to study. 
Therefore, we have a limited understanding of the system, which seriously hampers 
attempts to predict, prevent and treat parturition complications. Advanced data analysis 
methods can help overcome barriers to parturition research by maximising the amount of 
useful data gleaned from existing data. The work for this PhD aimed to explore the use of 
special methods to analyse novel and published data to study the molecular mechanisms 
initiating human parturition and the epidemiology of parturition complications. The work 
has provided several original contributions. Specifically, these are: 
 The largest myometrial microarray experiment to compare labouring and non-
labouring samples to date. The study used 48 samples compared to the previous 
largest study of this kind, which used 39 samples.  
o This study provided further support for the hypothesis that labour is 
associated with an upregulation of inflammatory genes. 
o It also suggested that other patient characteristics such as BMI and 
maternal age do not play a large role in shaping the myometrial 
transcriptome. 
 The first meta-analysis of microarray data comparing labouring and non-labouring 
tissue: 
o Providing further support for the hypothesis that labour is associated with 
an upregulation of inflammatory genes, while increasing the statistical 
power, reliability and generalisability of this finding. 
 The first kinetic model of a signalling pathway to study parturition, and the first 
model of NF-kappa B activation to include reactions upstream of IKK activation. 
 The first attempt to explore the network graph approach to study epidemiological 
data on non-communicable health outcomes, and the first use of computational 
epidemiology in pregnancy research. 
 The first study to investigate intergenerational PPH, and the first to show that the 
odds of a woman experiencing PPH is not higher in women whose 
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mothers/grandmothers experienced PPH in their own pregnancies, compared to 
women whose mothers/grandmothers did not. 
 The first systematic review to explore the efficacy of fetal assessment in improving 
maternal and neonatal outcomes following PPROM. 
8.2 SUMMARY OF FINDINGS  
8.2.1  M ICROARRAY ANALYSIS OF THE MYOMETRIAL TRANSCRIPTOME  
 ‘Systems biology’ provides a way to consolidate and extend current knowledge to 
characterise complex processes through describing the components of a system and their 
interactions at a global level. It considers biological systems from a holistic perspective 
and attempts to identify emergent properties that would not have been obvious using 
more conventional, reductionist techniques. One of the main techniques in systems 
biology involves generating and analysing high-throughput data, such as that generated by 
microarray experiments. 
In Chapter 3, it was hypothesised that exploring myometrial microarray data using 
functional analysis and a network graph approach would reveal genes and molecular 
pathways associated with labour and other patient characteristics. To test this, a large 
microarray experiment was conducted using myometrial samples from 22 labouring and 
26 non-labouring women. This study was 100% powered to detect a fold change of 1.2 
with an alpha of 0.05. This means that there is a very low probability that true differences 
between labouring and non-labouring samples will not be discovered.1761 genes were 
significantly differentially expressed between the two groups. Network graph and Gene 
Ontology analysis showed that labour was associated with an upregulation of biological 
processes such as inflammation and cell movement/migration, and a downregulation of 
muscle-specific processes and pathways such as muscle development, smooth muscle 
contraction and calcium signalling. Both of these observations are in agreement with the 
results of previous myometrial microarray studies (115,140), and provide further 
evidence to support the hypothesis that parturition is associated with inflammation.  
However, it was also hypothesised that these observations may be in part due to a change 
in the composition of the myometrial tissue. It has previously been demonstrated that 
more leukocytes are present in the myometrium at labour (4), and this was confirmed in 
the samples used in this microarray through immunohistochemistry staining for the 
leukocyte marker CD45.  
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When choosing samples to include in the microarray, an effort was made to maximise the 
number of samples rather than to reduce inter-patient variation. Network graph and 
heatmap analysis suggested that other patient characteristics such as BMI, maternal age 
and gestational age were unlikely to have a significant impact on the results; samples 
clustered by labour status rather than any other characteristic. Parity appeared to have a 
small effect, with 421 genes being significantly differentially expressed in first deliveries 
(para=0) compared to subsequent deliveries (para≥1), although there were no clear 
differences in the biological processes identified as associated with para=0 and those 
identified as associated with para≥1. However, it is worth noting that “lumping” patients 
together to increase numbers is only useful if it increases the power of subsequent 
analyses. Network graphs of sample-sample relationships only show global, genome-wide 
differences in expression, which may mask significant differences in the expression of 
individual genes. Therefore interesting differences between individuals, other than 
labour-status, cannot be detected using this method. Network graphs built using 
individual gene expression profiles do allow these differences to be detected, but ignore 
genes that don’t share a similar expression profile with any other genes. Ideally, samples 
should be chosen in an effort to maximise numbers, but also reduce inter-patient 
variability. 
It was also hypothesised that the reliability and generalisability of the findings from this 
microarray analysis would be increased through meta-analysis with other, similar 
myometrial microarray datasets. Therefore, the first meta-analysis of microarray data to 
study parturition using raw, complete data was conducted. Meta-analysis methods similar 
to those described for more traditional meta-analyses of randomised controlled trials (as 
in Chapter 7) were used. The meta-analysis showed that although different studies show 
limited agreement on the precise myometrial gene signature associated with labour, 
studies do agree that labour is associated with an upregulation of inflammatory processes 
and a downregulation of muscle-specific processes. 
Appropriate analysis of high throughput studies such as this are essential for improving 
our understanding of the molecular mechanisms underlying parturition, and will provide a 
basis for understanding differences between normal and dysfunctional or preterm labour. 
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8.2.2  COMPUTER MODELLING OF  A SIGNALLING PATHWAY  RELEVANT TO 
PRETERM LABOUR  
In addition to high-throughput data generation and analysis, systems biology also involves 
building computational models to integrate complex interactions. Such models can be 
used to develop comprehensive in silico reproductions of “pregnant” tissues  that 
demonstrate “emergent” properties, not obvious by conventional analysis (156). 
In Chapter 4 it was hypothesised that published knowledge of a signalling pathway 
relevant to preterm labour could be integrated to build a computational model that 
successfully simulates in vitro behaviour. To test this, a pathway relevant to infection-
induced preterm labour (LPS activation of NF-κB) was chosen to model. This pathway 
results in activation of NF-κB, which plays a key role in many of the inflammatory 
processes found to be associated with labour in Chapter 3. Detailed information about the 
structure and kinetics of this pathway were collated from the literature. A formalised 
pathway diagram and a kinetic model based on ordinary differential equations were built. 
The kinetic model successfully recapitulated in silico the published behaviour (205) of the 
system in vitro in mouse embryo fibroblasts (MEFs). The model extended previous models 
of LPS-induced NF-κB activation by using LPS as an input and explicitly modelling 
molecular interactions upstream of IKK activation, including LPS to IKK and the 
production and action of TNFα. This allowed closer analysis of the interactions that 
activate IKK and therefore affect downstream NF-kB activity. 
Computational modelling is a good example of how the systems biology approach 
complements the traditional reductionist approach. It is essential that models are 
validated using wet-lab experiments to measure the activity of individual proteins over 
time. The model described in this thesis was built using data taken from only one paper  
(205) and could therefore be described as “underpowered” Although the model described 
here needs to be validated in uterine smooth muscle cells, it provides proof of concept that 
it is possible to build computational models of signalling pathways relevant to labour. 
When validated appropriately, such models could be used for drug testing in silico, 
providing a rapid, safe, economical and ethical strategy to identify candidate effective 
therapies for further testing. Thus, these models have the potential to improve our 
understanding of parturition and translate into improved pregnancy outcomes. 
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8.2.3   A  NETWORK GRAPH APPROA CH TO EXPLORE BIRTH RECORDS  
Systems and computational approaches such as those explored in Chapters 3 and 4 have 
been increasingly applied to molecular research over the past decade. However, most 
epidemiological studies still use traditional statistical approaches, and ‘computational 
epidemiology’, which looks for patterns in unstructured sources of data, is in its infancy  
(170–172). 
There are currently no reports of computational epidemiology being applied to pregnancy 
research, although it could be a useful, novel approach that may help generate interesting 
hypotheses about the epidemiology of parturition complications. These hypotheses could 
then be tested using traditional epidemiological approaches that analyse associations 
between exposures and outcomes, providing a good example of how the systems and 
reductionist approaches are complementary. 
The network graph approach used to analyse gene expression data in Chapter 3 is an 
interesting, novel method that works well with large datasets and is not restricted to 
analysing molecular data. Therefore, in Chapter 5 it was hypothesised that a network 
graph approach could be used to visualise and explore epidemiological data relating to 
obstetric complications and birth outcomes. 
Specifically, this work described the use of 3D, interactive, unbiased network graphs to 
visually explore the Walker Cohort – a database of nearly 50,000 birth records collected 
from 1952 to 1966 in Dundee. BioLayout Express3D was used to build network graphs in 
which each ‘node’ represents either a clinical characteristic or a delivery episode, 
connected by weighted ‘edges’ based on Pearson correlation coefficients. The large size of 
the Walker cohort means the analyses are well powered to detect true relationships in the 
data. 
By building graphs in which nodes to represent obstetric characteristics, relationships can 
be visualised and traced to a wider network to generate hypotheses about covariates. This 
approach copes well with missing data and allows discovery of ‘emergent’ relationships 
that could not be identified using a purely statistical approach. Graphs in which nodes 
represent deliveries are larger and can be explored to reveal factors that often occur 
together in different deliveries. This is useful for highlighting pregnancy risk factors for 
parturition complications. 
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Although the network graph approach did not highlight any novel associations, it provided 
an effective way to quickly explore relationships within the data and was particularly 
useful in identifying non-informative variables. 
8.2.4  RECORD-LINKING TO STUDY INTERGEN ERATIONAL TRANSMISSI ON OF 
PPH 
Records from clinical databases or epidemiological studies can often be linked to other 
datasets to increase the breadth of data available for each patient. Pooling similar datasets 
can also increase the power of analyses by increasing the number of participants. 
However, datasets must be directly comparable (i.e. containing similar variables and 
participants from similar populations). If datasets are not comparable, pooling data can in 
fact reduce the power of the study. The historical nature of the Walker cohort (analysed in 
Chapter 5) allows its records to be linked with a large number of current health-outcome 
databases, and allows linkage of records over generations. Therefore, in Chapter 6 it was 
hypothesised that data from Walker and another similar database of Scottish birth records 
(SMR02) could be record-linked to assess if the risk of postpartum haemorrhage (PPH) is 
higher in women whose mothers had PPH in their pregnancies (Chapter 6).  PPH was 
chosen because previous PPH is a significant risk factor for subsequent PPH,(325–328) 
which raises the possibility that this predisposition could be heritable. No previous studies 
had addressed this. 
The analyses did not support a large increased risk of PPH for women whose 
mothers/grandmothers had PPH. These analyses were underpowered to detect odds 
ratios above 1.3, so results should be interpreted cautiously. Caesarean delivery, genital 
trauma or episiotomy, high birth weight and nulliparity were identified as risk factors for 
PPH, which confirms the results of previous studies.(64,327,329–331)  This work suggests 
that pregnant women whose mothers had PPH can be reassured that they are unlikely to 
be at any significantly increased risk, compared to those whose mothers did not have PPH. 
8.2.5  SYSTEMATIC REVIEW AND  META-ANALYSIS TO EVALUATE  THE EFFICACY  
OF FETAL ASSESSMENT IN IMPROVING OUTCOME S FOLLOWING 
PRETERM PRELABOUR RU PTURE OF MEMBRANES  
In addition to studying patterns in disease as discussed in Chapters 5 and 6, epidemiology 
is also concerned with how clinical interventions affect the health of a population. The 
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efficacy of medical interventions is assessed through randomised controlled trials (RCTs), 
but the reliability of the evidence is greatly increased through systematic review and 
meta-analysis of all available data from comparable RCTs. Systematic reviews are most 
useful when there are enough comparable RCTs to allow meta-analysis on a range of 
outcomes. However, it is worth noting that the results of RCTs may be different in different 
populations, and meta-analysis (which treats all populations as alike) may mask such 
differences. Therefore, it is necessary for systematic reviews to discuss the design and 
results of individual RCTs as well as the results of any meta-analyses. 
Complications at parturition are often difficult to predict, prevent and manage due to an 
incomplete understanding of their aetiology. Furthermore, the efficacy of current 
interventions to improve outcomes following parturition complications is often unclear. In 
Chapter 7, a systematic review was conducted to study fetal assessment methods for 
improving neonatal and maternal outcomes following a major obstetric complication, 
preterm prelabour rupture of membranes (PPROM). After PPROM, accurate methods for 
assessing fetal wellbeing and prognosis are needed to aid obstetricians’ decisions in 
planning the time and mode of delivery. However, the value of the various methods of fetal 
assessment in ultimately improving neonatal and maternal outcomes had yet to be 
established. 
The review was conducted in collaboration with the Cochrane group, who carried out the 
literature search. This returned six reports describing four studies. Of the three studies 
that met the inclusion criteria of the review, all investigated different fetal assessment 
methods: endovaginal ultrasound versus no assessment (351), amniocentesis versus no 
assessment, (351) and daily nonstress tests versus daily modified biophysical profiling. 
(352) Overall, there were few significant differences in maternal or fetal outcomes 
between the two groups in any of the studies, and there were no significant differences in 
a meta-analysis of any assessment method versus no assessment.  
Therefore, currently there is insufficient evidence on the benefits and harms of fetal 
assessment methods for improving neonatal and maternal outcomes in women with 
PPROM to make firm recommendations to guide clinical practice. However, this is an 
important clinical question, so further randomised controlled trials are required. 
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8.3 SUGGESTIONS FOR FUTURE WORK  
Several of the results in this thesis would benefit from further exploration.  
The expression of genes and pathways of interest highlighted by the microarray 
experiment should be investigated at the protein level. Additionally, although more 
difficult to obtain, it would be interesting to carry out a similarly large microarray 
experiment using tissue from the uterine fundus, which is more contractile. It would also 
be interesting to study the myometrial transcriptome at different stages of labour. Cervical 
dilation could be used to estimate the stage of labour, however this estimate would be 
very rough and the experiment would require large numbers of samples at each stage in 
order to minimise the effect of noise in the data and maximise the chances of seeing any 
real effect. Our finding that labouring samples show more variation than non-labouring 
samples suggests that the myometrial gene expression signature does vary with the stage 
of labour. Future microarray experiments should use a sufficient number of samples in 
each group (we suggest 20 or more) in order to ensure analyses are well-powered. Finally, 
the quality of input material should be assessed in all molecular investigations, because it 
has a large effect on the results of downstream analyses. Details of how input quality is 
assessed should also be reported in papers describing such studies, 
The LPS-NF-κB model could be extended to include more LPS targets and/or model inputs, 
which would allow the model to incorporate pathway crosstalk and more possible targets 
for pharmaceutical intervention. However, this would take a long time and the size of the 
model might make it difficult to run simulations. Different modelling techniques (such as 
Boolean modelling that uses qualitative rather than quantitative data) could be explored 
to produce a model that is less reliant on specific kinetic information and models 
molecular interactions in the uterus at a broader level. Either way, the model must be 
validated using wet-lab in vitro experiments in myometrial smooth muscle cells before it 
can be used to make predictions about the pathway in human parturition. Care should be 
taken to ensure that wet-lab experiments are designed to provide useful data at 
appropriate timepoints and that analyses are well-powered. The reliability and usefulness 
of the model hinges on the quality of this input data. 
The network graph approach to explore epidemiological data could be applied to other 
datasets. The relationships between the factors collected for the Walker cohort are already 
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understood, we believe that the network graph approach could generate new insights if 
applied to a dataset in which less is known about the associations between its variables 
(for example, a dataset containing data about the intergenerational transmission of 
pregnancy complications). 
As with all the analyses described in this thesis, care should be taken to ensure the data 
used to build network graphs is high quality. Datasets may need to be “cleaned” to remove 
erroneous values, and less useful/meaningless variables should be omitted. A range of 
MCL algorithm parameter values should also be explored. However, the size of the dataset 
(around 50,000 cases minimum) is the most important factor in producing useful network 
graphs.  
Network graphs are useful for exploring associations in large datasets and are not 
intended to make any suggestions about causality or the “direction” of those associations. 
Directed Acyclic Graphs (DAGs) may be a more appropriate technique for assessing 
causality. DAGs are increasingly being used in epidemiological studies for this purpose.  
The intergenerational transmission of PPH could be assessed using other large datasets. 
The intergenerational transmission of other pregnancy-related conditions could also be 
assessed by linking SMR02 to Walker. Again, the quality of data is a key factor in the 
reliability and generalisability of results. Larger datasets collected from several different 
centres are most likely to require some level of “cleaning”, however large databases 
(>50,000 participants) are also most likely to provide sufficient power for analyses. 
Finally, as discussed in Chapter 7, there is a need for more high quality randomised 
controlled trials to assess the effectiveness of fetal assessment methods in improving 
neonatal and maternal outcomes following PPROM. High quality, well-powered RCTs are 
essential for carrying out meta-analyses that yield useful, generalisable results. 
8.4 GENERAL CONCLUSION  
Taken collectively, the results in this thesis suggest that in-depth analysis of molecular and 
epidemiological data related to parturition and associated complications is helpful in 
maximising the amount of useful information that can be gleaned. This provides useful 
insights into not only the molecular mechanisms initiating parturition, but also the 
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10.1  APPENDIX 1 
Table 10.1.  A list  of computer software  applications and online tools used for data 
analysis. 





















Software for drawing and 




An online repository of 
computational models of 
biological processes. 
Cell Designer 4.2 http://www.celldesigner.org/ 
A diagram editor for 
drawing gene-regulatory 
and biochemical networks. 
Copasi 4.8 http://www.copasi.org/ 
A software application for 
simulation and analysis of 








An online tool to mine 
microarray data, built by 









National Institute of Allergy and 
Infectious Diseases  
http://david.abcc.ncifcrf.gov/ 
A set of functional 
annotation tools for 
investigators to understand 
biological meaning behind 




An online repository of 
microarray data. 
KEGG Pathway  
http://www.genome.jp/kegg/path
way.html 
An online collection of 
manually drawn pathway 
maps representing 
knowledge on molecular 
interaction and reaction 
networks. 
Reactome  http://www.reactome.org/ 
An online collection of 
manually drawn pathway 
maps representing 
knowledge on molecular 





A software application to 













Review Manager 5.2 http://ims.cochrane.org/revman 
Software for preparing and 
maintaining Cochrane 
reviews. 




Used to access servers at 
the Health Informatics 





An online repository of 
abstracts used to search for 
literature. 
UniProt  http://www.uniprot.org/ 
An online resource of 
protein sequence and 
functional information. 
AxioVision Rel 4.8 Carl Zeiss Microscopy, Germany 
Software for viewing and 
taking photographs through 

























An online tool for creating 
proportional Venn 
diagrams. 
GraphPad Prism 6.0 
http://www.graphpad.com/scienti
fic-software/prism/ 
A software application 
for organising data, 
performing statistical 
analyses and drawing 
scientific graphs. 
Microsoft Excel 2010 Microsoft Office 
A spreadsheet application 
for organising data, 
performing calculations and 
drawing graphs. 
R 2.15.1 http://www.r-project.org/ 
R is a free software 
programming language 
and a software 
environment for 
statistical computing and 
graphics. 




An application for 
organising data, performing 





An online tool for creating 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10.3 APPENDIX 3 
R  CODE  
CREATING A CORRELATION MATRIX 
Compute the correlation between all columns in a dataframe and return a symmetrical 
matrix of these correlation values. 
DATA <- read.csv(“file path.csv”) #read the data into R 
CMATRIX <- cor(DATA) #create a correlation matrix using 
the Pearson method (matrix is classed as a dataframe) 
 
CREATING A HEATMAP BA SED ON A CORRELATION MATRIX  
Create a heatmap to visualise a correlation matrix (as in Figure 3.3). The function is part of 
the gplots package. 
data.matrix(cmatrix)->cmatrix #make the correlation matrix 
object into a matrix 
tiff("hm.tif", width=4000, height=3500, res=400) #tell R 
how to save heatmap 
heatmap.2(cmatrix, Rowv=NA, Colv=NA trace=c("none"), 
scale="none", revC=TRUE, density.info="none") #create 
heatmap without sorting rows or columns 
dev.off() #tell R to save heatmap to the working directory 
 
CALCULATING FOLD CHAN GES AND CONFIDENCE I NTERVALS USING F IELLER ’S  THEOREM  
As described in Chapter 2, Section 2.1.14.10. 
# x is a vector of expression values for the labouring 
group 
# y is a vector of expression values for the non-labouring 
group 
FC <- function(x, y){  
x.mu <- mean(x) 
y.mu <- mean(y) 
FC <- x.mu/y.mu #calculate the fold change (FC) 
df <-length(x) + length(y) - 2 
t<- -qt(0.05/2, df) 
# standard error of x (square root of variance/length) 
SEx <- sqrt(var(x)/length(x)) 
# standard error of y (square root of variance/length) 
SEy <- sqrt(var(y)/length(y)) 
##### If SEy > y.mu, then: ###### 
g <- (t * SEy/y.mu)^2 
SEFC2 <- (FC/(1-g)) * (sqrt((1-g)*((SEx^2)/x.mu^2) + 
(SEy^2)/y.mu^2)) 
lower2 <- (FC/(1-g)) - t * SEFC2 
upper2 <- (FC/(1-g)) + t * SEFC2 
data.frame(FC, lower2, upper2) 
} 
##### If SEy < y.mu, then: ###### 
SEFC1 <- FC * sqrt(((SEx^2)/x.mu^2)+((SEy^2)/y.mu^2)) 




upper1 <- FC + (t*SEFC1) 
data.frame(FC, lower1, upper1) 
FC(nominator, denominator) 
# where ‘nominator’ is a vector of numbers belonging to 
one group, and ‘denominator’ is a vector of numbers 
belonging to another. 
 
MULTIVARIATE LOGISTIC  REGRESSION MODELLING  
Perform a logistic regression model to assess the adjusted effect of exposure variables on 
an outcome variable. 
DATA <- read.csv(“file path.csv”) #read the data into R 
log_model <- glm(OUTCOME ~ EXPOSURE1 + EXPOSURE2 + 
EXPOSURE3 + EXPOSURE4, data = DATA, family = 
binomial(logit)) #calculate the logistic model 
OR_log_model <- exp(1)^coef(summary(log_model)) #calculate 
the odds ratios for each exposure variable using the 
coefficients produced by the model. 
lowerCI_OR_log_model <- exp(coef(summary(log_model))[,1] + 
qnorm(0.025) * coef(summary(log_model))[,2]) #calculate 
the lower confidence limits of the ORs 
upperCI_OR_log_model <- exp(coef(summary(log_model))[,1] + 
qnorm(0.975) * coef(summary(log_model))[,2]) #calculate 
the upper confidence limits of the ORs 
log_model_OR_results <- cbind(OR_log_model[,1], 
lowerCI_OR_log_model, upperCI_OR_log_model) #create a 
table of final results 
 
GENERALISED L INEAR MI XED MODELLING (GLMM)  
Perform a generalised linear mixed model to assess the effect of exposure variables on an 
outcome variable, while adjusting for fixed and random effects. 
DATA <- read.csv(“file path.csv”) #read the data into R 
GLMM <- glmer(outcome~ FIXEDEFFECTEXPOSURE1 + 
FIXEDEFFECTEXPOSURE2 + FIXEDEFFECTEXPOSURE3 + 
FIXEDEFFECTEXPOSURE4 + (1|RANDOMEFFECT1) + 
(1|RANDOMEFFECT2), data = DATA, family = binomial(logit)) 
#calculate the model 
OR_GLMM<- exp(1)^coef(summary(log_model)) #calculate the 
odds ratios for each exposure variable using the 
coefficients produced by the model. 
lowerCI_OR_GLMM <- exp(coef(summary(GLMM))[,1] + 
qnorm(0.025) * coef(summary(GLMM))[,2]) #calculate the 
lower confidence limits of the ORs 
upperCI_OR_GLMM <- exp(coef(summary(GLMM))[,1] + 
qnorm(0.975) * coef(summary(GLMM))[,2]) #calculate the 
upper confidence limits of the ORs 
GLMM_OR_results <- cbind(OR_GLMM[,1], lowerCI_OR_GLMM, 







CALCUL ATING THE  LO WES T  O D D S  RATIO  AN ANALYS IS  IS  PO WERED  TO  D ETECT  
This calculation returns the lowest odds ratio a Fisher’s exact test would be powered to 
detect. It uses the “clinfun” R package. 
fe.mdor(ncase, ncontrol, pcontrol, alpha=0.05, power=0.8) 
# where ncase is the number of cases, ncontrols is the 
number of controls, pcontrol is the probability of the 
outcome in the control group, alpha is the size of the 
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10.4  APPENDIX 5 
Table 10.3 Walker variables used in the development of the network graph (Chapter 5). 
Variables highlighted in red were derived from  continuous variables.  






B_C_H_LARGE Large crown heel length (≥90th centile [≥53.34cm]) 48% 
B_C_H_CM_SMALL Small crown heel length (≤10th centile [≤38cm]) 48% 
B_C_R_LARGE Large crown rump length (≥90th centile [≥53.34cm]) 17% 
B_C_R_SMALL Small crown rump length (≤10th centile [≤28.6cm]) 17% 
B_EXCH_TRANSF Fetal exchange transfusion 27% 
B_FETAL_DEATH Fetal death 31% 
B_FETAL_DISTRESS Fetal distress 57% 
B_GESTATION_MOD_PT_32-37 Moderately preterm (32-37 weeks – WHO definition) 25% 
B_GESTATION_V_PT_28-31 Very preterm (28-31 – WHO definition) 25% 
B_GESTATION_E_PT_UNDER28 Extremely preterm (under 28 weeks – WHO definition) 25% 
B_GESTATION_POST_OVER42 Postterm (over 42 weeks – WHO definition) 25% 
B_HAEMORRHAGIC Haemorrhagic baby 42% 
B_HEAD_CIRCUM_LARGE Large head circumference (≥90
th
 centile [≥36.8cm]) 24% 
B_HEAD_CIRCUM_SMALL Small head circumference (<10th centile [≤32.9cm]) 24% 
B_MORBIDITY Neonatal morbidity 31% 
B_NND Neonatal death 31% 
B_RH_DISEASE Rhesus disease 72% 
B_SEV_ASPHYXIA Severe asphyxia (baby) 27% 
B_SEX_F Female baby 99% 
B_SEX_M Male baby 99% 
B_SL_ASPHYXIA Slight asphyxia (baby) 27% 
B_WEIGHT_BIRTH_UNDER2.5kg Birth weight under 2.5kg (WHO definition) 99% 
B_WEIGHT_BIRTH_OVER4kg Birth weight over 4kg (WHO definition) 99% 
B_WEIGHT_DISCHARGE_LARGE Large discharge weight (<10th centile [≥3912.2cm]) 18% 
B_WEIGHT_DISCHARGE_SMALL Small discharge weight (>90th centile [≤2749.9cm]) 18% 
CB_ PLAC_RETAINED_PPH Retained placenta or postpartum haemorrhage 31% 
CB_EMERGENCY Mother admitted as an emergency 31% 
CB_INDUCTION_ARM Artificial rupture of membranes 31% 
CB_INDUCTION_MED Medical induction of labour 31% 
CB_INDUCTION_SURG Surgical induction of labour 42% 
CB_LABOUR_OVER_24HRs Labour lasting over 24 hours 94% 
CB_MOD_CAESAREAN Delivery via Caesarean section 99% 
CB_MOD_FORCEPS_VENT Delivery using forceps or ventouse 99% 




CB_PITOCIN_DRIP Pitocin drip 31% 
CB_PLAC_MAN_REMOVAL Manual removal of placenta 42% 
CB_PR_BREECH Breech presentation 99% 
CB_PR_BROW_FACE Brow face presentation 42% 
CB_PR_COMPOUND Compound presentation 42% 
CB_PR_TRANSVERSE Transverse presentation 42% 
CB_TEARS_EPIS Tears or episiotomy 99% 
CB_VERSION_ANT External version 42% 
CB_VERSION_INT Internal version 42% 
CB_VERSION_UA Version under anaesthetic 31% 
F_AGE_YOUNG Young paternal age (≤20) 49% 
F_AGE_OLD Old paternal age (≥50) 49% 
F_HEIGHT_SHORT Short paternal height (≤1st centile [≤154.94cm]) 19% 
F_HEIGHT_TALL Tall paternal height (≥99th centile [≥187.96cm]) 19% 
F_HSC_1_2 Husband’s Social Class - 1 or 2 57% 
F_HSC_3 Husband’s Social Class - 3 57% 
F_HSC_4_5 Husband’s Social Class - 4 or 5 57% 
M_ABORTION Maternal history of abortion 42% 
M_AGE_UNDER20 Young maternal age (under 20) 99% 
M_AGE_35_39 Older maternal age (35 to 39) 99% 
M_AGE_OVER40 Very old maternal age (over 40) 99% 
M_ALBUMINURIA Maternal albuminuria 31% 
M_ANAEMIA_ANY Maternal anaemia 99% 
M_ANTENATAL_ADMISSION Antenatal admission 31% 
M_CEP_PEL_DISP Cephalopelvic disproportion 42% 
M_ECLAMPSIA Eclampsia 72% 
M_EXCESS_VOMITING Excess vomiting 72% 
M_HAEM_APH Antepartum haemorrhage 57% 
M_HAEM_PPH Postpartum haemorrhage 42% 
M_HEIGHT_SHORT Short maternal height (<1st centile [≤147.32cm]) 52% 
M_HEIGHT_TALL Tall maternal height (>99th centile [≥171.45cm]) 52% 
M_HISTORY_CS History of Caesarean section 31% 
M_HISTORY_DIFF_LAB History of difficult labour 57% 
M_HISTORY_GYN_OP History of gynaecological surgery 31% 
M_HISTORY_SB_NND History of stillbirth or neonatal death 57% 
M_HYDRAMNIOS Polyhydramnios 42% 
M_HYPERTENSION Maternal hypertension 72% 
M_MAT_DEATH Maternal death 42% 
M_MEMB_RAGGED Ragged membranes 57% 
M_MULTI_PREG Multiple pregnancy 99% 
M_NEPHRITIS Maternal nephritis 42% 
M_OEDEMA Maternal oedema 31% 




M_PARITY_1plus Parity ≥1 95% 
M_PELVIC_DEFORMITY Pelvic deformity 42% 
M_PLAC_ACCID_HAEM Placental abruption 42% 
M_PLAC_BATTLEDORE Battledore placenta 57% 
M_PLAC_CALCIFIED Calcified placenta 57% 
M_PLAC_CIRCUMVALLATE Circumvallate placenta 57% 
M_PLAC_INCOMPLETE Incomplete placenta 57% 
M_PLAC_INFARCTED Infarcted placenta 57% 
M_PLAC_PRAEVIA Placenta praevia 68% 
M_PLAC_RETROP_CLOT Retroperineal clot 57% 
M_PLACENTA_HEAVY Heavy placenta (>90th centile [≥830g]) 51% 
M_PLACENTA_LIGHT Light placenta (<10th centile [≤481.94g]) 51% 
M_PRE_ECLAMPSIA Preeclampsia 42% 
M_PROLAPSED_TANGLED_CORD Prolapsed or tangled umbilical cord 68% 
M_PU_BREAST Puerperal breast complications 27% 
M_PU_GENITAL Puerperal genital complications 27% 
M_PU_MORBIDITY Puerperal morbidity 42% 
M_PU_NOTI_PYREXIA Notification of puerperal pyrexia 42% 
M_PU_PPS Postpartum sterilisation 27% 
M_PU_RESPIRATORY Puerperal maternal respiratory distress 27% 
M_PYELITIS Pyelitis 42% 
M_RESP_DISEASE Maternal respiratory disease 42% 
M_RH_SENSITISED Rhesus disease sensitisation 27% 
M_SCIMD_4_5 Scottish Index of Multiple Deprivation - 4 or 5 93% 
M_SCIMD_3 Scottish Index of Multiple Deprivation - 3 93% 
M_SCSIMD_1_2 Scottish Index of Multiple Deprivation - 1 or 2 93% 
M_SEUR6_RURAL 
ScottishGovernment 2 fold Urban Rural Classification – 
Rural (SEUR6 code 5 or 6) 
93% 
M_SEUR6_URBAN 
ScottishGovernment 2 fold Urban Rural Classification – 
Urban (SEUR6 code 1, 2, 3 or 4) 
93% 
M_TUMOURS Uterine tumours 42% 
M_UTERINE_DYS Uterine dysfunction 42% 
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